RayKnowChina Research Map
Shortlist

GuangzhouSun Yat-sen University

Sun Yat-sen University Cancer Center

中山大学肿瘤防治中心

Listed for 16 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Sun Yat-sen University Cancer Center

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌483 papers led57 open trials led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌137 papers led8 open trials led
  3. Hepatocellular carcinoma肝细胞癌281 papers led18 open trials led
  4. Stomach cancer胃癌103 papers led4 open trials led
  5. Hepatoblastoma肝母细胞瘤0 papers led1 open trial led
  6. Chordoma脊索瘤0 papers led
  7. Osteosarcoma骨肉瘤19 papers led1 open trial led
  8. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  9. Neuroblastoma神经母细胞瘤7 papers led5 open trials led
  10. Ewing sarcoma尤文肉瘤3 papers led1 open trial led
  11. Multiple myeloma多发性骨髓瘤16 papers led
  12. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病3 papers led
  13. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
  14. Beta thalassaemiaβ 地中海贫血1 paper led
  15. Fanconi anaemia范可尼贫血0 papers led
  16. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led

Not listed for: Retinoblastoma, Aplastic anaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 483 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 20.3%.

Papers led
483
2021–2025
Trials led
167
any status, ClinicalTrials.gov
Open trials led
57
recruiting or about to
Open trials as a site
22
led by another institution
Papers led per year
2021: 858520212022: 787820222023: 11611620232024: 10410420242025: 94942025

24 hospitals in Guangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 79

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07235319

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou, Hangzhou, Nanning

  2. Recruiting
    LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07325539

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shenzhen

  3. Recruiting
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07332247

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  4. Recruiting
    Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07362979

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesDongguan, Guangzhou, Shenzhen, Zhanjiang

  5. Recruiting
    A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07392320

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  6. Recruiting
    Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07496190

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  7. Recruiting
    Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07528183

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuhan

  8. Recruiting
    Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07567742

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  9. Recruiting
    Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07584499

    Age 2 years to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  10. Recruiting
    Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07661771

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChangsha, Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan

  11. Recruiting
    Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07796789

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou

  12. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  13. Recruiting
    EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06802835

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  14. Recruiting
    Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06831357

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  15. Recruiting
    GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06851247

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  16. Recruiting
    Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06912698

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  17. Recruiting
    TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06912711

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  18. Recruiting
    Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07101744

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  19. Recruiting
    Adaptive Immunotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07154069

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  20. Recruiting
    IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT05941741

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Nanchang, Nanning

  21. Recruiting
    Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06197776

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  22. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

  23. Recruiting
    A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Registry
    NCT06241599

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  24. Recruiting
    Individualized Elective Neck Irradiation in NPC Patients
    Phase
    Phase 3
    Started
    2024-04
    Registry
    NCT06241612

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  25. Recruiting
    De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06313450

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  26. Recruiting
    SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06323239

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  27. Recruiting
    Adebrelimab and Chemoradiotherapy in High-risk LANPC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06349889

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesChengdu, Guangzhou, Xiamen

  28. Recruiting
    Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06445088

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuzhou, Zhongshan

  29. Recruiting
    Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2024-05
    Registry
    NCT06516133

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  30. Recruiting
    Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
    Phase
    Phase 1
    Started
    2024-08
    Registry
    NCT06611150

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  31. Recruiting
    A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06829147

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  32. Recruiting
    Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05854849

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  33. Recruiting
    Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05877872

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  34. Recruiting
    Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
    Phase
    Phase 3
    Started
    2023-10
    Registry
    NCT06092957

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  35. Recruiting
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05340491

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  36. Recruiting
    Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05342792

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  37. Recruiting
    Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2022-06
    Registry
    NCT05352321

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou

  38. Recruiting
    Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT05397769

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  39. Recruiting
    Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05447169

    Age 30 years to 62 years; men only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  40. Recruiting
    Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
    Phase
    Phase 3
    Started
    2021-08
    Registry
    NCT04436965

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  41. Recruiting
    Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-06
    Registry
    NCT04944914

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  42. Recruiting
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    Phase
    Phase 3
    Started
    2020-03
    Registry
    NCT03907826

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  43. Recruiting
    Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-08
    Registry
    NCT04448522

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan

  44. Recruiting
    Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
    Phase
    Not given
    Started
    2020-04
    Registry
    NCT04544969

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  45. Not yet recruiting
    Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07064902

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Guilin, Xiamen

  46. Not yet recruiting
    Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07388758

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  47. Not yet recruiting
    GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07540390

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  48. Not yet recruiting
    Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07756190

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  49. Not yet recruiting
    Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07824856

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  50. Not yet recruiting
    Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07902713

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  51. Not yet recruiting
    GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06605131

    Age 6 years to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  52. Not yet recruiting
    PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06900218

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  53. Not yet recruiting
    KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial
    Phase
    Early phase 1
    Started
    2024-05
    Registry
    NCT06370026

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  54. Not yet recruiting
    A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
    Phase
    Phase 3
    Started
    2023-04
    Registry
    NCT05780294

    Age 18 years to 60 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  55. Not yet recruiting
    Umbrella Biomarker-Guided Therapy in NPC
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT04605562

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  56. Not yet recruiting
    A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
    Phase
    N/A
    Started
    2022-11
    Registry
    NCT05622474

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  57. Not yet recruiting
    An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
    Phase
    Phase 2/Phase 3
    Started
    2021-07
    Registry
    NCT04890522

    Age 18 years to 60 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  58. Recruiting
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06839066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan

  59. Recruiting
    A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06976190

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  60. Recruiting
    Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07070479

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Guangzhou, Zhongshan, Zhuhai

  61. Recruiting
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Registry
    NCT07258979

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen

  62. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

  63. Recruiting
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328841

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai

  64. Recruiting
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328854

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai

  65. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  66. Recruiting
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06301165

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan

  67. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

  68. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06475300

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  69. Recruiting
    Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04778956

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesFoshan, Guangzhou, Zhongshan

  70. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
    Phase
    Phase 1
    Started
    2021-11
    Registry
    NCT05194982

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan

  71. Recruiting
    Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2020-06
    Registry
    NCT04425265

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai

  72. Recruiting
    Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-07
    Registry
    NCT04453813

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai

  73. Recruiting
    Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-09
    Registry
    NCT04453826

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai

  74. Recruiting
    To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2020-06
    Registry
    NCT04547673

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou

  75. Recruiting
    Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
    Phase
    N/A
    Started
    2017-10
    Registry
    NCT03353467

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Nanning, Zhongshan

  76. Not yet recruiting
    A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07783321

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  77. Not yet recruiting
    A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07797881

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  78. Not yet recruiting
    A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Registry
    NCT07818486

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChongqing, Guangzhou

  79. Not yet recruiting
    Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07072000

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Wuzhou, Zhanjiang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueInduction / concurrent chemotherapy
Departments in papersRadiation oncologyNasopharyngeal carcinoma dept.Medical oncologyRadiology / nuclear medicine
Papers it led483
  1. The Tumor-to-Endothelial Transfer of FTO Promotes Vascular Remodeling and Metastasis in Nasopharyngeal Carcinoma.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study.2026British journal of cancerFree full text
  3. USP18 promotes nasopharyngeal carcinoma radioresistance via TRIM29 oligomerization and ubiquitination.2026Cell death and differentiationFree full text
  4. [18F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinoma.2026European journal of nuclear medicine and molecular imaging
  5. Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma.2026Oral oncology
  6. Comparison of PICC versus PICC-port in terms of complications and cost-effectiveness in nasopharyngeal carcinoma patients: A randomized controlled trial.2026The journal of vascular accessRCT
  7. DDAH1 Promotes Cisplatin Chemoresistance in Patients with Locally Advanced Nasopharyngeal Carcinoma via the EGFR-JAK2-STAT3 Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  8. Integrative Transcriptome-Wide Association Study With Expression Quantitative Trait Loci Colocalization Identifies a Causal VAMP8 Variant for Nasopharyngeal Carcinoma Susceptibility.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  9. Prognostic Value of Skull Base Foramen Invasion Subclassification in T Category Modification and Induction Chemotherapy Management for Nasopharyngeal Carcinoma: Post-Hoc Analysis of a Dual-Center Retrospective Cohort Study.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  10. Reproduction outcomes and prognostic significance of pregnancy after nasopharyngeal carcinoma treatment.2025Annals of medicineFree full text
  11. Efficacy of metastasis-directed therapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy and local regional radiotherapy: a multicenter retrospective study.2025BMC cancerFree full text
  12. Predictive value of nasopharyngeal microbiota for necrosis after re-irradiation in recurrent nasopharyngeal carcinoma.2025BMC cancerFree full text
  13. A subgroup analysis of locally advanced nasopharyngeal carcinoma patients with small lymph nodes and large nodes using adaptive radiotherapy.2025BMC cancerFree full text
  14. Nasopharyngeal carcinoma detected noninvasively in the real world using three gene methylation analyses from automatically processed bilateral nasal swab samples.2025BMC cancerFree full text
  15. Diagnostic performance of EBV DNA load testing for nasopharyngeal carcinoma in nasopharyngeal swab outperforms the approach in other specimens.2025BMC cancerFree full text
  16. Effect and safety of immunotherapy among elder patients (age ≥ 65) with recurrent or metastatic nasopharyngeal carcinoma.2025BMC cancerFree full text
  17. Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial.2025BMC medicineFree full text
  18. Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.2025BMC medicineFree full text
  19. Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial.2025BMJ (Clinical research ed.)RCTFree full text
  20. Multi-Omics Characterization of Genome-Wide Abnormal DNA Methylation Reveals FGF5 as a Diagnosis of Nasopharyngeal Carcinoma Recurrence After Radiotherapy.2025BiomoleculesFree full text
  21. Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.2025British journal of cancerFree full text
  22. Determining the optimal duration of oral adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.2025British journal of cancerFree full text
  23. Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial.2025CA: a cancer journal for cliniciansFree full text
  24. Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma.2025Cancer cell
  25. Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial.2025Cancer cell
  26. Automated Patient-specific Quality Assurance for Automated Segmentation of Organs at Risk in Nasopharyngeal Carcinoma Radiotherapy.2025Cancer control : journal of the Moffitt Cancer CenterFree full text
  27. Establishment of a deep-learning-assisted recurrent nasopharyngeal carcinoma detecting simultaneous tactic (DARNDEST) with high cost-effectiveness based on magnetic resonance images: a multicenter study in an endemic area.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  28. AK4 promotes nasopharyngeal carcinoma metastasis and chemoresistance by activating NLRP3 inflammatory complex.2025Cell death & diseaseFree full text
  29. CLPTM1L interacts with ERLIN2 to stabilize SREBP1 and drive tumorigenesis in nasopharyngeal carcinoma.2025Cell death & diseaseFree full text
  30. Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-κB and STAT3 signaling pathways in nasopharyngeal carcinoma.2025Cell death & diseaseFree full text
  31. Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.2025Cell reports. MedicineFree full text
  32. Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma.2025Cell reports. MedicineFree full text
  33. Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma.2025Cell reports. MedicineRCTFree full text
  34. Unveiling familial aggregation of nasopharyngeal carcinoma: Insights from oral microbiome dysbiosis.2025Cell reports. MedicineFree full text
  35. Advanced image-identified extranodal extension of retropharyngeal lymph nodes in the refinement of N classification for nasopharyngeal carcinoma.2025Cell reports. MedicineFree full text
  36. Efficacy and safety of immune checkpoint inhibitors in the treatment of recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.2025Chinese medical journalFree full text
  37. GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study.2025Clinical cancer research : an official journal of the American Association for Cancer Research
  38. Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial.2025Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  39. Tumour and adipose tissue uptake on 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) predict immunotherapy response in recurrent or metastatic nasopharyngeal carcinoma.2025Clinical radiology
  40. Multimodal AI-based risk stratification for distant metastasis in nasopharyngeal carcinoma.2025ESMO openFree full text
  41. The efficacy of immunotherapy combined with capecitabine versus immunotherapy alone as maintenance therapy in patients with de novo metastatic nasopharyngeal carcinoma: a retrospective propensity score matching study.2025ESMO openFree full text
  42. Loss of survivorship in nasopharyngeal carcinoma attributable to fine particulate matter and its constituents.2025Ecotoxicology and environmental safety
  43. Cholesterol-to-lymphocyte ratio (CLR)-based nomogram as a prognostic tool in nasopharyngeal carcinoma: a large-scale long-term retrospective study.2025European journal of medical researchFree full text
  44. Potential values of uEXPLORER total-body PET/CT in nasopharyngeal carcinoma: dynamic imaging and kinetic parameters.2025European journal of radiology
  45. Reduced expression of UPF1 promotes tumor progression through stabilizing COX-2 mRNA in nasopharyngeal carcinoma.2025Frontiers in immunologyFree full text
  46. Combining interleukin 6 and EBV DNA levels predicts survival outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving chemoimmunotherapy.2025Frontiers in immunologyFree full text
  47. Predictive biomarkers for immunotherapy in nasopharyngeal carcinoma: from tumor microenvironment to macroenvironment.2025Frontiers of medicine
  48. A genome-wide association study integrated with single-cell and bulk profiles uncovers susceptibility genes for nasopharyngeal carcinoma involved in tumorigenesis via regulation of T cells.2025Genome biologyFree full text
  49. Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma.2025Head & neck
  50. Comparing outcomes and toxicities among patients with nasopharyngeal carcinoma treated with daytime versus evening radiotherapy: A retrospective analysis with propensity score matching.2025International journal of cancer
  51. Efficacy and optimal duration of maintenance immunotherapy following systemic chemoimmunotherapy and locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A multicenter retrospective cohort study.2025International journal of cancer
  52. Optimal therapeutic strategies for hepatic metachronous oligometastatic nasopharyngeal carcinoma: Insights from a retrospective study.2025International journal of cancer
  53. Artificial Intelligence-Empowered Multistep Integrated Radiation Therapy Workflow for Nasopharyngeal Carcinoma.2025International journal of radiation oncology, biology, physics
  54. Long-term Outcomes Following Individualized Primary Tumor Clinical Target Volume Delineation Based on Stepwise Spread Patterns of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy.2025International journal of radiation oncology, biology, physics
  55. RRFERV stabilizes TEAD1 expression to mediate nasopharyngeal cancer radiation resistance rendering tumor cells vulnerable to ferroptosis.2025International journal of surgery (London, England)Free full text
  56. Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.2025JAMAFree full text
  57. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.2025JAMARCTFree full text
  58. Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.2025JAMA oncologyRCTFree full text
  59. Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial.2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  60. Endoplasmic reticulum-localized circular RNA FAM13B restrains nasopharyngeal carcinoma lymphatic metastasis through downregulating XBP1.2025Journal of experimental & clinical cancer research : CRFree full text
  61. A rare KLHDC4 variant Glu510Lys is associated with genetic susceptibility and promotes tumor metastasis in nasopharyngeal carcinoma.2025Journal of genetics and genomics = Yi chuan xue bao
  62. Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial.2025Journal of hematology & oncologyFree full text
  63. Locoregional Radiotherapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: Real-World Insights in the Immunotherapy Era.2025Journal of the National Comprehensive Cancer Network : JNCCN
  64. Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.2025Lancet (London, England)RCT
  65. TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial.2025Med (New York, N.Y.)
  66. Association of anti-PD-1 therapy with severe radiation-induced oral mucositis: A retrospective cohort study and validation in the CONTINUUM trial.2025Med (New York, N.Y.)
  67. Risk assessment and quality management in AIO based on CT-linac for nasopharyngeal carcinoma: An improved FMEA and FTA approach.2025Medical physicsFree full text
  68. Tissue-resident microbiota signature in nasopharyngeal carcinoma.2025MicrobiomeFree full text
  69. Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma.2025NEJM evidenceRCT
  70. Extracellular vesicles derived EBV tegument protein BRRF2 suppresses cGAS phase separation to promote anti-viral innate immune evasion.2025Nature communicationsFree full text
  71. Ulinastatin in the treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma: a phase 3 randomized clinical trial.2025Nature communicationsRCTFree full text
  72. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.2025Nature medicineFree full text
  73. Efficacy of primary lesion re-irradiation in nasopharyngeal carcinoma with synchronous recurrence and distant metastasis.2025Oral oncology
  74. Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging.2025Oral oncology
  75. Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study.2025Oral oncology
  76. Clinical significance of post-chemoradiotherapy 2-[18F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study.2025Oral oncology
  77. Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.2025Oral oncology
  78. Composite quantitative structural magnetic resonance imaging-based risk scoring model for predicting radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma: a novel risk stratification model.2025Radiation oncology (London, England)Free full text
  79. Real-time morphological and dosimetric adaptation in nasopharyngeal carcinoma radiotherapy: insights from autosegmented fractional fan-beam CT.2025Radiation oncology (London, England)Free full text
  80. MRI-based Middle Neck Involvement in Stage N1-N2 Nasopharyngeal Carcinoma: A Marker for Risk Stratification.2025Radiology
  81. A Serial MRI-based Deep Learning Model to Predict Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.2025Radiology. Artificial intelligence
  82. Efficacy of metastatic lesion radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving local regional radiotherapy and chemo-immunotherapy: a multicenter retrospective study.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  83. Harnessing deep learning to optimize induction chemotherapy choices in nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  84. CNG (Collaborative Nasopharyngeal Carcinoma Group) stage: Improved prognostic stratification of nasopharyngeal carcinoma and association with Epstein-Barr virus DNA in the intensity-modulated radiation therapy era.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  85. Multimodal prognostic model for de novo metastatic nasopharyngeal carcinoma after first-line immunochemotherapy.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  86. Non-linear early rapid hippocampal atrophy and associated microstructural injury in patients with nasopharyngeal carcinoma after radiotherapy: Implications for hippocampal protection.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  87. Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  88. A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  89. Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiation in nasopharyngeal carcinoma: A real-world study.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  90. Endoscopic surgery versus conservative treatment in nasopharyngeal carcinoma patients with nasopharyngeal necrosis.2025Rhinology
  91. Integrating pretreatment 18F-FDG PET-CT parameters, peripheral blood indicators and clinical characteristics in predicting chemotherapy plus immunotherapy outcomes for de novo metastatic nasopharyngeal carcinoma.2025Rhinology
  92. Positioning accuracy and dosimetric evaluation of customized immobilization for FBCT guided VMAT in nasopharyngeal carcinoma.2025Scientific reportsFree full text
  93. The multi-target mechanism of action of Selaginella doederleinii Hieron in the treatment of nasopharyngeal carcinoma: a network pharmacology and multi-omics analysis.2025Scientific reportsFree full text
  94. Epstein-Barr virus hijacks histone demethylase machinery to drive epithelial malignancy progression through KDM5B upregulation.2025Signal transduction and targeted therapyFree full text
  95. 'Line' Constraints Optimization for Improved Dose Distribution in Locally Recurrent Nasopharyngeal Carcinoma Using Knowledge-Based Planning.2025Technology in cancer research & treatmentFree full text
  96. Whole-exome sequencing association study reveals genetic effects on tumor microenvironment components in nasopharyngeal carcinoma.2025The Journal of clinical investigationFree full text
  97. A Comparative Study of Epstein-Barr Virus Genomes Detected in Tumor, Nasopharyngeal Swab, and Saliva Samples From Patients With Nasopharyngeal Carcinoma.2025The Journal of infectious diseasesFree full text
  98. Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.2025The Lancet. Oncology
  99. Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.2025The Lancet. Oncology
  100. Anti-PD-1 antibody with or without capecitabine as maintenance therapy after first-line therapy of recurrent or metastatic nasopharyngeal carcinoma.2025The oncologistFree full text
  101. Optimal Size Threshold for MRI-Detected Retropharyngeal Lymph Nodes to Predict Outcomes in Nasopharyngeal Carcinoma: A Two-Center Study.2024AJR. American journal of roentgenology
  102. Role of combined surgical and radiotherapy treatment in nonmetastatic WHO I nasopharyngeal carcinoma patients.2024Acta oto-laryngologica
  103. Primary and Orthotopic Murine Models of Nasopharyngeal Carcinoma Reveal Molecular Mechanisms Underlying its Malignant Progression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  104. DCAF7 Acts as A Scaffold to Recruit USP10 for G3BP1 Deubiquitylation and Facilitates Chemoresistance and Metastasis in Nasopharyngeal Carcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  105. Comparison of long-term quality of life and their predictors in survivors between paediatric and adult nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.2024BMC cancerFree full text
  106. Peripheral hemoglobin to albumin ratio predicts prognosis in patients with nasopharyngeal carcinoma underwent concurrent chemoradiotherapy.2024BMC cancerFree full text
  107. Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.2024BMC cancerFree full text
  108. Outcomes of patients in nasopharyngeal adenoid cystic carcinoma in the IMRT era: a single-center experience.2024BMC cancerFree full text
  109. Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis.2024BMC cancerFree full text
  110. The mediating role of loneliness between psychological resilience and health-related quality of life among patients with nasopharyngeal carcinoma: a cross-sectional study using structural equation modeling.2024BMC psychiatryFree full text
  111. Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.2024BMJ (Clinical research ed.)RCTFree full text
  112. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study.2024Cancer cell
  113. Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma.2024Cancer cell
  114. Optimization and Local Cost-Effectiveness of Nasopharyngeal Carcinoma Screening Strategies in Southern China: Secondary Analysis of the Guangdong Randomized Trial.2024Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyRCT
  115. TSPAN1 inhibits metastasis of nasopharyngeal carcinoma via suppressing NF-kB signaling.2024Cancer gene therapy
  116. A novel model for predicting prognosis and response to immunotherapy in nasopharyngeal carcinoma patients.2024Cancer immunology, immunotherapy : CIIFree full text
  117. The Treatment of Primary Lymphoepithelioma-Like Carcinoma in the Head and Neck and Nasopharyngeal Carcinoma.2024Cancer medicineFree full text
  118. Whether Primary Bone-Only Oligometastatic Nasopharyngeal Carcinoma Patients Benefit From Radiotherapy to the Bones on the Basis of Palliative Chemotherapy Plus Locoregional Radiotherapy?-A Large-Cohort Retrospective Study.2024Cancer medicineFree full text
  119. ALYREF promotes the metastasis of nasopharyngeal carcinoma by increasing the stability of NOTCH1 mRNA.2024Cell death & diseaseFree full text
  120. The circadian gene ARNTL2 promotes nasopharyngeal carcinoma invasiveness and metastasis through suppressing AMOTL2-LATS-YAP pathway.2024Cell death & diseaseFree full text
  121. PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.2024Cell death & diseaseFree full text
  122. Transcription factor ATMIN facilitates chemoresistance in nasopharyngeal carcinoma.2024Cell death & diseaseFree full text
  123. High expression of PPP1CC promotes NHEJ-mediated DNA repair leading to radioresistance and poor prognosis in nasopharyngeal carcinoma.2024Cell death and differentiationFree full text
  124. Host genetic variants, Epstein-Barr virus subtypes, and the risk of nasopharyngeal carcinoma: Assessment of interaction and mediation.2024Cell genomicsFree full text
  125. Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL).2024Cell reports. MedicineFree full text
  126. A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.2024Cell reports. MedicineFree full text
  127. Leucine restriction ameliorates Fusobacterium nucleatum-driven malignant progression and radioresistance in nasopharyngeal carcinoma.2024Cell reports. MedicineFree full text
  128. Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma.2024Cell reports. MedicineFree full text
  129. Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  130. Single-cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma.2024Clinical and translational medicineFree full text
  131. Development and analytical validation of a novel nasopharynx swab-based Epstein-Barr virus C promoter methylation quantitative assay for nasopharyngeal carcinoma detection.2024Clinical chemistry and laboratory medicine
  132. EBV DNA methylation profiles and its application in distinguishing nasopharyngeal carcinoma and nasal NK/T-cell lymphoma.2024Clinical epigeneticsFree full text
  133. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein.2024Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  134. Recursive partitioning analysis model for de novo metastatic nasopharyngeal carcinoma treated with locoregional radiotherapy following chemoimmunotherapy.2024ESMO openFree full text
  135. Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.2024ESMO openFree full text
  136. Acquisition and reconstruction with motion suppression DWI enhance image quality in nasopharyngeal carcinoma patients: Non-echo-planar DWI comparison with single-shot echo-planar DWI.2024European journal of radiology
  137. Radiomics-based nomogram guides adaptive de-intensification in locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy.2024European radiology
  138. Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies.2024Expert review of anticancer therapy
  139. Nasopharyngeal carcinoma-associated inflammatory cytokines: ongoing biomarkers.2024Frontiers in immunologyFree full text
  140. Prevalence of mental disorders and their associations with age at diagnosis and time since diagnosis of nasopharyngeal cancer.2024Frontiers in public healthFree full text
  141. Polygenic risk-stratified screening for nasopharyngeal carcinoma in high-risk endemic areas of China: a cost-effectiveness study.2024Frontiers in public healthFree full text
  142. Optimal cut-off value for identifying objective response in patients with nasopharyngeal carcinoma after induction chemotherapy.2024Head & neck
  143. Neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in elderly patients with stage III-IVa nasopharyngeal carcinoma: A real-world study based on medical comorbidities.2024Head & neck
  144. Clinical characteristics and prognostic factors in nasopharyngeal carcinoma with brain metastasis: A retrospective, single-center study.2024Head & neck
  145. A novel endoscopic nasopharyngectomy by low-temperature plasma radiofrequency ablation in localized recurrent nasopharyngeal carcinoma.2024Head & neck
  146. Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report.2024ImmunotherapyFree full text
  147. Multiplex assays reveal anti-EBV antibody profile and its implication in detection and diagnosis of nasopharyngeal carcinoma.2024International journal of cancer
  148. HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype.2024Journal for immunotherapy of cancerFree full text
  149. Anatomical changes and dosimetric analysis of the neck region based on FBCT for nasopharyngeal carcinoma patients during radiotherapy.2024Journal of X-ray science and technology
  150. Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial.2024Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  151. The E3 ligase NEURL3 suppresses epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma by promoting vimentin degradation.2024Journal of experimental & clinical cancer research : CRFree full text
  152. A positive feedback loop between PLD1 and NF-κB signaling promotes tumorigenesis of nasopharyngeal carcinoma.2024Journal of genetics and genomics = Yi chuan xue bao
  153. The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study.2024Journal of hematology & oncologyFree full text
  154. Matted Lymph Nodes on MRI in Nasopharyngeal Carcinoma: Prognostic Factor and Potential Indication for Induction Chemotherapy Benefits.2024Journal of magnetic resonance imaging : JMRI
  155. Modulation Effects of the CEP128 Gene on Radiotherapy-Related Brain Injury: A Longitudinal Structural Study Using Multi-Parametric Brain MR Images.2024Journal of magnetic resonance imaging : JMRI
  156. Disparate Radiation-Induced Microstructural Injuries in Whole-Brain White Matter of Patients With Nasopharyngeal Carcinoma: A Longitudinal Study Using Multishell Diffusion MRI.2024Journal of magnetic resonance imaging : JMRI
  157. Radiomic signatures associated with tumor immune heterogeneity predict survival in locally recurrent nasopharyngeal carcinoma.2024Journal of the National Cancer Institute
  158. EBV-induced upregulation of CD55 reduces the efficacy of cetuximab treatment in nasopharyngeal carcinoma.2024Journal of translational medicineFree full text
  159. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.2024Lancet (London, England)RCT
  160. Development and application of a serious adverse events risk model for concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.2024MedicineFree full text
  161. Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma.2024Nature communicationsFree full text
  162. PJA1-mediated suppression of pyroptosis as a driver of docetaxel resistance in nasopharyngeal carcinoma.2024Nature communicationsFree full text
  163. FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity.2024Nature communicationsFree full text
  164. Microbes translocation from oral cavity to nasopharyngeal carcinoma in patients.2024Nature communicationsFree full text
  165. Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial.2024Nature communicationsFree full text
  166. Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial.2024Nature communicationsFree full text
  167. Ac4C modification of lncRNA SIMALR promotes nasopharyngeal carcinoma progression through activating eEF1A2 to facilitate ITGB4/ITGA6 translation.2024Oncogene
  168. KLF5 regulates actin remodeling to enhance the metastasis of nasopharyngeal carcinoma.2024Oncogene
  169. Characteristics and treatment of epistaxis in nasopharyngeal carcinoma.2024Oral oncology
  170. Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.2024Oral oncology
  171. Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models.2024Oral oncology
  172. The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads.2024Oral oncology
  173. The prognostic value of pretreatment 18F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.2024Oral oncology
  174. Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.2024Oral oncology
  175. Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040.2024Oral oncology
  176. Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.2024Oral oncology
  177. Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.2024Oral oncology
  178. Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.2024Oral oncology
  179. Discontinuation and nonpublication of nasopharyngeal carcinoma clinical trials.2024Oral oncology
  180. Assessment of Prophylactic Internal Carotid Artery Management in Postradiation Nasopharyngeal Necrosis Patients.2024Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  181. Joint modeling of longitudinal health-related quality of life during concurrent chemoradiotherapy period and long-term survival among patients with advanced nasopharyngeal carcinoma.2024Radiation oncology (London, England)Free full text
  182. Automatic IMRT treatment planning through fluence prediction and plan fine-tuning for nasopharyngeal carcinoma.2024Radiation oncology (London, England)Free full text
  183. Guiding induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma with ternary classification of predicted individual treatment effect.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  184. Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  185. Non-complete recovery of temporal lobe white matter diffusion metrics at one year Post-Radiotherapy: Implications for Radiation-Induced necrosis risk.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  186. A novel fully automatic segmentation and counting system for metastatic lymph nodes on multimodal magnetic resonance imaging: Evaluation and prognostic implications in nasopharyngeal carcinoma.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  187. Response to "Comments on 'Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study'".2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  188. Anxiety and depression in nasopharyngeal carcinoma patients and network analysis to identify central symptoms: A cross-sectional study from a high-incidence area.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  189. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  190. The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-world study with a large population.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  191. Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  192. Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  193. Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  194. A comprehensive predictive model for radiation-induced brain injury in risk stratification and personalized radiotherapy of nasopharyngeal carcinoma.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  195. Strategies for patients with recurrent nasopharyngeal carcinoma involved internal carotid artery who are intolerant to embolization.2024Rhinology
  196. Surgical treatment of nasopharyngeal cancer - a consensus recommendation from two Chinese associations.2024Rhinology
  197. Advances of biomarkers in nasopharyngeal carcinoma's early detection.2024Science bulletin
  198. Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy.2024Scientific reportsFree full text
  199. Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials.2024Signal transduction and targeted therapyFree full text
  200. Deep Learning-Based Prediction of Radiation Therapy Dose Distributions in Nasopharyngeal Carcinomas: A Preliminary Study Incorporating Multiple Features Including Images, Structures, and Dosimetry.2024Technology in cancer research & treatmentFree full text
  201. The noncanonical RNA-binding protein RAN stabilizes the mRNA of intranuclear stress granule assembly factor G3BP1 in nasopharyngeal carcinoma.2024The Journal of biological chemistryFree full text
  202. A large-scale population-based study reveals that gp42-IgG antibody is protective against EBV-associated nasopharyngeal carcinoma.2024The Journal of clinical investigationRCTFree full text
  203. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.2024The Lancet. OncologyRCT
  204. Identification of HLA-A*11:01 and A*02:01-Restricted EBV Peptides Using HLA Peptidomics.2024VirusesFree full text
  205. Nanovaccines Fostering Tertiary Lymphoid Structure to Attack Mimicry Nasopharyngeal Carcinoma.2023ACS nano
  206. The investigation of reduced field-of-view diffusion-weighted imaging (DWI) in patients with nasopharyngeal carcinoma: comparison with conventional DWI.2023Acta radiologica (Stockholm, Sweden : 1987)
  207. Chemotherapy-Induced Senescence Reprogramming Promotes Nasopharyngeal Carcinoma Metastasis by circRNA-Mediated PKR Activation.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  208. Significance of Dynamic Changes of VCA-IgA Levels in Pre- and Post-treatment Plasma of Patients with Nasopharyngeal Carcinoma: Development of a Clinically-Oriented Model.2023Advances in therapy
  209. High-throughput identification of regulatory elements and functional assays to uncover susceptibility genes for nasopharyngeal carcinoma.2023American journal of human geneticsFree full text
  210. Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors.2023Annals of medicineFree full text
  211. Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy.2023Annals of oncology : official journal of the European Society for Medical OncologyFree full text
  212. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonuc2023BMC cancerFree full text
  213. Clinical characteristics and prognostic factors affecting survival after radical radiotherapy for early and late post-treatment metastatic nasopharyngeal carcinoma.2023BMC cancerFree full text
  214. Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter study.2023BMC medicineFree full text
  215. Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.2023BMC medicineFree full text
  216. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.2023BMC medicineFree full text
  217. Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response.2023BMC medicineFree full text
  218. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial.2023BMJ (Clinical research ed.)RCTFree full text
  219. Correlated with better prognosis, CSTA inhibits metastasis of nasopharyngeal carcinoma cells via suppressing AKT signaling through promoting METTL3 degradation.2023Biochimica et biophysica acta. Molecular basis of disease
  220. CRISPR Cas12a-mediated amplification-free digital DNA assay improves the diagnosis and surveillance of Nasopharyngeal carcinoma.2023Biosensors & bioelectronics
  221. Preclinical study of LMP1-RNAi-based anti-tumor therapy in EBV-positive nasopharyngeal carcinoma.2023Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicasFree full text
  222. Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma.2023Cancer control : journal of the Moffitt Cancer CenterFree full text
  223. Long noncoding RNA LINC00173 induces radioresistance in nasopharyngeal carcinoma via inhibiting CHK2/P53 pathway.2023Cancer gene therapy
  224. EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression.2023Cancer immunology research
  225. Distribution of regional lymph lode metastasis in unilateral nasopharyngeal carcinoma and the suggestions for selective prophylactic irradiation with intensity-modulated radiotherapy.2023Cancer medicineFree full text
  226. The map of bone metastasis in nasopharyngeal carcinoma: A real-world study.2023Cancer medicineFree full text
  227. Predictive and prognostic role of early apolipoprotein A-I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti-PD-1 therapy.2023Cancer medicineFree full text
  228. Incidence, consequences, and predictors of serious chemotherapy-induced thrombocytopenia in nasopharyngeal carcinoma.2023Cancer medicineFree full text
  229. Risk stratification and beneficiary selection among elderly nasopharyngeal carcinoma patients from concurrent chemoradiotherapy combined with induction chemotherapy.2023Cancer medicineFree full text
  230. Clinical outcomes of non-nasopharyngeal lymphoepithelial carcinoma treated with a combined modality approach: A single-institution study.2023Cancer medicineFree full text
  231. Prognostic models for early and late tumor progression prediction in nasopharyngeal carcinoma: An analysis of 8292 endemic cases.2023Cancer medicineFree full text
  232. Patterns and prognosis of regional recurrence in nasopharyngeal carcinoma after intensity-modulated radiotherapy.2023Cancer medicineFree full text
  233. TRIM29 acts as a potential senescence suppressor with epigenetic activation in nasopharyngeal carcinoma.2023Cancer scienceFree full text
  234. DNAJA4 suppresses epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma via PSMD2-mediated MYH9 degradation.2023Cell death & diseaseFree full text
  235. Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma.2023Cell death & diseaseFree full text
  236. SRSF3/AMOTL1 splicing axis promotes the tumorigenesis of nasopharyngeal carcinoma through regulating the nucleus translocation of YAP1.2023Cell death & diseaseFree full text
  237. ZIC2 induces pro-tumor macrophage polarization in nasopharyngeal carcinoma by activating the JUNB/MCSF axis.2023Cell death & diseaseFree full text
  238. Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial.2023Cell reports. MedicineFree full text
  239. P4HA1 activates HMGCS1 to promote nasopharyngeal carcinoma ferroptosis resistance and progression.2023Cellular signalling
  240. Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients.2023Critical reviews in oncology/hematology
  241. Ulinastatin inhibits the metastasis of nasopharyngeal carcinoma by involving uPA/uPAR signaling.2023Drug development research
  242. Super-enhancer driven SOX2 promotes tumor formation by chromatin re-organization in nasopharyngeal carcinoma.2023EBioMedicineFree full text
  243. Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.2023ESMO openFree full text
  244. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.2023European journal of cancer (Oxford, England : 1990)
  245. A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients.2023European journal of cancer (Oxford, England : 1990)RCT
  246. Benefit of [18F] FDG PET/CT in the diagnosis and salvage treatment of recurrent nasopharyngeal carcinoma.2023European journal of nuclear medicine and molecular imaging
  247. Deep learning-based recurrence detector on magnetic resonance scans in nasopharyngeal carcinoma: A multicenter study.2023European journal of radiology
  248. Head and neck MRI-based T stage and [18F]FDG PET/CT-based N/M stage improved prognostic stratification in primary nasopharyngeal carcinoma.2023European radiology
  249. AI-assisted compressed sensing and parallel imaging sequences for MRI of patients with nasopharyngeal carcinoma: comparison of their capabilities in terms of examination time and image quality.2023European radiologyFree full text
  250. Nasopharyngeal necrosis contributes to overall survival in nasopharyngeal carcinoma without distant metastasis: a comprehensive nomogram model.2023European radiology
  251. Prediction of outcomes in patients with local recurrent nasopharyngeal carcinoma: development and validation of a four-factor prognostic model integrating baseline characteristics and [18F]FDG PET/CT parameters.2023European radiologyFree full text
  252. Using ultrasound radiomics analysis to diagnose cervical lymph node metastasis in patients with nasopharyngeal carcinoma.2023European radiology
  253. Characteristics of immunotherapy trials for nasopharyngeal carcinoma over a 15-year period.2023Frontiers in immunologyFree full text
  254. Comprehensive analysis of circular RNAs in nasopharyngeal cancer.2023Genes & genomics
  255. Effective of metastasis-directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis.2023Head & neck
  256. Why subclinical involvement is prescribed the same high dose as gross tumor volume: A study on high-dose clinical target volume in intensity-modulated radiotherapy plan of nasopharyngeal carcinoma.2023Head & neck
  257. Clinical and genome-wide association analysis of chemoradiation-induced hearing loss in nasopharyngeal carcinoma.2023Human geneticsFree full text
  258. Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.2023Human vaccines & immunotherapeuticsFree full text
  259. Saliva biopsy: Detecting the difference of EBV DNA methylation in the diagnosis of nasopharyngeal carcinoma.2023International journal of cancer
  260. Quantitative detection of Epstein-Barr virus DNA methylation in the diagnosis of nasopharyngeal carcinoma by blind brush sampling.2023International journal of cancer
  261. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).2023International journal of oncologyFree full text
  262. Upper-Neck Versus Whole-Neck Irradiation at the Contralateral Uninvolved Neck in Patients With Unilateral N3 Nasopharyngeal Carcinoma.2023International journal of radiation oncology, biology, physics
  263. Dosiomics Risk Model for Predicting Radiation Induced Temporal Lobe Injury and Guiding Individual Intensity-Modulated Radiation Therapy.2023International journal of radiation oncology, biology, physics
  264. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.2023JAMARCTFree full text
  265. Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma-Reply.2023JAMA
  266. Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy-Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial.2023JAMA network openRCT
  267. Synergistic Association of Hepatitis B Surface Antigen and Plasma Epstein-Barr Virus DNA Load on Distant Metastasis in Patients With Nasopharyngeal Carcinoma.2023JAMA network openFree full text
  268. Multiple TMA-aided CRISPR/Cas13a platform for highly sensitive detection of IL-15 to predict immunotherapeutic response in nasopharyngeal carcinoma.2023Journal for immunotherapy of cancerFree full text
  269. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.2023Journal for immunotherapy of cancerFree full text
  270. Set-up errors of the neck are underestimated using the overall registration frame of head and neck in IMRT for NPC.2023Journal of X-ray science and technology
  271. Effects of induction chemotherapy on nutrition status in locally advanced nasopharyngeal carcinoma: a multicentre prospective study.2023Journal of cachexia, sarcopenia and muscleFree full text
  272. Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study.2023Journal of cancer research and clinical oncologyFree full text
  273. Prognostic value of MR-detected mandibular nerve involvement: potential indication for future individual induction chemotherapy in T4 nasopharyngeal carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  274. Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis.2023Journal of cancer research and clinical oncologyRCTFree full text
  275. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyFree full text
  276. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.2023Journal of hematology & oncologyFree full text
  277. Integrating Postradiotherapy MRI-Detected Lymph Node Necrosis and Pre- and Posttreatment Epstein-Barr Virus-DNA for Risk Stratification in Nasopharyngeal Carcinoma.2023Journal of magnetic resonance imaging : JMRI
  278. MRI-Based Metastatic Nodal Number and Associated Nomogram Improve Stratification of Nasopharyngeal Carcinoma Patients: Potential Indications for Individual Induction Chemotherapy.2023Journal of magnetic resonance imaging : JMRI
  279. The interaction and mediation effects between the host genetic factors and Epstein-Barr virus VCA-IgA in the risk of nasopharyngeal carcinoma.2023Journal of medical virology
  280. Peptidome-wide association analysis of Epstein-Barr virus identifies epitope repertoires associated with nasopharyngeal carcinoma.2023Journal of medical virology
  281. Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison.2023Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialeFree full text
  282. FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway.2023Journal of translational medicineFree full text
  283. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.2023Lancet (London, England)RCT
  284. Widely targeted quantitative lipidomics and prognostic model reveal plasma lipid predictors for nasopharyngeal carcinoma.2023Lipids in health and diseaseFree full text
  285. Oral Microbiota Alteration and Roles in Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma.2023Microbiology spectrumFree full text
  286. LINC00173 facilitates tumor progression by stimulating RAB1B-mediated PA2G4 and SDF4 secretion in nasopharyngeal carcinoma.2023Molecular oncologyFree full text
  287. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.2023Nature communicationsFree full text
  288. TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models.2023Nature communicationsFree full text
  289. Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance.2023Nature communicationsFree full text
  290. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment.2023Nature medicine
  291. Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor.2023NutrientsFree full text
  292. The m6A reader IGF2BP3 preserves NOTCH3 mRNA stability to sustain Notch3 signaling and promote tumor metastasis in nasopharyngeal carcinoma.2023OncogeneFree full text
  293. Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma.2023Oral oncology
  294. Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma.2023Oral oncology
  295. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.2023Oral oncology
  296. A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy.2023Oral oncology
  297. Improved accuracy of auto-segmentation of organs at risk in radiotherapy planning for nasopharyngeal carcinoma based on fully convolutional neural network deep learning.2023Oral oncology
  298. Simultaneous dose distribution and fluence prediction for nasopharyngeal carcinoma IMRT.2023Radiation oncology (London, England)Free full text
  299. Efficacy of concurrent chemoradiotherapy alone for loco-regionally advanced nasopharyngeal carcinoma: long-term follow-up analysis.2023Radiation oncology (London, England)Free full text
  300. Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis.2023Radiation oncology (London, England)Free full text
  301. A Rulefit-based prognostic analysis using structured MRI report to select potential beneficiaries from induction chemotherapy in advanced nasopharyngeal carcinoma: A dual-centre study.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  302. Prognostic value of metastatic cervical lymph node stiffness in nasopharyngeal carcinoma: A prospective cohort study.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  303. Clinical treatment considerations in the intensity-modulated radiotherapy era for parotid lymph node metastasis in patients with nasopharyngeal carcinoma.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  304. Multi-trajectories of health-related quality of life and their associated factors in patients with nasopharyngeal carcinoma: A longitudinal study.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  305. Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  306. Endonasopharyngeal ultrasound and magnetic resonance imaging features of recurrent retropharyngeal nodes in nasopharyngeal carcinoma patients: A radiologic-histopathologic study.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  307. In reply to the Letter to the Editor by Cengiz Beyan and Esin Beyan regarding ''Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?".2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  308. Response to the letter by Dr Sari regarding the article "The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy".2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  309. Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  310. Metastatic patterns of level II-V cervical lymph nodes assessed per vertebral levels in nasopharyngeal carcinoma.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  311. The role of radiologic extranodal extension in predicting prognosis and chemotherapy benefit for T1-2 N1 nasopharyngeal carcinoma: A multicenter retrospective study.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  312. The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  313. Radiation-induced cancer after treatment for nasopharyngeal carcinoma: a study from a high prevalence area.2023Rhinology
  314. TEAD4 is a master regulator of high-risk nasopharyngeal carcinoma.2023Science advancesFree full text
  315. Clinicopathologic characteristics of second primary squamous cell carcinoma in patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy.2023Scientific reportsFree full text
  316. Accumulated Dose Deviation of Rotational and Residual Setup Errors on Nasopharyngeal Carcinoma Using MIM Treated by Helical Tomotherapy.2023Technology in cancer research & treatmentFree full text
  317. m6A-enriched lncRNA LINC00839 promotes tumor progression by enhancing TAF15-mediated transcription of amine oxidase AOC1 in nasopharyngeal carcinoma.2023The Journal of biological chemistryFree full text
  318. VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner.2023The Journal of biological chemistryFree full text
  319. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.2023The Lancet. OncologyRCT
  320. Association between hypertension and Epstein-Barr virus reactivation among the population in a high-risk area for nasopharyngeal carcinoma.2023Virus researchFree full text
  321. N6 -Methyladenosine-Modified CBX1 Regulates Nasopharyngeal Carcinoma Progression Through Heterochromatin Formation and STAT1 Activation.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  322. Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure.2022BMC cancerFree full text
  323. Identifying optimal candidates for postoperative adjuvant therapy among regional persistent/recurrent nasopharyngeal carcinoma patients after neck dissection.2022BMC cancerFree full text
  324. Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma.2022BMC cancerFree full text
  325. The prognostic value of weight loss during radiotherapy among patients with nasopharyngeal carcinoma: a large-scale cohort study.2022BMC cancerFree full text
  326. A novel causal model for nasopharyngeal carcinoma.2022Cancer causes & control : CCC
  327. Low-dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma.2022Cancer communications (London, England)Free full text
  328. Transcriptome-wide association analysis identified candidate susceptibility genes for nasopharyngeal carcinoma.2022Cancer communications (London, England)Free full text
  329. First-Line Immunochemotherapy Versus Palliative Chemotherapy Plus Definitive Radiation Therapy for de novo Metastatic Nasopharyngeal Carcinoma: A Matched Cohort Study.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  330. EBF3 reactivation by inhibiting the EGR1/EZH2/HDAC9 complex promotes metastasis via transcriptionally enhancing vimentin in nasopharyngeal carcinoma.2022Cancer letters
  331. The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma.2022Cancer medicineFree full text
  332. Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity-modulated radiotherapy era.2022Cancer medicineFree full text
  333. EBV Infection in Epithelial Malignancies Induces Resistance to Antitumor Natural Killer Cells via F3-Mediated Platelet Aggregation.2022Cancer research
  334. Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up.2022Cancer research and treatmentFree full text
  335. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma.2022Cell death and differentiationFree full text
  336. WTAP-mediated m6A modification of lncRNA DIAPH1-AS1 enhances its stability to facilitate nasopharyngeal carcinoma growth and metastasis.2022Cell death and differentiationFree full text
  337. CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization.2022Clinical cancer research : an official journal of the American Association for Cancer Research
  338. Utility of Epstein-Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs.2022Clinical chemistry
  339. The contrast-enhanced MRI can be substituted by unenhanced MRI in identifying and automatically segmenting primary nasopharyngeal carcinoma with the aid of deep learning models: An exploratory study in large-scale population of endemic area2022Computer methods and programs in biomedicine
  340. Rare POLN mutations confer risk for familial nasopharyngeal carcinoma through weakened Epstein-Barr virus lytic replication.2022EBioMedicineFree full text
  341. DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway.2022EBioMedicineFree full text
  342. Association between solid fuel use and seropositivity against Epstein-Barr virus in a high-risk area for nasopharyngeal carcinoma.2022Environmental pollution (Barking, Essex : 1987)
  343. Development and validation of a transcriptomics-based gene signature to predict distant metastasis and guide induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.2022European journal of cancer (Oxford, England : 1990)
  344. Deep learning signatures reveal multiscale intratumor heterogeneity associated with biological functions and survival in recurrent nasopharyngeal carcinoma.2022European journal of nuclear medicine and molecular imagingRCT
  345. Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma.2022European journal of nuclear medicine and molecular imagingFree full text
  346. Value of skull base invasion subclassification in nasopharyngeal carcinoma: implication for prognostic stratification and use of induction chemotherapy.2022European radiologyFree full text
  347. Determining the suitability of definitive radiation therapy in patients with metastatic nasopharyngeal carcinoma based on PET/CT: a large cohort study.2022European radiology
  348. Prognostic value of quantitative cervical nodal necrosis burden on MRI in nasopharyngeal carcinoma and its role as a stratification marker for induction chemotherapy.2022European radiology
  349. Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma.2022European radiologyFree full text
  350. MRI of nasopharyngeal carcinoma: parapharyngeal subspace involvement has prognostic value and influences T-staging in the IMRT era.2022European radiology
  351. The prognostic value of adding systemic inflammation response index to Epstein-Barr virus DNA in childhood nasopharyngeal carcinoma: A real-world study.2022Head & neck
  352. Definitive radiation therapy and liver local therapy in de novo liver metastatic nasopharyngeal carcinoma: Large cohort study.2022Head & neck
  353. Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: Cost-effectiveness analysis.2022Head & neck
  354. Management of first-line palliative chemotherapy for post-treatment metastasis after gemcitabine plus cisplatin induction chemotherapy: Gemcitabine plus cisplatin and non-gemcitabine plus cisplatin chemotherapy.2022Head & neck
  355. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA.2022Head & neck
  356. Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 Trial.2022International journal of radiation oncology, biology, physics
  357. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.2022JAMARCTFree full text
  358. Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020.2022JAMA network openFree full text
  359. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.2022JAMA network openFree full text
  360. Association of Intratumoral Microbiota With Prognosis in Patients With Nasopharyngeal Carcinoma From 2 Hospitals in China.2022JAMA oncologyFree full text
  361. Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma-Reply.2022JAMA oncology
  362. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Tria2022JAMA oncologyRCTFree full text
  363. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy:2022JAMA oncologyRCTFree full text
  364. Individualized clinical target volume delineation and efficacy analysis in unilateral nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT): 10-year summary.2022Journal of cancer research and clinical oncologyFree full text
  365. Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?2022Journal of cancer research and clinical oncologyFree full text
  366. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.2022Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  367. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.2022Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  368. Supplemental folic acid and/or multivitamins in pregnancy is associated with a decreased risk of childhood and adolescent nasopharyngeal carcinoma.2022Journal of developmental origins of health and disease
  369. OTUD4-mediated GSDME deubiquitination enhances radiosensitivity in nasopharyngeal carcinoma by inducing pyroptosis.2022Journal of experimental & clinical cancer research : CRFree full text
  370. Quantifying the dosimetric effects of neck contour changes and setup errors on the spinal cord in patients with nasopharyngeal carcinoma: establishing a rapid estimation method.2022Journal of radiation researchFree full text
  371. Whole-Exome Sequencing Study of Familial Nasopharyngeal Carcinoma and Its Implication for Identifying High-Risk Individuals.2022Journal of the National Cancer Institute
  372. Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties.2022Journal of virologyFree full text
  373. Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.2022Med (New York, N.Y.)
  374. STRESS granule-associated RNA-binding protein CAPRIN1 drives cancer progression and regulates treatment response in nasopharyngeal carcinoma.2022Medical oncology (Northwood, London, England)Free full text
  375. A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma.2022Nature communicationsFree full text
  376. A polygenic risk score for nasopharyngeal carcinoma shows potential for risk stratification and personalized screening.2022Nature communicationsFree full text
  377. USP44 regulates irradiation-induced DNA double-strand break repair and suppresses tumorigenesis in nasopharyngeal carcinoma.2022Nature communicationsFree full text
  378. Carotid space involvement is a prognostic factor and marker for induction chemotherapy in patients with nasopharyngeal carcinoma.2022Oral oncology
  379. Development and validation of a joint model for dynamic prediction of overall survival in nasopharyngeal carcinoma based on longitudinal post-treatment plasma cell-free Epstein-Barr virus DNA load.2022Oral oncology
  380. Cost-Effectiveness analysis of combining plasma Epstein-Barr virus DNA testing and different surveillance imaging modalities for nasopharyngeal carcinoma patients in first remission.2022Oral oncology
  381. Differential benefit of induction chemotherapy according to body mass index in nasopharyngeal carcinoma - Pooled analysis of two randomized trials.2022Oral oncology
  382. Endoscopic Nasopharyngectomy Combined With Internal Carotid Artery Pretreatment for Recurrent Nasopharyngeal Carcinoma.2022Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  383. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.2022Radiation oncology (London, England)Free full text
  384. Radiotherapy interruption due to holidays adversely affects the survival of patients with nasopharyngeal carcinoma: a joint analysis based on large-scale retrospective data and clinical trials.2022Radiation oncology (London, England)Free full text
  385. Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  386. Response to Gargi S Sarode, Sachin C Sarode, and Rahul Anand's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sp2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  387. Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  388. Longitudinal study of irradiation-induced brain functional network alterations in patients with nasopharyngeal carcinoma.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  389. Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in locally recurrent nasopharyngeal carcinoma patients.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  390. Impact of salvage radiotherapy on survival of patients with advanced locally recurrent nasopharyngeal carcinoma: Derivation and validation of a predictive model.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  391. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  392. Development of a web-based prognostic model to quantify the survival benefit of cumulative cisplatin dose during concurrent chemoradiotherapy in childhood nasopharyngeal carcinoma.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  393. Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma.2022Signal transduction and targeted therapyFree full text
  394. BCL6-SPECC1L: A Novel Fusion Gene in Nasopharyngeal Carcinoma.2022Technology in cancer research & treatmentFree full text
  395. Genomic landscape of Epstein-Barr virus in familial nasopharyngeal carcinoma.2022The Journal of general virology
  396. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma - Authors' reply.2022The Lancet. Oncology
  397. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial.2022The Lancet. OncologyRCT
  398. A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma.2022The oncologistRCTFree full text
  399. RBFOX2/GOLIM4 Splicing Axis Activates Vesicular Transport Pathway to Promote Nasopharyngeal Carcinogenesis.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  400. Heat Shock Protein 90α Provides an Effective and Novel Diagnosis Strategy for Nasopharyngeal Carcinoma.2021Advances in therapy
  401. ASO Author Reflections: Pulmonary Metastasectomy in Patients with Lung Metastases from Nasopharyngeal Carcinoma.2021Annals of surgical oncology
  402. Pulmonary Metastasectomy in Patients with Lung Metastases from Nasopharyngeal Carcinoma.2021Annals of surgical oncology
  403. Percent change in apparent diffusion coefficient and plasma EBV DNA after induction chemotherapy identifies distinct prognostic response phenotypes in advanced nasopharyngeal carcinoma.2021BMC cancerFree full text
  404. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.2021BMC cancerFree full text
  405. Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy.2021BMC cancerFree full text
  406. Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA.2021BMC medicineFree full text
  407. Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival.2021Biology of sex differencesFree full text
  408. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.2021Cancer communications (London, England)Free full text
  409. Development and validation of a web-based calculator to predict individualized conditional risk of site-specific recurrence in nasopharyngeal carcinoma: Analysis of 10,058 endemic cases.2021Cancer communications (London, England)Free full text
  410. The Evolving Epidemiology of Nasopharyngeal Carcinoma.2021Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  411. Intake of Alcohol and Tea and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China.2021Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  412. LACTB promotes metastasis of nasopharyngeal carcinoma via activation of ERBB3/EGFR-ERK signaling resulting in unfavorable patient survival.2021Cancer letters
  413. Prognostic value of radiation interruption in different periods for nasopharyngeal carcinoma patients in the intensity-modulated radiation therapy era.2021Cancer medicineFree full text
  414. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma.2021Cancer research
  415. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.2021Cancer research and treatmentFree full text
  416. Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area.2021Cancer research and treatmentFree full text
  417. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.2021Cell death & diseaseFree full text
  418. A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer.2021Clinical cancer research : an official journal of the American Association for Cancer ResearchRCTFree full text
  419. Excessive vitamin B6 during treatment is related to poor prognosis of patients with nasopharyngeal carcinoma: A U-shaped distribution suggests low dose supplement.2021Clinical nutrition (Edinburgh, Scotland)
  420. Investigation of the feasibility of synthetic MRI in the differential diagnosis of non-keratinising nasopharyngeal carcinoma and benign hyperplasia using different contoured methods for delineation of the region of interest.2021Clinical radiology
  421. Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial.2021ESMO openRCTFree full text
  422. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy.2021ESMO openFree full text
  423. Is Surgery an Inevitable Treatment for Advanced Salivary Lymphoepithelial Carcinoma? Three Case Reports.2021Ear, nose, & throat journal
  424. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.2021European journal of cancer (Oxford, England : 1990)
  425. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.2021European journal of cancer (Oxford, England : 1990)
  426. Nomogram for the prediction of primary distant metastasis of nasopharyngeal carcinoma to guide individualized application of FDG PET/CT.2021European journal of nuclear medicine and molecular imaging
  427. Low value of whole-body dual-modality [18f]fluorodeoxyglucose positron emission tomography/computed tomography in primary staging of stage I-II nasopharyngeal carcinoma: a nest case-control study.2021European radiologyFree full text
  428. Epstein-Barr virus microRNA BART10-3p promotes dedifferentiation and proliferation of nasopharyngeal carcinoma by targeting ALK7.2021Experimental biology and medicine (Maywood, N.J.)Free full text
  429. Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth.2021FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  430. Transcervical endoscopic retropharyngeal lymph node (RPLN) dissection in nasopharyngeal carcinoma with RPLN recurrence.2021Head & neck
  431. Clinicopathological and prognostic features of nasopharyngeal carcinoma in children and adolescents: A retrospective study of 196 cases in South China.2021International journal of cancer
  432. Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study.2021International journal of radiation oncology, biology, physicsFree full text
  433. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized 2021JAMA network openRCTFree full text
  434. Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma.2021JAMA network openFree full text
  435. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.2021JAMA network openFree full text
  436. Locoregional Radiotherapy in Metastatic Nasopharyngeal Cancer-Reply.2021JAMA oncology
  437. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).2021Journal for immunotherapy of cancerFree full text
  438. Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial.2021Journal for immunotherapy of cancerFree full text
  439. PD-1+CXCR5-CD4+ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma.2021Journal for immunotherapy of cancerFree full text
  440. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.2021Journal for immunotherapy of cancerFree full text
  441. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.2021Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  442. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).2021Journal of clinical oncology : official journal of the American Society of Clinical OncologyFree full text
  443. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.2021Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  444. RNA-binding motif protein RBM47 promotes tumorigenesis in nasopharyngeal carcinoma through multiple pathways.2021Journal of genetics and genomics = Yi chuan xue bao
  445. Grading Soft Tissue Involvement in Nasopharyngeal Carcinoma Using Network and Survival Analyses: A Two-Center Retrospective Study.2021Journal of magnetic resonance imaging : JMRI
  446. Prognostic Value of Nodal Matting on MRI in Nasopharyngeal Carcinoma Patients.2021Journal of magnetic resonance imaging : JMRI
  447. A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.2021Journal of the National Cancer InstituteFree full text
  448. A Prognostic Predictive System Based on Deep Learning for Locoregionally Advanced Nasopharyngeal Carcinoma.2021Journal of the National Cancer InstituteFree full text
  449. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.2021Lancet (London, England)RCT
  450. Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses.2021Molecular cancerFree full text
  451. A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinoma.2021Nature communicationsFree full text
  452. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution.2021Nature communicationsFree full text
  453. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.2021Nature medicineRCT
  454. Spatial heterogeneity of immune infiltration predicts the prognosis of nasopharyngeal carcinoma patients.2021OncoimmunologyFree full text
  455. WIPI-1 inhibits metastasis and tumour growth via the WIPI-1-TRIM21 axis and MYC regulation in nasopharyngeal carcinoma.2021Oral oncology
  456. Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma.2021Oral oncology
  457. Do all patients with locoregionally advanced nasopharyngeal carcinoma benefit from the maintenance chemotherapy using S-1/capecitabine?2021Oral oncology
  458. The impact of induction chemotherapy on long-term quality of life in patients with locoregionally advanced nasopharyngeal carcinoma: Outcomes from a randomised phase 3 trial.2021Oral oncologyRCT
  459. Radiation-induced hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy with or without chemotherapy: Development of a nomogram based on the equivalent dose.2021Oral oncology
  460. An interpretable machine learning prognostic system for locoregionally advanced nasopharyngeal carcinoma based on tumor burden features.2021Oral oncology
  461. Benefit of chemotherapy in stage III nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database.2021Oral oncology
  462. Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas.2021Oral oncology
  463. EBV latent membrane proteins promote hybrid epithelial-mesenchymal and extreme mesenchymal states of nasopharyngeal carcinoma cells for tumorigenicity.2021PLoS pathogensFree full text
  464. Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up.2021Radiation oncology (London, England)Free full text
  465. Management of suboptimal response to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Re-induction therapy or direct to Radiotherapy?2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  466. Impact of smoking on survival in nasopharyngeal carcinoma: A cohort study with 23,325 patients diagnosed from 1990 to 2016.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  467. Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  468. Extent of paranasal sinus involvement and its prognostic value in nasopharyngeal carcinoma: Proposed modification in the current UICC/AJCC staging system.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  469. Establishment and validation of a prognostic nomogram to predict early metastasis in nasopharyngeal carcinoma patients within six months after radiotherapy and to guide intensive treatment.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  470. Development and validation of a normal tissue complication probability model for acquired nasal cavity stenosis and atresia after radical radiotherapy for nasopharyngeal carcinoma.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  471. Standard radiotherapy for patients with nasopharyngeal carcinoma results in progressive tract-specific brain white matter alterations: A one-year follow-up via diffusion tensor imaging.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  472. Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  473. Normal tissue complication probability (NTCP) models for predicting temporal lobe injury after intensity-modulated radiotherapy in nasopharyngeal carcinoma: A large registry-based retrospective study from China.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  474. Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  475. Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma.2021Signal transduction and targeted therapyFree full text
  476. Construction of a comprehensive nutritional index and comparison of its prognostic performance with the PNI and NRI for survival in older patients with nasopharyngeal carcinoma: a retrospective study.2021Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  477. Multidimensional fatigue in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: incidence, severity, and risk factors.2021Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  478. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.2021The Lancet. OncologyRCT
  479. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 32021The Lancet. OncologyRCT
  480. Efficacy of Transnasal Endoscopic Fine-Needle Aspiration Biopsy in Diagnosing Submucosal Nasopharyngeal Carcinoma.2021The Laryngoscope
  481. Transoral Robotic Retropharyngeal Lymph Node Dissection in Nasopharyngeal Carcinoma With Retropharyngeal Lymph Node Recurrence.2021The Laryngoscope
  482. Association between HLA alleles and Epstein-Barr virus Zta-IgA serological status in healthy males from southern China.2021The journal of gene medicineFree full text
  483. Neoantigen landscape in metastatic nasopharyngeal carcinoma.2021TheranosticsFree full text
Chinese-language papers (not in the count)7
  1. [The advances of artificial intelligence in the diagnosis and treatment of nasopharyngeal carcinoma].2025Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [Clinical characteristics and treatment strategies of nasopharyngeal carcinoma with concurrent thyroid cancer].2025Zhonghua yi xue za zhi
  3. [Diagnostic value of apparent diffusion coefficient histograms using multiplexed sensitivity encoding diffusion-weighted imaging for distinguishing nasopharyngeal carcinoma from benign hyperplasia].2024Zhonghua yi xue za zhi
  4. [Treatment advances in locoregionally advanced nasopharyngeal carcinoma:2023 ASCO Voice of China].2023Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  5. [The consensus recommendation of surgical treatment for nasopharyngeal cancer].2023Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  6. [Retropharyngeal lymph node dissection in head and neck cancers treated with transoral robotic surgery].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. [Exploration of surgical treatment of newly untreated nasopharyngeal carcinoma].2021Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
All its trials on ClinicalTrials.gov, any status218
  1. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Lead sponsorPhase 3Start 2025-05
  2. Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal CarcinomaRecruitingNCT07528183Lead (inferred)Phase 2Start 2026-07
  3. Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal CarcinomaRecruitingNCT07567742Lead (inferred)Phase 2Start 2026-05
  4. GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.Not yet recruitingNCT07540390Lead (inferred)Phase 3Start 2026-05
  5. Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT07584499Lead (inferred)Phase 1Start 2026-05
  6. Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With ImmunotherapyRecruitingNCT07496190Lead (inferred)Phase 2Start 2026-02
  7. A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT07392320Lead (inferred)Phase 2Start 2026-02
  8. Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal CarcinomaRecruitingNCT07796789Lead (inferred)Phase 3Start 2026-09
  9. Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07362979Lead (inferred)Phase 2Start 2026-03
  10. Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07388758Lead (inferred)Phase 2Start 2026-02
  11. Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07902713Lead (inferred)Phase 2Start 2026-11
  12. LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPCRecruitingNCT07325539Lead (inferred)Phase 2Start 2026-01
  13. PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPCRecruitingNCT07235319Lead (inferred)Phase 3Start 2026-04
  14. Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal CarcinomaRecruitingNCT07661771Lead (inferred)Phase 3Start 2026-07
  15. Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II StudyNot yet recruitingNCT07756190Lead (inferred)Phase 2Start 2026-09
  16. Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07064902Lead (inferred)Phase 2Start 2026-08
  17. PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPCRecruitingNCT07332247Lead (inferred)Phase 2Start 2026-02
  18. Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal CarcinomaNot yet recruitingNCT07824856Lead (inferred)Phase 2Start 2026-10
  19. Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical TrialRecruitingNCT07101744Lead (inferred)Phase 2Start 2025-10
  20. Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRIRecruitingNCT06831357Lead (inferred)Start 2025-02
  21. Adaptive Immunotherapy for Nasopharyngeal CarcinomaRecruitingNCT07154069Lead (inferred)Phase 3Start 2025-11
  22. TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal CarcinomaRecruitingNCT06912711Lead (inferred)Phase 2Start 2025-05
  23. GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.RecruitingNCT06851247Lead (inferred)Phase 2Start 2025-01
  24. PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal CarcinomaNot yet recruitingNCT06900218Lead (inferred)Phase 3Start 2025-05
  25. EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal CarcinomaRecruitingNCT06802835Lead (inferred)Phase 1/Phase 2Start 2025-07
  26. Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal CarcinomaRecruitingNCT06912698Lead (inferred)Phase 3Start 2025-05
  27. GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal CarcinomaNot yet recruitingNCT06605131Lead (inferred)Phase 2Start 2025-04
  28. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Lead (inferred)Phase 3Start 2024-03
  29. Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal CarcinomaRecruitingNCT06445088Lead (inferred)Start 2024-05
  30. A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)RecruitingNCT06829147Lead (inferred)Start 2024-11
  31. IC Plus Low-dose Radiation Plus Cadonilimab in LANPCRecruitingNCT05941741Lead (inferred)Phase 3Start 2024-01
  32. De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06313450Lead (inferred)N/AStart 2024-03
  33. A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)RecruitingNCT06241599Lead (inferred)Phase 2/Phase 3Start 2024-02
  34. Adebrelimab and Chemoradiotherapy in High-risk LANPCRecruitingNCT06349889Lead (inferred)Phase 2Start 2024-07
  35. KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical TrialNot yet recruitingNCT06370026Lead (inferred)Early phase 1Start 2024-05
  36. Online Adaptive Radiotherapy for Nasopharyngeal CarcinomaRecruitingNCT06516133Lead (inferred)Phase 3Start 2024-05
  37. Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPCRecruitingNCT06197776Lead (inferred)Start 2024-07
  38. Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal CarcinomaRecruitingNCT06611150Lead (inferred)Phase 1Start 2024-08
  39. Individualized Elective Neck Irradiation in NPC PatientsRecruitingNCT06241612Lead (inferred)Phase 3Start 2024-04
  40. SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal CarcinomaRecruitingNCT06323239Lead (inferred)Phase 2Start 2024-07
  41. A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPCNot yet recruitingNCT05780294Lead (inferred)Phase 3Start 2023-04
  42. Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction ChemotherapyRecruitingNCT06092957Lead (inferred)Phase 3Start 2023-10
  43. Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPCRecruitingNCT05854849Lead (inferred)Phase 3Start 2023-05
  44. Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal CarcinomaRecruitingNCT05877872Lead (inferred)Phase 3Start 2023-05
  45. A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and ChemotherapyNot yet recruitingNCT05622474Lead (inferred)N/AStart 2022-11
  46. Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal CarcinomaRecruitingNCT05352321Lead (inferred)N/AStart 2022-06
  47. Umbrella Biomarker-Guided Therapy in NPCNot yet recruitingNCT04605562Lead (inferred)Phase 2Start 2022-06
  48. Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal CarcinomaRecruitingNCT05342792Lead (inferred)Phase 3Start 2022-04
  49. Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.RecruitingNCT05397769Lead (inferred)Phase 2Start 2022-06
  50. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Lead (inferred)Phase 3Start 2022-04
  51. Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma ScreeningRecruitingNCT05447169Lead (inferred)Start 2022-07
  52. An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPCNot yet recruitingNCT04890522Lead (inferred)Phase 2/Phase 3Start 2021-07
  53. Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With MalnutritionRecruitingNCT04436965Lead (inferred)Phase 3Start 2021-08
  54. Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT04944914Lead (inferred)Phase 3Start 2021-06
  55. Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPCRecruitingNCT04544969Lead (inferred)Start 2020-04
  56. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Lead (inferred)Phase 3Start 2020-03
  57. Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal CarcinomaRecruitingNCT04448522Lead (inferred)Phase 3Start 2020-08
  58. Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma.Active, not recruitingNCT06854510Lead (inferred)Phase 2/Phase 3Start 2025-02
  59. Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.Active, not recruitingNCT07201337Lead (inferred)Phase 3Start 2025-11
  60. Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06712888Lead (inferred)Phase 3Start 2025-02
  61. Artificial Intelligence-supported Reading Versus Standard Double Reading for the Interpretation of Magnetic Resonance Imaging in the Detection of Local Recurrence for Nasopharyngeal Carcinoma: a Randomised Controlled Multicenter StudyStatus unknownNCT06356441Lead (inferred)Start 2024-04
  62. Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Post-Radiotherapy in Nasopharyngeal Carcinoma: An MRI StudyActive, not recruitingNCT06881225Lead (inferred)Start 2024-01
  63. Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal CarcinomaCompletedNCT06367049Lead (inferred)Start 2023-06
  64. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Lead (inferred)Phase 3Start 2023-08
  65. Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05807880Lead (inferred)Phase 2Start 2023-09
  66. Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep LearningStatus unknownNCT06032767Lead (inferred)Start 2023-08
  67. Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal CarcinomaActive, not recruitingNCT05780372Lead (inferred)Phase 3Start 2023-08
  68. Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal CarcinomaStatus unknownNCT05913414Lead (inferred)Phase 2Start 2023-05
  69. The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving RadiotherapyStatus unknownNCT06472739Lead (inferred)Phase 2Start 2023-09
  70. Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal CarcinomaActive, not recruitingNCT05979961Lead (inferred)Phase 3Start 2023-09
  71. Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated RadiotherapyStatus unknownNCT06170021Lead (inferred)Start 2023-12
  72. Steroid-Eluting Stent Implant for the Treatment of Radiation-Related SinusitisStatus unknownNCT05757479Lead (inferred)Phase 3Start 2023-02
  73. CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPCStatus unknownNCT05724355Lead (inferred)Phase 2Start 2022-09
  74. Ovarian Function of Nasopharyngeal Carcinoma Women SurvivorsStatus unknownNCT05183724Lead (inferred)Start 2022-01
  75. Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nutritional InterventionCompletedNCT05834712Lead (inferred)N/AStart 2022-05
  76. Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal CarcinomaStatus unknownNCT05431764Lead (inferred)Phase 2Start 2022-06
  77. Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC PatientsCompletedNCT05389306Lead (inferred)N/AStart 2022-05
  78. SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05524168Lead (inferred)Phase 2Start 2022-11
  79. PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT05341193Lead (inferred)Phase 1/Phase 2Start 2022-04
  80. Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled TrialActive, not recruitingNCT05531916Lead (inferred)N/AStart 2022-11
  81. Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal CarcinomaActive, not recruitingNCT05201859Lead (inferred)Phase 2Start 2022-05
  82. G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05222009Lead (inferred)Phase 1Start 2022-01
  83. Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPCStatus unknownNCT05549466Lead (inferred)Phase 2Start 2022-10
  84. Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter StudyStatus unknownNCT05417139Lead (inferred)Phase 2Start 2022-07
  85. Olfactory Change After Chemo-radiotherapy for Nasopharyngeal CarcinomaStatus unknownNCT05146050Lead (inferred)Start 2021-12
  86. Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPCCompletedNCT04833257Lead (inferred)Phase 2Start 2021-04
  87. Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation StudyStatus unknownNCT04850235Lead (inferred)Phase 1Start 2021-04
  88. Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical StudyStatus unknownNCT05008471Lead (inferred)N/AStart 2021-04
  89. Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)CompletedNCT04996758Lead (inferred)Phase 2Start 2021-10
  90. Verification of Harmonization of Plasma Epstein-Barr Virus DNA MeasurementsStatus unknownNCT05037357Lead (inferred)Start 2021-08
  91. Deep Learning Model for Diagnosis and Contour of Cervical Lymph Node for Nasopharyngeal CarcinomaStatus unknownNCT05231616Lead (inferred)Start 2021-01
  92. Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma PatientsStatus unknownNCT04394091Lead (inferred)Start 2020-05
  93. Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment FailureStatus unknownNCT04586088Lead (inferred)Phase 2Start 2020-05
  94. EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)Status unknownNCT04072107Lead (inferred)Phase 2Start 2020-06
  95. Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04547088Lead (inferred)Phase 2Start 2020-09
  96. Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04548271Lead (inferred)Phase 2Start 2020-09
  97. Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal CarcinomaCompletedNCT04636632Lead (inferred)Phase 1Start 2020-11
  98. Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal CarcinomaActive, not recruitingNCT03930498Lead (inferred)Phase 2Start 2020-03
  99. uEXPLORER Total-body PET/CT in Nasopharyngeal CarcinomaCompletedNCT04394065Lead (inferred)Start 2020-06
  100. Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal CarcinomaStatus unknownNCT03837808Lead (inferred)Phase 3Start 2019-04
  101. Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma PatientsStatus unknownNCT03855020Lead (inferred)Start 2019-05
  102. Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal CarcinomaStatus unknownNCT04764149Lead (inferred)Start 2019-11
  103. Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04472403Lead (inferred)Start 2019-11
  104. Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal CarcinomaCompletedNCT04108338Lead (inferred)Start 2019-06
  105. PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03619824Lead (inferred)Phase 2Start 2019-01
  106. IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.Status unknownNCT03854838Lead (inferred)Phase 2Start 2019-05
  107. Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.Status unknownNCT04073784Lead (inferred)Phase 1Start 2019-06
  108. GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT03840421Lead (inferred)Phase 3Start 2019-04
  109. Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04398056Lead (inferred)Phase 2Start 2019-04
  110. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03427827Lead (inferred)Phase 3Start 2018-07
  111. Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma PatientsStatus unknownNCT03290820Lead (inferred)Phase 2Start 2018-01
  112. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Lead (inferred)Phase 3Start 2018-12
  113. Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal CarcinomaStatus unknownNCT03344068Lead (inferred)Phase 2/Phase 3Start 2018-01
  114. Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma PatientsCompletedNCT03387774Lead (inferred)Phase 3Start 2018-01
  115. Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPCCompletedNCT03601390Lead (inferred)Start 2018-10
  116. Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPCStatus unknownNCT03503136Lead (inferred)Phase 3Start 2018-06
  117. The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC PatientsCompletedNCT03240835Lead (inferred)Start 2017-09
  118. A Study of Nasopharyngeal Carcinoma From GuangdongStatus unknownNCT03003182Lead (inferred)Start 2017-05
  119. Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC PatientsCompletedNCT02973386Lead (inferred)Phase 3Start 2017-01
  120. Prospective Study for Prognostic Biomarkers of Nasopharyngeal CarcinomaStatus unknownNCT03025854Lead (inferred)Start 2017-01
  121. Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal CarcinomaStatus unknownNCT03093649Lead (inferred)N/AStart 2017-07
  122. A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.Status unknownNCT03210389Lead (inferred)Phase 2Start 2017-07
  123. The Influence of Anxiety and Depression on Survival in Nasopharyngeal Carcinoma PatientsStatus unknownNCT03290001Lead (inferred)Start 2017-08
  124. Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT03047265Lead (inferred)Phase 2Start 2017-02
  125. Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal TissueStatus unknownNCT03048305Lead (inferred)Start 2017-02
  126. Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02958111Lead (inferred)Phase 3Start 2017-01
  127. To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal CarcinomaStatus unknownNCT03346109Lead (inferred)N/AStart 2017-11
  128. Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal CarcinomaStatus unknownNCT03321539Lead (inferred)Phase 3Start 2017-10
  129. Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by ChemoradiotherapyStatus unknownNCT03045484Lead (inferred)N/AStart 2016-05
  130. Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02786641Lead (inferred)Phase 3Start 2016-08
  131. Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRTStatus unknownNCT02735317Lead (inferred)Phase 2Start 2016-04
  132. Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal CarcinomaStatus unknownNCT02610556Lead (inferred)Phase 2Start 2016-01
  133. A Study of DC-CIK Immunotherapy in the Treatment of Solid TumorsStatus unknownNCT04476641Lead (inferred)Phase 2Start 2016-05
  134. Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal CarcinomaStatus unknownNCT02621970Lead (inferred)Phase 3Start 2016-01
  135. Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02871518Lead (inferred)Phase 2Start 2016-08
  136. Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRTStatus unknownNCT02729324Lead (inferred)Phase 2Start 2016-04
  137. Individualized Elective Neck Irradiation Based on MRI in NPC PatientsCompletedNCT02642107Lead (inferred)Phase 3Start 2016-01
  138. A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPCStatus unknownNCT02590133Lead (inferred)Phase 2Start 2015-07
  139. Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal CarcinomaStatus unknownNCT02627807Lead (inferred)N/AStart 2015-12
  140. Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal CarcinomaStatus unknownNCT02610010Lead (inferred)Phase 3Start 2015-11
  141. Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC PatientsCompletedNCT02575547Lead (inferred)Start 2015-06
  142. Endostar for Locally Recurrent Nasopharyngeal CarcinomaStatus unknownNCT02636231Lead (inferred)Phase 2Start 2015-11
  143. Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated RadiotherapyWithdrawnNCT02289807Lead (inferred)N/AStart 2015-03
  144. The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRTActive, not recruitingNCT02460887Lead (inferred)Phase 3Start 2015-06
  145. Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy EraCompletedNCT02633202Lead (inferred)Phase 3Start 2015-11
  146. Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.Status unknownNCT02456506Lead (inferred)N/AStart 2015-06
  147. Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal CarcinomaStatus unknownNCT02211677Lead (inferred)Start 2014-08
  148. EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) PatientsStatus unknownNCT03006588Lead (inferred)Phase 2/Phase 3Start 2014-01
  149. Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical TrialCompletedNCT02143388Lead (inferred)Phase 3Start 2014-03
  150. Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02111460Lead (inferred)Phase 3Start 2013-10
  151. Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPCStatus unknownNCT01854203Lead (inferred)Phase 2/Phase 3Start 2013-07
  152. Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral MucositisStatus unknownNCT01806272Lead (inferred)Phase 2Start 2013-03
  153. Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing StrategyStatus unknownNCT01891123Lead (inferred)N/AStart 2013-06
  154. Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT01872962Lead (inferred)Phase 3Start 2013-11
  155. Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal CarcinomaCompletedNCT01616849Lead (inferred)Phase 2Start 2012-05
  156. Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal CarcinomaStatus unknownNCT01735409Lead (inferred)Phase 1/Phase 2Start 2012-11
  157. GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT01655628Lead (inferred)Phase 2Start 2012-07
  158. Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal CarcinomaCompletedNCT01540136Lead (inferred)Phase 3Start 2012-02
  159. Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT01245959Lead (inferred)Phase 3Start 2011-01
  160. Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal CarcinomaCompletedNCT01271439Lead (inferred)Phase 2Start 2010-09
  161. A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT00705627Lead (inferred)Phase 3Start 2008-06
  162. Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With ChemoradiotherapyCompletedNCT00700440Lead (inferred)Phase 2Start 2008-07
  163. Trial of E10A in Head and Neck CancerStatus unknownNCT00634595Lead (inferred)Phase 2Start 2008-03
  164. Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal CarcinomaCompletedNCT02360501Lead (inferred)Phase 2Start 2008-01
  165. Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT00677118Lead (inferred)Phase 3Start 2006-06
  166. Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma PatientsCompletedNCT03839602Lead (inferred)Phase 2Start 2001-05
  167. Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRTCompletedNCT03283293Lead (inferred)Phase 2Start 2001-02
  168. A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)Not yet recruitingNCT07783321Study sitePhase 3Start 2026-09
  169. A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07797881Study sitePhase 2Start 2026-09
  170. A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid TumorsNot yet recruitingNCT07818486Study sitePhase 1/Phase 2Start 2026-09
  171. A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaRecruitingNCT06976190Study sitePhase 3Start 2025-05
  172. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  173. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyRecruitingNCT07328841Study sitePhase 3Start 2025-11
  174. Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal CavityNot yet recruitingNCT07072000Study sitePhase 3Start 2025-08
  175. Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingNCT07070479Study sitePhase 2Start 2025-06
  176. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  177. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  178. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04
  179. A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT06475300Study sitePhase 2Start 2024-06
  180. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  181. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Study siteStart 2024-04
  182. TPC Versus GP Induction Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06301165Study sitePhase 2Start 2024-03
  183. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid TumorRecruitingNCT05194982Study sitePhase 1Start 2021-11
  184. Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal CarcinomaRecruitingNCT04778956Study sitePhase 3Start 2021-03
  185. To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal CarcinomaRecruitingNCT04547673Study siteStart 2020-06
  186. Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT04453826Study sitePhase 3Start 2020-09
  187. Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal CarcinomaRecruitingNCT04453813Study sitePhase 3Start 2020-07
  188. Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal CarcinomaRecruitingNCT04425265Study siteN/AStart 2020-06
  189. Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma PatientsRecruitingNCT03353467Study siteN/AStart 2017-10
  190. A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)Active, not recruitingNCT06629597Study sitePhase 3Start 2024-12
  191. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  192. A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal CarcinomaCompletedNCT05864924Study sitePhase 1Start 2023-05
  193. A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)Active, not recruitingNCT06118333Study sitePhase 3Start 2023-12
  194. Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPCStatus unknownNCT05513573Study sitePhase 2Start 2022-12
  195. TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaCompletedNCT05563480Study sitePhase 2Start 2022-10
  196. A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal CarcinomaCompletedNCT05751486Study sitePhase 1Start 2022-11
  197. A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal CarcinomaStatus unknownNCT05576272Study sitePhase 2/Phase 3Start 2022-05
  198. Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04955886Study sitePhase 2Start 2021-08
  199. SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05020925Study sitePhase 1/Phase 2Start 2021-09
  200. A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal CarcinomaCompletedNCT04895345Study sitePhase 2Start 2021-06
  201. IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPCCompletedNCT04945421Study sitePhase 1Start 2021-07
  202. Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic ImagesStatus unknownNCT05202626Study siteStart 2021-12
  203. A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal NecrosisStatus unknownNCT05228093Study siteN/AStart 2021-11
  204. SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04282070Study sitePhase 1Start 2020-03
  205. A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal CarcinomaCompletedNCT04220307Study sitePhase 2Start 2020-04
  206. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
  207. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  208. Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid StenosisSuspendedNCT02022293Study sitePhase 2Start 2017-01
  209. ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following RadiotherapyTerminatedNCT02874651Study sitePhase 2Start 2016-10
  210. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  211. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02633176Study sitePhase 3Start 2015-01
  212. A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal CarcinomaStatus unknownNCT02512315Study sitePhase 3Start 2015-08
  213. Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in ChinaCompletedNCT02586532Study siteStart 2015-10
  214. Early Use of Opioid in Radiation MucositisCompletedNCT02309437Study sitePhase 2Start 2015-01
  215. Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNAActive, not recruitingNCT02135042Study sitePhase 2/Phase 3Start 2014-07
  216. A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine RegimensStatus unknownNCT01762514Study sitePhase 2Start 2013-01
  217. The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRTStatus unknownNCT01817023Study sitePhase 3Start 2013-04
  218. The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal CarcinomaCompletedNCT01187238Study sitePhase 2Start 2010-05
More papers found outside PubMed (not counted)286
  1. 1321O Concurrent chemoradiotherapy with/without adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A randomized controlled phase III trial2025Annals of Oncologyarticle
  2. 1356P Anti-angiogenic drugs reverse immune resistance in recurrent/metastatic nasopharyngeal carcinoma: A real-world study2025Annals of Oncologyarticle
  3. 1370P Long-term outcomes of paclitaxel, cisplatin, and capecitabine vs. cisplatin and fluorouracil as induction chemotherapy in nasopharyngeal carcinoma: A multicenter randomized clinical trial2025Annals of Oncologyarticle
  4. 1371P Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial2025Annals of Oncologyarticle
  5. 1377P TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial2025Annals of Oncologyarticle
  6. 1378P Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial2025Annals of Oncologyarticle
  7. 1380P Establishment and validation of a recursive partitioning analysis prognosis model to identify beneficiaries of metronomic capecitabine adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma2025Annals of Oncologyarticle
  8. 1381P Defining the optimal number of cycles of adjuvant treatment for metastatic nasopharyngeal carcinoma2025Annals of Oncologyarticle
  9. 1390P Updated long term efficacy results of phase II study for becotatug vedotin combined with pucotenlimab in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)2025Annals of Oncologyarticle
  10. 1413P DDAH1 promotes cisplatin chemoresistance in patients with locally advanced nasopharyngeal carcinoma via the EGFR-JAK2-STAT3 pathway2025Annals of Oncologyarticle
  11. 199eP A metabolic subtype classifier for guiding personalized immunotherapy strategies in nasopharyngeal carcinoma: Biomarker analysis of two phase III trials2025Annals of Oncologyarticle
  12. 434 Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study2025Journal for ImmunoTherapy of Cancerconference-abstract
  13. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncologyarticle
  14. 670MO Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor–refractory recurrent or metastatic nasopharyngeal carcinoma: A single-arm, open-label, phase II trial2025Annals of Oncologyarticle
  15. 671MO Long-term outcomes of reduced-dose radiotherapy in patients with epstein-barr virus DNA-selected stage III nasopharyngeal carcinoma: A 5-year follow-up secondary analysis of a phase II trial2025Annals of Oncologyarticle
  16. 672MO Efficacy of immunotherapy rechallenge in locoregionally advanced nasopharyngeal carcinoma after progression on prior immunotherapy: A real-word analysis2025Annals of Oncologyarticle
  17. 673MO Optimizing induction chemotherapy cycles in locally advanced nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis2025Annals of Oncologyarticle
  18. 697P Who may omit locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A failure-pattern–based strategy in the immunotherapy era2025Annals of Oncologyarticle
  19. 701P Development of an interpretable machine learning-based prediction model for long-term dysphagia following intensity-modulated radiotherapy in nasopharyngeal carcinoma2025Annals of Oncologyarticle
  20. 703P Prognostic value of pre-treatment PET/CT parameters and serum metabolomic profiles in locally advanced nasopharyngeal carcinoma2025Annals of Oncologyarticle
  21. 704P Presentation delay, lnitial symptoms, and tumor growth rate influence survival in non-metastatic nasopharyngeal carcinoma2025Annals of Oncologyarticle
  22. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncologyarticle
  23. 837P Digital-based weight management during radiotherapy in locoregionally advanced nasopharyngeal carcinoma2025Annals of Oncologyarticle
  24. A Deep-Learning Model Integrating Multi-Modality Data for Predicting the Recurrence of Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  25. A Novel Mamba-Based 3D Dose Prediction Model with Channel-Aware Scan for Nasopharyngeal Carcinoma Radiotherapy2025International Journal of Radiation Oncology*Biology*Physicsarticle
  26. A prospective randomized controlled study about oral nutrition supplement in local advanced nasopharyngeal carcinoma patients: An update of long-term survival.2025Journal of Clinical Oncologyarticle
  27. AI-Enhanced Automated Planning System for Online Adaptive Radiotherapy in Nasopharyngeal Carcinoma: Development and Prospective Clinical Validation2025International Journal of Radiation Oncology*Biology*Physicsarticle
  28. ASO Visual Abstract: Endoscopic Transoropharyngeal Retropharyngeal Lymph Node (RPLN) Dissection for RPLN Recurrence Nasopharyngeal Carcinoma2025Annals of Surgical Oncologyarticle
  29. Abstract 1106: RNA-based risk model for nasopharyngeal carcinoma distant metastasis2025Cancer Researchconference-abstract
  30. Abstract 211: Epstein-Barr virus (EBV)‒human host chromatin interactions rearrange spatial DNA genome organisation and hijack KDM5B to distant metastasis proneness in EBV-associated nasopharyngeal carcinoma (NPC)2025Cancer Researchconference-abstract
  31. Abstract 4686: Efficacy and safety of efbemalenograstim alfa as primary prophylaxisfor concurrent chemo-radiotherapy induced neutropenia2025Cancer Researchconference-abstract
  32. Abstract 5288: Identification of cancer cells with metastatic potential in nasopharyngeal carcinoma through spatial multi-omics analysis2025Cancer Researchconference-abstract
  33. Abstract 6035: The role of EBV+ nasopharyngeal carcinoma in shaping double-negative B cells to form a pro-metastatic niche2025Cancer Researchconference-abstract
  34. Anti-programmed death-1 inhibitors and nimotuzumab in combination with induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.2025Journal of Clinical Oncologyconference-abstract
  35. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncologyarticle
  36. CACA guidelines for holistic integrative management of adolescent and childhood nasopharyngeal carcinoma2025Holistic Integrative Oncologyarticle
  37. Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.2025Journal of Clinical Oncologyconference-abstract
  38. Combined Liquid Biopsy of On-Treatment Plasma Epstein-Barr Virus DNA with Clinical Stage to Guide Induction Chemotherapy Cycles in Locally Advanced Nasopharyngeal Carcinoma Patients: A Multicenter Development and Validation Study2025International Journal of Radiation Oncology*Biology*Physicsarticle
  39. Concurrent chemoradiotherapy with or without nimotuzumab in induction chemotherapy resistant locoregionally advanced nasopharyngeal carcinoma: An open-label randomised, controlled, phase 2 trial.2025Journal of Clinical Oncologyconference-abstract
  40. Cone Beam Computed Tomography (CBCT)-Based Imaging Tracking of Primary Tumor, Lymph Nodes, and Parotid Glands in Nasopharyngeal Carcinoma (NPC) for Tailored Treatment Strategy and Functional Preservation2025International Journal of Radiation Oncology*Biology*Physicsarticle
  41. DIAGNOSTIC VALUE OF CONVENTIONAL ULTRASOUND FOR SMALL NECK NODE METASTASIS IN NASOPHARYNGEAL CARCINOMA2025Ultrasound in Medicine & Biologyarticle
  42. Database for high-risk nasopharyngeal carcinoma treated with chemoradiotherapy and immunotherapy2025DRYADdataset
  43. Development and Performance Evaluation of an LLM-Based Automated Recommendation System for Radiotherapy Treatment Planning2025International Journal of Radiation Oncology*Biology*Physicsarticle
  44. Development and Prospective Validation of a Fully AI-Driven Online Adaptive Radiotherapy Workflow2025International Journal of Radiation Oncology*Biology*Physicsarticle
  45. Dosimetric Benefits of Adaptive Radiotherapy for Nasopharyngeal Carcinoma: A Weekly FBCT-Based Dose Accumulation Study2025International Journal of Radiation Oncology*Biology*Physicsarticle
  46. Dynamic circulating tumor DNA-driven, risk-adapted systematic therapy in nasopharyngeal carcinoma: The EP-STAR trial.2025Journal of Clinical Oncologyconference-abstract
  47. Effect of induction chemo-immunotherapy on the chance for re-irradiation in high-risk recurrent nasopharyngeal carcinoma: A prospective, single-arm, phase II trial.2025Journal of Clinical Oncologyconference-abstract
  48. Efficacy and safety of induction chemoimmunotherapy versus induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A meta-analysis.2025Journal of Clinical Oncologyarticle
  49. Electronic patient-reported outcome-based weight management versus usual care during induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: A phase II randomized controlled trial.2025Journal of Clinical Oncologyconference-abstract
  50. Establishment and validation of a dynamic prognostic model using serial circulating tumor DNA (ctDNA) for endemic EBV-related nasopharyngeal carcinoma (NPC): A secondary analysis of EP-SEASON.2025Journal of Clinical Oncologyconference-abstract
  51. Financial toxicity status and influencing factors in 1,108 nasopharyngeal carcinoma patients: A cross-sectional study2025Research Squarepreprint
  52. From immune architecture to clinical decision: Insights into the TLS‐based RNA model for metastatic risk in nasopharyngeal carcinoma2025Clinical and Translational Discoveryarticle
  53. Immunotherapy for Nasopharyngeal Carcinoma: Advances, Challenges, and Future Directions2025Venue not listedpreprint
  54. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncologyconference-abstract
  55. Multimodal Large Model for Automated Delineation of Primary Gross Tumor Volume in Nasopharyngeal Carcinoma Radiotherapy: A Pilot Study2025International Journal of Radiation Oncology*Biology*Physicsarticle
  56. Novel genetic algorithm‐based individual treatment effect scoring model for optimizing decision‐making: Induction chemotherapy in nasopharyngeal carcinoma2025Open Research (University of Surrey)article
  57. Omission of concurrent chemotherapy in and out of a phase III randomized controlled trial for stage II nasopharyngeal carcinoma.2025Journal of Clinical Oncologyconference-abstract
  58. Optimal maintenance therapy strategy for metastatic nasopharyngeal carcinoma: Insights from a cohort study in an endemic region.2025Journal of Clinical Oncologyconference-abstract
  59. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncologyarticle
  60. Post‑irradiation mastoid mucosa disease in patients with nasopharyngeal carcinoma after radiotherapy: A large‑cohort and long‑term study2025Oncology Lettersarticle
  61. Prior Knowledge-Guided Deep Learning Segmentation Algorithm for Online Adaptive Radiotherapy in Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  62. Prognostic Value of Serum Lambda Free Light Chains in Nasopharyngeal Carcinoma2025Research Squarepreprint
  63. Radiotherapy plus nimotuzumab versus cisplatin in low-risk locoregionally advanced nasopharyngeal carcinoma who had favorable response to induction chemotherapy: A randomised, phase III, non-inferiority trial.2025Journal of Clinical Oncologyconference-abstract
  64. Recent advances in refinement of the NPC TNM staging system2025Holistic Integrative Oncologyarticle
  65. Small Molecule G07 Exhibits Dual Effects on Cell Motility by Enhancing Skin Wound Healing and Inhibiting Nasopharyngeal Carcinoma Metastasis2025International Journal of Radiation Oncology*Biology*Physicsarticle
  66. Synthetic Contrast-Enhanced CT Generation Based on Generative Adversarial Networks for Lymph Node Delineation in Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  67. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncologyconference-abstract
  68. The Immunoradiotherapy in Nasopharyngeal Carcinoma2025Springer eBooksbook-chapter
  69. Tracking circulating tumor DNA through liquid biopsy after radiotherapy for dynamic risk monitoring in cancer patients.2025Journal of Clinical Oncologyconference-abstract
  70. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncologyconference-abstract
  71. Use of early EBV DNA clearance to select optimal induction chemotherapy cycles for locoregional advanced nasopharyngeal carcinoma.2025Journal of Clinical Oncologyconference-abstract
  72. Validation and Development of a Refined M1 Category for Nasopharyngeal Carcinoma Based on the Ninth-Version of AJCC/UICC TNM Staging System in the Immunotherapy Era: A Multicenter Cohort Study2025International Journal of Radiation Oncology*Biology*Physicsarticle
  73. WITHDRAWN: 1402P Development of an interpretable machine learning-based prediction model for long-term dysphagia following intensity-modulated radiotherapy in nasopharyngeal carcinoma2025Annals of Oncologyretraction
  74. 1498 Safety, tolerability and preliminary efficacy of QLP2117, a novel CCR8 antibody, in patients with advanced solid tumors: results from a dose-escalation phase 1a clinical trial2024Journal for ImmunoTherapy of Cancerconference-abstract
  75. 153P Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study2024Immuno-Oncology Technologyarticle
  76. 402O Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)2024Annals of Oncologyarticle
  77. 407MO Capecitabine combined with PD-1 antibody as maintenance therapy after first-line treatment of recurrent or metastatic nasopharyngeal carcinoma: A propensity score matching study2024Annals of Oncologyarticle
  78. 408MO Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma2024Annals of Oncologyarticle
  79. 420P Pretreatment 18F-FDG PET-CT parameters can predict survival in patients with de novo metastatic nasopharyngeal carcinoma receiving chemotherapy combination anti-programmed death-1 immunotherapy2024Annals of Oncologyarticle
  80. 435P Efficacy and toxicity of different adjuvant chemotherapy administration methods and regimens in locoregionally advanced nasopharyngeal carcinoma2024Annals of Oncologyarticle
  81. 888P Comparing paclitaxel plus cisplatin versus cisplatin in concurrent chemoradiotherapy for stage IV locoregionally advanced nasopharyngeal carcinoma: A phase II randomized trial2024Annals of Oncologyarticle
  82. 892P Camrelizumab plus dalpiciclib in anti-PD-1 refractory recurrent or metastatic nasopharyngeal carcinoma2024Annals of Oncologyarticle
  83. 893P Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial2024Annals of Oncologyarticle
  84. Abstract 1109: LINC01770 stabilizes TEAD1 expression to mediates nasopharyngeal cancer radiation resistance rendering tumor cells vulnerable to ferroptosis2024Cancer Researchconference-abstract
  85. Abstract 1113: USP18 impairs the sensitivity of radiotherapy for nasopharyngeal carcinoma by promoting the ubiquitination and nuclear translocation of TRIM292024Cancer Researchconference-abstract
  86. Abstract 1999: DCAF7 acts as a scaffold to recruit USP10 for G3BP1 deubiquitylation and facilitates chemoresistance and metastasis in nasopharyngeal carcinoma2024Cancer Researchconference-abstract
  87. Abstract 3272: PJA1 inhibits docetaxel-induced pyroptosis and results in chemoresistance in nasopharyngeal carcinoma2024Cancer Researchconference-abstract
  88. Abstract 4025: A phase II trial of neoadjuvant gemcitabine, cisplatin plus tislelizumab followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Clinical efficacy, safety and the biomarker analysis2024Cancer Researchconference-abstract
  89. Abstract 4456: De novo pyrimidine synthesis is a druggable vulnerability for chemotherapy resistant nasopharyngeal carcinoma with wild type IDH12024Cancer Researchconference-abstract
  90. Abstract CT113: A dose-exploring, randomized, open-label, Phase I study for toripalimab subcutaneous injection in patients with advanced nasopharyngeal carcinoma2024Cancer Researchconference-abstract
  91. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Researchconference-abstract
  92. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncologyconference-abstract
  93. Advances in basic and translational research into nasopharyngeal carcinoma2024Oncology and Translational Medicinearticle
  94. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncologyconference-abstract
  95. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncologyconference-abstract
  96. Association between heavy metal concentrations and chemotherapy-related acute adverse events in the patients with nasopharyngeal carcinoma: A prospective, longitudinal, observational study.2024Journal of Clinical Oncologyconference-abstract
  97. Changing Nasopharyngeal Carcinoma Survival in Southern China during 2000-2015: Results of a Retrospective Cohort Study2024Journal of Biosciences and Medicinesarticle
  98. Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1 resistant recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II clinical trial2024Research Squarepreprint
  99. DEEP LEARNING BASED SYNTHETIC CT GENERATED FROM MRI FOR DOSE CALCULATION IN CARBON ION RADIOTHERAPY OF NASOPHARYNGEAL CARCINOMA2024International Journal of Particle Therapyarticle
  100. Delineation of Tumor Metabolic Volume in Nasopharyngeal Carcinoma on Computed Tomography Images Using a 3D U-Net Model2024International Journal of Radiation Oncology*Biology*Physicsarticle
  101. Domain knowledge-driven encoder–decoder for nasopharyngeal carcinoma segmentation2024Expert Systems with Applicationsarticle
  102. Dosimetric Benefit of Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  103. First implementation of artificial intelligence empowered all-in-one radiotherapy workflow for nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  104. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncologyconference-abstract
  105. Frequent Copy Gains of Viral LMP-1 Confers Radiosensitivity in Natural-Killer/T Cell Lymphoma2024Bloodconference-abstract
  106. From data to decisions: Big data and AI are shaping the future of radiotherapy and individualized treatment of nasopharyngeal carcinoma2024Intelligent Oncologyeditorial
  107. Gemcitabine and cisplatin chemotherapy plus penpulimab combined with or without anlotinib as neoadjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A prospective, phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  108. Guard 01: A randomized, multicentre, controlled trail on the prophylactic use of efbemalenograstim alfa for concurrent chemo-radiotherapy induced neutropenia.2024Journal of Clinical Oncologyconference-abstract
  109. High extracellular matrix stiffness promotes the metastasis of nasopharyngeal carcinoma through STAT3/FGF1 positive feedback regulation activated by JAK22024Precision medicine and engineering.article
  110. Induction-concurrent versus concurrent-adjuvant chemoradiotherapy in patients with high-risk N2–3 nasopharyngeal carcinoma: An open-label, randomised, controlled, phase 3 trial.2024Journal of Clinical Oncologyconference-abstract
  111. Inspiring art pieces and legendary stories for cancer patients and medical staff: experience from a single institution2024Visualized Cancer Medicinearticle
  112. Joint Segmentation of Primary Nasopharyngeal Carcinoma Tumors and Lymph Nodes via Global Attention2024IEEE International Conference on Bioinformatics and Biomedicine (BIBM)conference-paper
  113. Longitudinal MRI monitoring of negative lymph node identifies prognostic diversity and therapeutic implications in nasopharyngeal carcinoma2024Research Squarepreprint
  114. Longitudinal tracing of on-treatment plasma Epstein-Barr virus DNA as a biomarker for real-time dynamic risk monitoring in patients with nasopharyngeal carcinoma: The EP-SEASON study.2024Journal of Clinical Oncologyconference-abstract
  115. Multi-Sequence Fusion Network via Single- Sequence CycleGANs for Improved Synthetic CT in Nasopharyngeal Carcinoma Treatment Planning2024IEEE Accessarticle
  116. Nature History, Presenting Symptoms, and Diagnosis of Nasopharyngeal Carcinoma2024Medical radiologybook-chapter
  117. Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial.2024Journal of Clinical Oncologyconference-abstract
  118. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  119. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncologyconference-abstract
  120. Optimal Target-Specific PTV Margins for Nasopharyngeal Carcinoma Radiotherapy with Daily FBCT Guidance2024International Journal of Radiation Oncology*Biology*Physicsarticle
  121. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  122. Pathogenesis and Etiology of Nasopharyngeal Carcinoma2024Medical radiologybook-chapter
  123. Prediction of cervical lymph nodes recurrence after radiotherapy for early nasopharyngeal carcinoma via unsupervised diagnostic feature learning and supervised ensemble classifier learning2024Biomedical Signal Processing and Controlarticle
  124. Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.2024Journal of Clinical Oncologyconference-abstract
  125. Prognostic Value of Parapharyngeal Involvement Subclassifications Divided by Parapharyngeal Muscles in Nasopharyngeal Carcinoma: A Study of 1752 Patients from Two Centers2024Research Squarepreprint
  126. Prognostic and immunological significance of tertiary lymphoid structures in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  127. Radiotherapy Target Volume Delineation Based on Post-Induction Chemotherapy Gross Tumor Volume vs. Pre-Induction Volume for Locoregionally Advanced Nasopharyngeal Carcinoma: An Open-label, Non-Inferiority, Multicenter, Randomized Phase III 2024International Journal of Radiation Oncology*Biology*Physicsarticle
  128. Radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy in patients with low-risk nasopharyngeal carcinoma: Updated results from a multicenter, open-label, non-inferiority, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  129. Safety and efficacy of iparomlimab and tuvonralimab in combination with gemcitabine and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 trial (DUBHE-N-2024Journal of Clinical Oncologyconference-abstract
  130. Supplementary Materials and Methods from Optimization and Local Cost-Effectiveness of Nasopharyngeal Carcinoma Screening Strategies in Southern China: Secondary Analysis of the Guangdong Randomized Trial2024Venue not listedsupplementary-materials
  131. Synthesis of New Fluorinated Tubastatin A Derivatives Based on Cyclopentane/Cyclohexane with Good Anti‐tumor Activity in Vitro2024ChemistrySelectarticle
  132. Synthesis of New Nifuroxazide Derivatives Based on Nitropyrrole Skeleton with Good Antitumor Activity in Vitro2024ChemistrySelectarticle
  133. The Process of the Execution of Intensity-Modulated Radiation Therapy for Nasopharyngeal Carcinoma2024Medical radiologybook-chapter
  134. The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial.2024Journal of Clinical Oncologyconference-abstract
  135. The prognostic value of deep learning-based percentage of tumour-infiltrating lymphocytes in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  136. Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomiz2024Journal of Clinical Oncologyconference-abstract
  137. Unified Prompt-Visual Interactive Segmentation of Clinical Target Volume in CT for Nasopharyngeal Carcinoma with Prior Anatomical Information2024Lecture notes in computer scienceconference-paper
  138. 356O Construction of an immune-related adverse events prediction model for teripulimab in the treatment of recurrent metastatic nasopharyngeal carcinoma and its analysis with survival prognosis2023Annals of Oncologyarticle
  139. 357MO Comparison of long-term quality of life between survivors of adolescent and adult nasopharyngeal carcinoma2023Annals of Oncologyarticle
  140. 359MO Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma2023Annals of Oncologyarticle
  141. 67MO Neoadjuvant and adjuvant toripalimab in high-risk locoregionally advanced nasopharyngeal carcinoma: A randomised, double-blind, placebo-controlled, phase II trial2023Immuno-Oncology Technologyarticle
  142. 718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies2023Journal for ImmunoTherapy of Cancerconference-abstract
  143. 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma2023Annals of Oncologyarticle
  144. 912P Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study2023Annals of Oncologyarticle
  145. 913P Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up2023Annals of Oncologyarticle
  146. 916P Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma2023Annals of Oncologyarticle
  147. 917P Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy2023Annals of Oncologyarticle
  148. 920P Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial2023Annals of Oncologyarticle
  149. 964 Single-cell spatial characterization of microenvironmental impacts on immunotherapy discrepancies between adult and pediatric nasopharyngeal carcinoma patients2023Journal for ImmunoTherapy of Cancerconference-abstract
  150. A Feasible Study for Auto Planning and Auto Re-Planning for Nasopharyngeal Carcinoma (NPC) Adaptive Radiation Therapy (ART)2023International Journal of Radiation Oncology*Biology*Physicsarticle
  151. A Novel Unsupervised MRI Synthetic CT Image Generation Framework with Registration Network2023Computers, materials & continua/Computers, materials & continua (Print)article
  152. A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).2023Journal of Clinical Oncologyconference-abstract
  153. Abstract 4450: SOX4 promotes tumor development and immune evasion via disruption of zinc homeostasis between nasopharyngeal carcinoma cells and T cells2023Cancer Researchconference-abstract
  154. Abstract PR002: Single-cell spatial analysis reveals microenvironmental features that contribute to immune discrepancies between adult and pediatric nasopharyngeal carcinomas2023Molecular Cancer Therapeuticsconference-abstract
  155. Additional file 1 of Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison2023Figsharearticle
  156. Additional file 2 of Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison2023Figsharearticle
  157. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figsharedataset
  158. Adverse prognosis of nasopharyngeal carcinoma following long-term exposure to multiple air pollutants2023Environmental Chemistry Lettersarticle
  159. All-in-One Online Radiotherapy for Nasopharyngeal Carcinoma: Preliminary Results of Treatment Time, Contouring Accuracy, Treatment Plan Quality and Patient Compliance2023International Journal of Radiation Oncology*Biology*Physicsarticle
  160. Automated Contouring of Cervical Lymph Nodes and Clinical Target Volumes for Nasopharyngeal Carcinoma Based on Deep Learning and Experience Constraints2023International Journal of Radiation Oncology*Biology*Physicsarticle
  161. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  162. CT Synthesis from MRI Using Generative Adversarial Network with Frequency-Aware Discriminator2023Journal of Electrical Engineering and Technologyarticle
  163. Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.2023Journal of Clinical Oncologyconference-abstract
  164. Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma2023Medical radiologybook-chapter
  165. Combination of MRI-based temporal tumor response and Epstein-Barr DNA level changes after radiotherapy leads to improved prognostic stratification of patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy2023Research Squarepreprint
  166. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.2023Journal of Clinical Oncologyconference-abstract
  167. Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer2023Venue not listedother
  168. Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer2023Venue not listedother
  169. Data from EBV Infection in Epithelial Malignancies Induces Resistance to Antitumor Natural Killer Cells via F3-Mediated Platelet Aggregation2023Venue not listedother
  170. Data from Long Noncoding RNA TINCR-Mediated Regulation of Acetyl-CoA Metabolism Promotes Nasopharyngeal Carcinoma Progression and Chemoresistance2023Venue not listedother
  171. Data from Long Noncoding RNA TINCR-Mediated Regulation of Acetyl-CoA Metabolism Promotes Nasopharyngeal Carcinoma Progression and Chemoresistance2023Venue not listedother
  172. Data from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis2023Venue not listedother
  173. Deep Active Learning for Computer-Aided Detection of Nasopharyngeal Carcinoma in MRI Images2023International Conference on Computing and Artificial Intelligence (ICCAI)conference-paper
  174. Deep Learning-Based Synthesis of Contrast-Enhanced MRI for Automated Delineation of Primary Gross Tumor Volume in Radiotherapy of Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  175. Deep Reinforcement Learning Method for 3D-CT Nasopharyngeal Cancer Localization with Prior Knowledge2023Applied Sciencesarticle
  176. Deep learning for the precise detection of recurrence in nasopharyngeal carcinoma from time-series medical imaging2023Research Squarepreprint
  177. Delta-Radiomics Guides Adaptive De-Intensification after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma in the IMRT Era2023International Journal of Radiation Oncology*Biology*Physicsarticle
  178. Do Elderly Patients with Locally Advanced Nasopharyngeal Carcinoma Benefit from Radiotherapy Combined with Chemotherapy?2023Research Squarepreprint
  179. Dosimetric Benefits of Online Adaptive Radiotherapy in Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  180. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.2023Journal of Clinical Oncologyconference-abstract
  181. Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison2023Figsharesupplementary-materials
  182. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncologyconference-abstract
  183. First Implementation of Full-Workflow Automation for Online Adaptive Radiotherapy of Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  184. General Introduction of PET/CT of Nasopharyngeal Carcinoma2023Springer eBooksbook-chapter
  185. Identification and Automated Delineation of Radioresistant Biological Tumor Volume in Nasopharyngeal Carcinoma Based on Magnetic Resonance Imaging Radiomics2023International Journal of Radiation Oncology*Biology*Physicsarticle
  186. Imaging in the Diagnosis of NPC2023Medical radiologybook-chapter
  187. Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.2023Journal of Clinical Oncologyconference-abstract
  188. Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.2023Journal of Clinical Oncologyconference-abstract
  189. Investigating transfer learning to improve the deep-learning-based segmentation of organs at risk among different medical centers for nasopharyngeal carcinoma2023Frontiers in Physicsarticle
  190. Is a Deep Learning Based Segmentation Model Trained on planning CTs Transferable for Segmentation of Organs at Risk in Replanning CTs?2023International Journal of Radiation Oncology*Biology*Physicsarticle
  191. Local Cost-Effectiveness of Nasopharyngeal Carcinoma Screening Strategies in Southern China: Secondary Analysis of the PRO-NPC-001 Cluster-Randomized Trial2023International Journal of Radiation Oncology*Biology*Physicsarticle
  192. MWSR-YLCA: Improved YOLOv7 Embedded with Attention Mechanism for Nasopharyngeal Carcinoma Detection from MR Images2023Electronicsarticle
  193. Mitigation of Dosimetric Uncertainty in MRI-Based Proton Planning Using Spot-Scanning Proton Arc (SPArc) Technique2023International Journal of Radiation Oncology*Biology*Physicsarticle
  194. Nab-paclitaxel plus cisplatin versus docetaxel plus cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A multicenter parallel controlled phase III trial.2023Journal of Clinical Oncologyconference-abstract
  195. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncologyconference-abstract
  196. PET/CT of Nasopharyngeal Carcinoma2023Springer eBooksbook-chapter
  197. Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies2023The Oncologistarticle
  198. Prognostic Significance of the Novel Nutrition-Inflammation Marker of Lymphocyte-C-Reactive Protein Ratio in Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  199. Prospective study of integrating post-radiotherapy [18F] fluorodeoxyglucose-positron emission tomography/computed tomography scan and plasma Epstein-Barr virus DNA in surveillance of locoregionally advanced nasopharyngeal carcinoma.2023Journal of Clinical Oncologyconference-abstract
  200. Quality of life and Its Association With Radiation-Induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma During Radiotherapy: A Prospective Study2023Research Squarepreprint
  201. Radiation-Induced Nasopharyngeal Necrosis in Locally-Recurrent Nasopharyngeal Carcinoma Patients after Re-Radiotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  202. Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy.2023Journal of Clinical Oncologyconference-abstract
  203. Refining the TNM M1 Subcategory for De Novo Metastatic Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  204. Synthetic computed tomography generation from multi-sequence magnetic resonance images for nasopharyngeal carcinoma treatment planning via cycle-consistent generative adversarial network2023Research Squarepreprint
  205. The Epidemiology of Nasopharyngeal Carcinoma2023Medical radiologybook-chapter
  206. The Impact of COVID-19 Vaccination on Plasma Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma Patients: A Real-World Study2023SSRN Electronic Journalpreprint
  207. The Lyman Normal Tissue Complication Probability Model and Risk Prediction for Temporal Lobe Injury after Re-Irradiation in Patients with Recurrent Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  208. WITHDRAWN: LINC01770 stabilizes TEAD1 expression to mediates nasopharyngeal cancer radiation resistance rendering tumor cells vulnerable to ferroptosis2023Research Squarepreprint
  209. m6A Reader YTHDC1 Inhibits Ferroptosis and Radiosensitivity by Promoting SREBF1 mRNA Nuclear Export in Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  210. 226MO Is induction chemotherapy beneficial in locally recurrent nasopharyngeal carcinoma before re-irradiation? A multicenter retrospective analysis2022Annals of Oncologyarticle
  211. 227MO Characterization of minimal residual disease (MRD) post-radiotherapy (RT) in nasopharyngeal carcinoma (NPC) patients identifies a favorable subgroup with low risk of relapse2022Annals of Oncologyarticle
  212. 662P Deep learning-enabled precise recurrence detection in nasopharyngeal carcinoma: A multicentre study2022Annals of Oncologyarticle
  213. 663P Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study2022Annals of Oncologyarticle
  214. A Novel Fully Automated MRI-Based Deep-Learning Method for Segmentation of Nasopharyngeal Carcinoma Lymph Nodes2022Journal of Medical and Biological Engineeringarticle
  215. A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).2022Journal of Clinical Oncologyconference-abstract
  216. Abstract 5128: Identification and characterization of nasopharyngeal carcinoma prognostic subtypes based on a circRNA classifier: Implications of stratified treatment2022Cancer Researchconference-abstract
  217. Abstract 5762: Genomic correlates of response to immune checkpoint blockade in Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma2022Cancer Researchconference-abstract
  218. Abstract 6127: Single-cell spatial transcriptome sequencing characterizes CD70+ immune-resilient nasopharyngeal carcinoma cells as a vital mediator of Treg-induced suppression2022Cancer Researchconference-abstract
  219. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Researchconference-abstract
  220. Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma2022Figsharedataset
  221. Anlotinib for patients with recurrent or metastatic nasopharyngeal carcinoma: A phase II study.2022Journal of Clinical Oncologyconference-abstract
  222. Anti-PD-1 Immunotherapy Changed the Spectrum of Thyroid Dysfunction during Radiotherapy in Patients with Nasopharyngeal Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  223. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.2022Journal of Clinical Oncologyconference-abstract
  224. Classifying the tumor microenvironment to stratify nasopharyngeal carcinoma patients2022Annals of Nasopharynx Cancerarticle
  225. Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer2022SSRN Electronic Journalpreprint
  226. Comprehensive immune landscape and molecular characteristics of clinical responses to chemotherapy, antiangiogenic agents, and PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma.2022Journal of Clinical Oncologyconference-abstract
  227. Computational codes for identification of master regulators of high-risk nasopharyngeal carcinoma2022Zenodo (CERN European Organization for Nuclear Research)article
  228. Efficacy and safety of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced nasopharyngeal carcinoma (NPC): Pooled cohort data from phase 1a/1b trials.2022Journal of Clinical Oncologyconference-abstract
  229. Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage T any N3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.2022Journal of Clinical Oncologyconference-abstract
  230. Efficacy and safety of camrelizumab combined with apatinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.2022Journal of Clinical Oncologyconference-abstract
  231. Efficacy and safety of chemotherapy plus subsequent locoregional radiotherapy and toripalimab in de novo metastatic nasopharyngeal carcinoma.2022Journal of Clinical Oncologyconference-abstract
  232. Immunotherapy in Locally Advanced Nasopharyngeal Carcinoma2022Cancer immunotherapybook-chapter
  233. Impact on xerostomia for patients with nasopharyngeal carcinoma treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.2022Journal of Clinical Oncologyconference-abstract
  234. Long non-coding RNA RGMB-AS1 represses nasopharyngeal carcinoma progression via binding to forkhead box A12022Figsharedataset
  235. Long-Term Outcome Following Intensity-Modulated Radiotherapy Delivered Using Individualized Clinical Target Volume Delineation Based on Stepwise Spread Pattern of Nasopharyngeal Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  236. MYL9 promotes nasopharyngeal carcinoma carcinogenesis, progression and paclitaxel resistance by regulating EMT signals2022Research Squarepreprint
  237. Mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers: A multicenter, open-label, single-arm, phase Ⅰb study.2022Journal of Clinical Oncologyconference-abstract
  238. Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial.2022Journal of Clinical Oncologyconference-abstract
  239. Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, noninferiority, randomised phase III trial.2022Journal of Clinical Oncologyconference-abstract
  240. Reduced-dose radiotherapy for pretreatment EBV DNA selected low-risk stage III nasopharyngeal carcinoma: A single-arm, phase II trial.2022Journal of Clinical Oncologyconference-abstract
  241. Reler: Relearning Controversial Regions to Accurately Segment Nasopharyngeal Carcinoma2022IEEE International Conference on Bioinformatics and Biomedicine (BIBM)conference-paper
  242. Sparing Irradiation vs. Conventional Irradiation to the Medial Retropharyngeal Space in Patients with Nasopharyngeal Carcinoma: An Open-Label, Non-Inferiority, Multicenter, Randomized Phase III Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  243. TIRA study: A phase III, multicenter, randomized controlled study of toripalimab plus radical chemoradiotherapy with or without concurrent cisplatin in patients with high-risk locoregionally advanced nasopharyngeal carcinoma.2022Journal of Clinical Oncologyconference-abstract
  244. The Clinicopathological Characteristics, MRI Features, And Radiation Dose Of Radio-Induced Brain Necrosis In Nasopharyngeal Carcinoma Patients2022Research Squarepreprint
  245. The clinicopathological characteristics, MRI features, and radiation dose of radio-induced brain necrosis in nasopharyngeal carcinoma patients2022Research Squarepreprint
  246. The whole family is nasopharyngeal cancer?2022SCIREA Journal of Clinical Medicinearticle
  247. Tumor Cell-Intrinsic E3 Ligase TRIM21 Restrains Radiation-Induced Antitumor Immunity by Decreasing Mitochondrial DNA Release from VDAC2 Oligomers2022International Journal of Radiation Oncology*Biology*Physicsarticle
  248. Weighted Concordance Index Loss-Based Multimodal Survival Modeling for Radiation Encephalopathy Assessment in Nasopharyngeal Carcinoma Radiotherapy2022Lecture notes in computer scienceconference-paper
  249. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancerconference-abstract
  250. 859O Refining TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma: A multicenter cohort study2021Annals of Oncologyarticle
  251. A Novel Machine Learning-Derived Radiomic Signature Predictive of Nasopharyngeal Necrosis to Guide Re-Radiotherapy for Recurrent Nasopharyngeal Carcinoma: A Multicentre Study2021SSRN Electronic Journalpreprint
  252. A preliminary study of a new high-resolution detector matrix applied to three-dimensional dose verification in intensity-modulated radiotherapy2021Radiation Medicine and Protectionarticle
  253. ASO Visual Abstract: Pulmonary Metastasectomy in Patients with Lung Metastases from Nasopharyngeal Carcinoma2021Annals of Surgical Oncologyconference-abstract
  254. Abstract 1609: Peripheral NK-cell immunophenotypes predict progression in nasopharyngeal carcinoma patients2021Cancer Researchconference-abstract
  255. Abstract 2204: Spectrum of pathogenic germline mutations in Chinese head and neck cancer patients through next-generation sequencing2021Cancer Researchconference-abstract
  256. Abstract 2258: Germline variants associated with poorer disease prognosis in nasopharyngeal carcinoma2021Cancer Researchconference-abstract
  257. Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.2021Journal of Clinical Oncologyconference-abstract
  258. Assessment of Dose Accuracy for MR-Guided Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle
  259. Associated with Immune Function, miR-150-5p is a Favorable Biomarker for Head and Neck Cancer Patients2021Research Squarepreprint
  260. Biological opportunities for personalized radiotherapy of nasopharyngeal carcinoma2021Annals of Nasopharynx Cancerarticle
  261. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncologyconference-abstract
  262. Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.2021Journal of Clinical Oncologyconference-abstract
  263. Clinical advances in nasopharyngeal carcinoma surgery and a video demonstration2021Visualized Cancer Medicinearticle
  264. Comprehensive end-to-end test for intensity-modulated radiation therapy for nasopharyngeal carcinoma using an anthropomorphic phantom and EBT3 film2021Internatuinal Journal of Radiation Researcharticle
  265. Contouring Methods and Atlas of Organs at Risk2021Practical guides in radiation oncologybook-chapter
  266. Correction: AR-induced long non-coding RNA LINC01503 facilitates proliferation and metastasis via the SFPQ-FOSL1 axis in nasopharyngeal carcinoma2021Oncogeneerratum
  267. De-intensified chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma based on plasma EBV DNA: A phase 2 randomized noninferiority trial.2021Journal of Clinical Oncologyconference-abstract
  268. Detection-and-Excitation Neural Network Achieves Accurate Nasopharyngeal Carcinoma Segmentation in Multi-modality MR Images2021IEEE International Conference on Bioinformatics and Biomedicine (BIBM)conference-paper
  269. Effect of the number of control points on the plan quality of intensity-modulated radiotherapy for nasopharyngeal carcinoma2021Journal of Radiation Research and Applied Sciencesarticle
  270. Efficacy of Concurrent Chemoradiotherapy In Subgroups of Stage III Nasopharyngeal Carcinoma: An Analysis Based On 10-Year Follow-Up2021Research Squarepreprint
  271. Endoscopic nasopharyngectomy in nasopharyngeal carcinoma2021Operative Techniques in Otolaryngology-Head and Neck Surgeryarticle
  272. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncologyconference-abstract
  273. MA01.08 Gemcitabine Plus Capecitabine in Patients With Primary Pulmonary Lymphoepithelioma-Like Carcinoma Previously Treated With Chemotherapy2021Journal of Thoracic Oncologyconference-abstract
  274. Management of Neck Disease in Early Stage Disease2021Practical guides in radiation oncologybook-chapter
  275. Management of Radiation-Induced Late Complications and Evidence-Based Surveillance for Nasopharyngeal Carcinoma2021Practical guides in radiation oncologybook-chapter
  276. Metastasis of nasopharyngeal carcinoma: What we know and do not know2021Visualized Cancer Medicinearticle
  277. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncologyconference-abstract
  278. Multimodality Management for Locally Advanced Nasopharyngeal Cancer2021Practical guides in radiation oncologybook-chapter
  279. Predictive effect of computed tomography imaging omics features under deep learning on metastatic lymph nodes of nasopharyngeal carcinoma2021Expert Systemsarticle
  280. Prognostic nomogram for pediatric nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.2021Journal of Clinical Oncologyconference-abstract
  281. Research Advances of Tumor-associated Macrophages in Nasopharyngeal Carcinoma2021DOAJ (DOAJ: Directory of Open Access Journals)article
  282. Risk Stratification and Individualized Chemotherapy for Elderly Patients with Locoregionally Advanced Nasopharyngeal Carcinoma2021Research Squarepreprint
  283. Synthetic CT Generation From Multi-Sequence MR Images for Head and Neck MRI-Only Radiotherapy via Cycle-Consistent Generative Adversarial Network2021International Journal of Radiation Oncology*Biology*Physicsarticle
  284. Time-to-Event Supervised Genetic Algorithm Enables Induction Chemotherapy Decision Making for Nasopharyngeal Carcinoma2021IEEE Accessarticle
  285. Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: An open-label single-arm, phase II trial.2021Journal of Clinical Oncologyconference-abstract
  286. WITHDRAWN: A Novel Endoscopic Nasopharyngectomy Technique Using Low-Temperature Plasma Radiofrequency Ablation with Piece Resection In Resectable Locally Recurrent Nasopharyngeal Carcinoma: Operative Video and Technical Nuances2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 137 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 4.7%.

Papers led
137
2021–2025
Trials led
26
any status, ClinicalTrials.gov
Open trials led
8
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 323220212022: 252520222023: 313120232024: 232320242025: 25252025

11 hospitals in Guangzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06912074

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  2. Recruiting
    Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07086469

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  3. Recruiting
    Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07177794

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  4. Recruiting
    Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06561178

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  5. Recruiting
    PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05357846

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  6. Recruiting
    Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2019-12
    Registry
    NCT04174079

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  7. Not yet recruiting
    Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07701681

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  8. Not yet recruiting
    A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06487702

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  9. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  10. Not yet recruiting
    Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07769658

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou University; 5 listed hospitals as study sitesChengdu, Guangzhou, Kunming, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentRadiotherapyMolecular markers & genomics
Departments in papersMedical oncologyRadiation oncologyPathology / laboratory medicineGastroenterology / hepatology
Papers it led137
  1. Integrating lymphovascular invasion and ypTNM staging system for esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy and surgery: a multi-institutional analysis.2026British journal of cancer
  2. CCL5hi Macrophages Interact with CD8+ T Cells and Potentiate Responsiveness to PD-1 Blockade Plus Chemotherapy in Esophageal Squamous Cell Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. SNORA58 Facilitates Radioresistance via Suppressing JNK1-Mediated Ferroptosis in Esophageal Squamous Cell Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Development and validation of a nomogram for predicting long-term survival in pN + esophageal squamous cell carcinoma treated using radical resection without neoadjuvant therapy.2025Annals of medicineFree full text
  5. Pan-immune-inflammation value predicts survival of patients with oesophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: a pooled analysis of two phase II trials.2025Annals of medicineFree full text
  6. Impact of Anastomotic Leaks on Long-Term Survival in Patients with Esophageal Squamous Cell Carcinoma Following McKeown Esophagectomy: A Propensity Score-Matched Analysis.2025Annals of surgical oncology
  7. Albumin-bound paclitaxel and cisplatin with radiotherapy in locally advanced oesophageal squamous cell carcinoma: a single-arm, phase II trial.2025BMC cancerFree full text
  8. Impact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study.2025Cancer immunology, immunotherapy : CIIFree full text
  9. Modification of Pathological Nodal Classification for pT1b Esophageal Squamous Cell Carcinoma With Lymphovascular Invasion: Over 10-Year Experience.2025Cancer reports (Hoboken, N.J.)Free full text
  10. Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy.2025Cancer research
  11. Single-Cell RNA-Seq Reveals the Effect of Commensal Bacteria on the Multistep Development of Esophageal Cancer.2025Cancer scienceFree full text
  12. The PLEKHA1-TACC2 fusion gene drives tumorigenesis via vascular mimicry formation in esophageal squamous-cell carcinoma.2025Cell death and differentiationFree full text
  13. m6A-mediated circG3BP1 translocation to stress granules promotes nucleation and senescence-linked chemoresistance.2025Cell reports
  14. Fibroblast-derived PI16 enhances tumor immune-suppressive microenvironment via inducing Tregs differentiation.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  15. Hypermethylated USP44 deubiquitinates SENP2: a critical mechanism in esophageal cancer progression and a new target for intervention.2025Clinical epigeneticsFree full text
  16. RNF217-KEAP1-NRF2 feedback loop confers therapeutic resistance by inhibiting ferroptosis in esophageal squamous cell carcinoma.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  17. Real-world applications of postneoadjuvant stage I of the staging system for oesophageal squamous cell cancer: what is beyond a pathological complete response?2025European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic SurgeryFree full text
  18. Neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma with non-regional cervical lymph node metastasis: a retrospective pilot study.2025Frontiers in immunologyFree full text
  19. An interpretable machine learning model using multimodal pretreatment features predicts pathological complete response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  20. The role of ZC3H13 in promoting M2 macrophage infiltration via m6A methylation in esophageal squamous cell carcinoma tumor progression.2025Frontiers in immunologyFree full text
  21. Long-term efficacy and progression patterns of paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced, borderline-resectable esophageal squamous cell carcinoma: results from a phase II NEOCRTEC1601 study.2025International journal of surgery (London, England)Free full text
  22. Inactivation of TACC2 epigenetically represses CDKN1A and confers sensitivity to CDK inhibitors.2025Med (New York, N.Y.)
  23. Circulating tumor DNA as a marker of molecular residual disease in resected esophageal squamous cell carcinoma.2025Molecular biomedicineFree full text
  24. Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis.2025Molecular cancerFree full text
  25. Induction chemotherapy plus chemoradiotherapy in esophageal cancer: long-term results and exploratory analyses of a randomized controlled trial.2025The oncologistRCTFree full text
  26. Multimodal CT and MRI Radiomics Integrated with Clinical Models Predict Pathological Complete Response in ESCC Following Neoadjuvant Immunochemotherapy.2025Tomography (Ann Arbor, Mich.)Free full text
  27. Identification and Characterization of Metastasis-Initiating Cells in ESCC in a Multi-Timepoint Pulmonary Metastasis Mouse Model.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  28. Nomograms for predicting the prognosis in multiple primary esophageal squamous cell carcinoma.2024Annals of medicineFree full text
  29. ASO Author Reflections: Treatment Strategies for Locally Advanced Borderline Resectable Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  30. A 3-Year Survival Update from a Phase 2 Study of Paclitaxel Plus Cisplatin and 5-Fuorouracil Induction Chemotherapy for Locally Advanced Borderline-Resectable Esophageal Squamous Cell Carcinoma: The NEOCRTEC-1601 Clinical Trial.2024Annals of surgical oncologyFree full text
  31. Prognostic value of immuno-inflammatory biomarkers in esophageal squamous cell carcinoma patients receiving immunotherapy combined with chemoradiotherapy and its association with immuno-genomic landscape.2024BMC cancerFree full text
  32. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.2024BMC cancerFree full text
  33. Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study.2024British journal of cancerFree full text
  34. Impaired TGF-β signaling via AHNAK family mutations elicits an esophageal cancer subtype with sensitivities to genotoxic therapy and immunotherapy.2024Cancer immunology, immunotherapy : CIIFree full text
  35. Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study.2024Cancer immunology, immunotherapy : CIIFree full text
  36. PYGB targeted by androgen receptor contributes to tumor progression and metabolic reprogramming in esophageal squamous carcinoma.2024Cellular signalling
  37. The patterns and risk factors for relapse in oesophageal squamous cell cancers that achieve pathological complete response to neoadjuvant chemoradiotherapy.2024European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  38. Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma.2024Frontiers in immunologyFree full text
  39. Cuproptosis/OXPHOS tendency prediction of prognosis and immune microenvironment of esophageal squamous cell carcinoma: Bioinformatics analysis and experimental validation.2024Gene
  40. VBP1 promotes tumor proliferation as a part of the hypoxia-related signature in esophageal squamous cell carcinoma.2024Human cellFree full text
  41. Evolution of genome and immunogenome in esophageal squamous cell carcinomas driven by neoadjuvant chemoradiotherapy.2024International journal of cancer
  42. Roles of long non‑coding RNAs in esophageal cell squamous carcinoma (Review).2024International journal of molecular medicineFree full text
  43. Comparison of Efficacy and Safety of Combined Chemoimmunotherapy With or Without Radiation Therapy for Stage IVB Esophageal Squamous Cell Carcinoma: A Multicenter Propensity Score Matching Analysis.2024International journal of radiation oncology, biology, physics
  44. Carbon dioxide gas-induced pneumothorax versus one-lung ventilation in minimally invasive esophagectomy: a multicenter propensity score matching cohort study.2024International journal of surgery (London, England)Free full text
  45. Intracellular Fusobacterium nucleatum infection increases METTL3-mediated m6A methylation to promote the metastasis of esophageal squamous cell carcinoma.2024Journal of advanced researchFree full text
  46. Oesophageal cancer.2024Lancet (London, England)
  47. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial.2024Med (New York, N.Y.)RCT
  48. Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab.2024Nature communicationsFree full text
  49. Highly sensitive detection platform-based diagnosis of oesophageal squamous cell carcinoma in China: a multicentre, case-control, diagnostic study.2024The Lancet. Digital health
  50. ASO Author Reflections: The Prophets of Postoperative Cardiopulmonary Complications in Esophageal Squamous Cell Carcinoma Patients Receiving Trimodality Therapy.2023Annals of surgical oncology
  51. Clinical and Dosimetric Predictors for Postoperative Cardiopulmonary Complications in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy and Surgery.2023Annals of surgical oncology
  52. The pretherapeutic systemic inflammation score is a prognostic predictor for elderly patients with oesophageal cancer: a case control study.2023BMC cancerFree full text
  53. Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint.2023BMC cancerFree full text
  54. Trafficking protein TMED3 promotes esophageal squamous cell carcinoma.2023Biomedical journalFree full text
  55. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma.2023Cancer cell
  56. Novel long noncoding RNA LINC02820 augments TNF signaling pathway to remodel cytoskeleton and potentiate metastasis in esophageal squamous cell carcinoma.2023Cancer gene therapyFree full text
  57. Th1-involved immune infiltrates improve neoadjuvant chemoradiotherapy response of esophageal squamous cell carcinoma.2023Cancer letters
  58. Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma.2023Cancer medicineFree full text
  59. Efficacy and cost-effectiveness analysis of pretreatment percutaneous endoscopic gastrostomy in unresectable locally advanced esophageal cancer patients treated with concurrent chemoradiotherapy (GASTO 1059).2023Cancer medicineFree full text
  60. Efficacy of adjuvant chemotherapy on overall survival in patients with lymph node-positive esophageal squamous cell carcinoma: Is oral chemotherapy promising?2023Cancer medicineFree full text
  61. The Macrophage-Associated LncRNA MALR Facilitates ILF3 Liquid-Liquid Phase Separation to Promote HIF1α Signaling in Esophageal Cancer.2023Cancer research
  62. Combined Wee1 and EGFR inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma.2023Carcinogenesis
  63. A Wnt-induced lncRNA-DGCR5 splicing switch drives tumor-promoting inflammation in esophageal squamous cell carcinoma.2023Cell reports
  64. Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma.2023Clinical and translational medicineFree full text
  65. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.2023Clinical drug investigation
  66. SPI1-Mediated Upregulation of the CST1 Gene as an Independent Poor Prognostic Factor Accelerates Metastasis in Esophageal Squamous Cell Carcinoma (ESCC) by Interacting with MMP2.2023Frontiers in bioscience (Landmark edition)
  67. TP53 Mutations in Esophageal Squamous Cell Carcinoma.2023Frontiers in bioscience (Landmark edition)
  68. Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation.2023Frontiers in immunologyFree full text
  69. A Surrogate Endpoint for Overall Survival in Locally Advanced and Resectable Esophageal Squamous Cell Carcinoma: A Reanalysis of Data From the NEOCRTEC5010 Trial.2023International journal of radiation oncology, biology, physics
  70. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.2023JAMA network openFree full text
  71. Establishment and validation of a prognostic risk classification for patients with stage T1-3N0M0 esophageal squamous cell carcinoma.2023Journal of cardiothoracic surgeryFree full text
  72. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyFree full text
  73. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.2023Journal of translational medicineFree full text
  74. Integrated proteomics and phosphoproteomics analyses of esophageal cancer cells with different invasive abilities.2023Life sciences
  75. A novel immune-related prognostic signature based on Chemoradiotherapy sensitivity predicts long-term survival in patients with esophageal squamous cell carcinoma.2023PeerJFree full text
  76. Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial.2023Radiation oncology (London, England)RCTFree full text
  77. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.2023The Lancet. Oncology
  78. Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy.2023The oncologistFree full text
  79. Are more courses of immunochemotherapy beneficial for the short-term outcome of locally advanced esophageal squamous cell carcinoma?2023Thoracic cancerFree full text
  80. Clinical value of station 4R node dissection in esophageal squamous cell carcinoma.2023World journal of surgical oncologyFree full text
  81. The Prognostic Value of Microvascular Density in Early Postoperative Recurrence and Metastasis of T1 Esophageal Squamous Cell Carcinoma.2022Annals of clinical and laboratory science
  82. High endothelial venules associated with better prognosis in esophageal squamous cell carcinoma.2022Annals of diagnostic pathology
  83. Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine Computed Tomography Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models.2022Annals of surgical oncology
  84. ASO Author Reflections: Radiomics-Based Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma.2022Annals of surgical oncology
  85. Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.2022BMC cancerFree full text
  86. Postoperative survival effect of the number of examined lymph nodes on esophageal squamous cell carcinoma with pathological stage T1-3N0M0.2022BMC cancerFree full text
  87. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.2022Cancer cellRCT
  88. Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma.2022Cancer medicineFree full text
  89. Clinical significance and outcomes of bilateral and unilateral recurrent laryngeal nerve lymph node dissection in esophageal squamous cell carcinoma: A large-scale retrospective cohort study.2022Cancer medicineFree full text
  90. HN1L/AP-2γ/PLK1 signaling drives tumor progression and chemotherapy resistance in esophageal squamous cell carcinoma.2022Cell death & diseaseFree full text
  91. The prognostic value and molecular properties of tertiary lymphoid structures in oesophageal squamous cell carcinoma.2022Clinical and translational medicineFree full text
  92. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma.2022EBioMedicineFree full text
  93. Risk factors and prognosis for esophageal fistula in patients with esophageal squamous cell carcinoma during radiotherapy.2022Esophagus : official journal of the Japan Esophageal Society
  94. Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial.2022Esophagus : official journal of the Japan Esophageal Society
  95. LncRNA TMPO-AS1 promotes esophageal squamous cell carcinoma progression by forming biomolecular condensates with FUS and p300 to regulate TMPO transcription.2022Experimental & molecular medicineFree full text
  96. Nomogram based on circulating lymphocyte subsets for predicting radiation pneumonia in esophageal squamous cell carcinoma.2022Frontiers in immunologyFree full text
  97. Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma-Reply.2022JAMA surgery
  98. Inactivation of Hippo pathway characterizes a poor-prognosis subtype of esophageal cancer.2022JCI insightFree full text
  99. Identification and characterization of FGFR2+ hematopoietic stem cell-derived fibrocytes as precursors of cancer-associated fibroblasts induced by esophageal squamous cell carcinoma.2022Journal of experimental & clinical cancer research : CRFree full text
  100. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma.2022Journal of translational medicineFree full text
  101. ATXN2-mediated translation of TNFR1 promotes esophageal squamous cell carcinoma via m6A-dependent manner.2022Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  102. Targeted demethylation at ZNF154 promotor upregulates ZNF154 expression and inhibits the proliferation and migration of Esophageal Squamous Carcinoma cells.2022OncogeneFree full text
  103. G3BP2 regulated by the lncRNA LINC01554 facilitates esophageal squamous cell carcinoma metastasis through stabilizing HDGF transcript.2022OncogeneFree full text
  104. CPT1A promotes anoikis resistance in esophageal squamous cell carcinoma via redox homeostasis.2022Redox biologyFree full text
  105. A Propensity Score-Matched Analysis of Thoracolaparoscopic vs Open McKeown's Esophagectomy.2022The Annals of thoracic surgery
  106. The upregulated expression of RFC4 and GMPS mediated by DNA copy number alteration is associated with the early diagnosis and immune escape of ESCC based on a bioinformatic analysis.2021AgingFree full text
  107. Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.2021AgingFree full text
  108. Prognostic Value of a Four-miRNA Signature in Patients With Lymph Node Positive Locoregional Esophageal Squamous Cell Carcinoma Undergoing Complete Surgical Resection.2021Annals of surgery
  109. ASO Author Reflection: Use of Endobronchial Ultrasound in the Evaluation of Recurrent Laryngeal Nerve Lymph Nodes in Esophageal Squamous Cell Carcinoma Patients.2021Annals of surgical oncology
  110. Endobronchial Ultrasound Improves Evaluation of Recurrent Laryngeal Nerve Lymph Nodes in Esophageal Squamous Cell Carcinoma Patients.2021Annals of surgical oncology
  111. Impact of Examined Lymph Node Count for Esophageal Squamous Cell Carcinoma in Patients who Underwent Right Transthoracic Esophagectomy.2021Annals of surgical oncology
  112. MEOX2 serves as a novel biomarker associated with macrophage infiltration in oesophageal squamous cell carcinoma and other digestive system carcinomas.2021Autoimmunity
  113. Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers.2021BMC cancerFree full text
  114. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.2021BMC cancerFree full text
  115. A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study.2021BMC gastroenterologyRCTFree full text
  116. Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study.2021BioMed research internationalFree full text
  117. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.2021Biochemical pharmacology
  118. Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers.2021Cancer research and treatmentFree full text
  119. Low GSTM3 expression is associated with poor disease-free survival in resected esophageal squamous cell carcinoma.2021Diagnostic pathologyFree full text
  120. Modeling the risk of radiation pneumonitis in esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.2021Esophagus : official journal of the Japan Esophageal Society
  121. The characteristics and prognostic significance of esophageal squamous cell carcinoma with synchronous multiple lesions: over 10-year experience.2021Esophagus : official journal of the Japan Esophageal Society
  122. Prognostic impact of sterilized lymph nodes in esophageal squamous cell carcinomas after neoadjuvant chemoradiotherapy.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  123. Elevated expression of the RNA-binding motif protein 43 predicts poor prognosis in esophageal squamous cell carcinoma.2021International journal of clinical oncologyFree full text
  124. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.2021Investigational new drugs
  125. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.2021JAMARCTFree full text
  126. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.2021JAMA surgeryRCTFree full text
  127. Prognostic impact of lymph node metastasis along the left gastric artery in esophageal squamous cell carcinoma.2021Journal of cardiothoracic surgeryFree full text
  128. ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling.2021Journal of experimental & clinical cancer research : CRFree full text
  129. The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates cell proliferation and invasion in esophageal squamous cell carcinoma.2021Molecular oncologyFree full text
  130. Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial.2021Nature communicationsRCTFree full text
  131. NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization.2021OncogeneFree full text
  132. Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma.2021OncoimmunologyFree full text
  133. High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  134. Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021).2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  135. Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  136. Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes.2021The oncologistFree full text
  137. The promoter hypermethylation of SULT2B1 accelerates esophagus tumorigenesis via downregulated PER1.2021Thoracic cancerFree full text
Chinese-language papers (not in the count)1
  1. [Neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status35
  1. Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)RecruitingNCT06561178Lead sponsorStart 2024-08
  2. Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell CarcinomaRecruitingNCT04174079Lead sponsorN/AStart 2019-12
  3. Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC PatientsCompletedNCT04548440Lead sponsorPhase 2Start 2020-08
  4. Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07701681Lead (inferred)Phase 2Start 2026-08
  5. Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCCRecruitingNCT07177794Lead (inferred)Phase 3Start 2025-09
  6. Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07086469Lead (inferred)Phase 2Start 2025-07
  7. Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT06912074Lead (inferred)Phase 2Start 2025-04
  8. A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06487702Lead (inferred)Phase 2Start 2024-07
  9. PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)RecruitingNCT05357846Lead (inferred)Phase 3Start 2022-11
  10. Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT06281886Lead (inferred)Phase 2Start 2024-02
  11. PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCCStatus unknownNCT05737563Lead (inferred)Phase 3Start 2023-02
  12. Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.Active, not recruitingNCT06020885Lead (inferred)Phase 1Start 2023-08
  13. Anastomotic Leaks in Esophageal Squamous Cell Carcinoma Patients After Trimodal TherapyCompletedNCT06556355Lead (inferred)Start 2022-11
  14. Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma(EC-CRT-003)Status unknownNCT05512520Lead (inferred)Phase 2Start 2022-09
  15. The Efficacy of Inflatable Mediastinoscopic-assisted Transhiatal Laparoscopic EsophagectomyCompletedNCT07581236Lead (inferred)N/AStart 2021-01
  16. Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaStatus unknownNCT04844385Lead (inferred)Phase 2Start 2021-02
  17. Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal CancerStatus unknownNCT04006041Lead (inferred)Phase 2Start 2019-06
  18. Combination of Toripalimab and Chemoradiotherapy in Esophageal CancerCompletedNCT04005170Lead (inferred)Phase 2Start 2019-06
  19. PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell CarcinomaStatus unknownNCT03791905Lead (inferred)Phase 2Start 2019-01
  20. Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard TreatmentCompletedNCT02976896Lead (inferred)Phase 2Start 2016-08
  21. Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell CarcinomaCompletedNCT02976909Lead (inferred)Phase 2Start 2016-10
  22. Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)Status unknownNCT02465736Lead (inferred)Phase 3Start 2015-07
  23. Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.CompletedNCT02606916Lead (inferred)Phase 2Start 2015-07
  24. Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal CancerCompletedNCT02350517Lead (inferred)Phase 2Start 2015-01
  25. Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional ChemotherapyCompletedNCT01973725Lead (inferred)Phase 2Start 2013-10
  26. ESI With EUS to Differentiate T3 and T4 ESCCStatus unknownNCT01930630Lead (inferred)Phase 1Start 2013-10
  27. Standardized MRI and Structured Reporting for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07769658Study siteStart 2026-09
  28. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Study sitePhase 1Start 2024-07
  29. A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06022861Study sitePhase 3Start 2023-10
  30. Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.Active, not recruitingNCT05043688Study sitePhase 3Start 2021-09
  31. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  32. A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsActive, not recruitingNCT04603287Study sitePhase 1Start 2020-04
  33. Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell CarcinomaCompletedNCT03829969Study sitePhase 3Start 2019-01
  34. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  35. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
More papers found outside PubMed (not counted)84
  1. 2094O SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurr2025Annals of Oncologyarticle
  2. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  3. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  4. 394P Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: A pooled analysis of two phase III trials2025Annals of Oncologyarticle
  5. A retrospective pilot study of neoadjuvant chemotherapy combined with immunotherapy in the treatment of thoracic esophageal squamous cell carcinoma with cervical lymph node metastasis.2025Journal of Clinical Oncologyarticle
  6. Abstract LB380: A novel LNP-Encapsulated mRNA vaccine reshapes the immune microenvironment to overcome immunotherapy and chemotherapy resistance in esophageal squamous cell carcinoma with PIK3CA hotspot mutation2025Cancer Researchconference-abstract
  7. LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study2025Annals of Oncologyconference-abstract
  8. LBA82 Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, phase II trial (EC-CRT-002)2025Annals of Oncologyconference-abstract
  9. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physicsarticle
  10. Molecular subtyping and precision therapy for esophageal cancer2025Interdisciplinary medicinearticle
  11. P80 Impact of smoking on overall survival in patients receiving PD-1 inhibitors as first-line treatment of metastatic esophageal squamous cell carcinoma2025Gutconference-abstract
  12. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyconference-abstract
  13. 1404P Predictive role of circulating cytokines in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD1 inhibitor: Pooled analyses of two phase II clinical trials2024Annals of Oncologyarticle
  14. 1405P Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for esophageal squamous cell carcinoma (EC-CRT-001 phase II trial)2024Annals of Oncologyarticle
  15. 1407P Pan-immune-inflammation value predicts the survival of patients with esophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: A pooled-analysis of two phase II trials2024Annals of Oncologyarticle
  16. 242. BRD4 INHIBITION ENHANCES THE RADIOSENSITIVITY OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA THROUGH REGULATING ATF3-MEDIATED SERINE AND NUCLEOTIDE SYNTHESIS2024Diseases of the Esophagusarticle
  17. Abstract 281: The function of FGFR2+ cancer-associated fibroblasts on cancer stem cell expansion of esophageal squamous cell carcinoma2024Cancer Researchconference-abstract
  18. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Researchconference-abstract
  19. Comparing toripalimab combined with chemoradiotherapy versus chemoradiotherapy alone for locally advanced esophageal squamous cell carcinoma: A multicenter, open-label, randomized phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  20. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  21. High versus standard radiation dose of definitive chemoradiotherapy combined with immunotherapy for inoperable esophageal squamous cell carcinoma: A multicenter propensity score matching analysis.2024Journal of Clinical Oncologyconference-abstract
  22. LOMIA-T: A Transformer-Based LOngitudinal Medical Image Analysis Framework for Predicting Treatment Response of Esophageal Cancer2024Lecture notes in computer scienceconference-paper
  23. Neoadjuvant toripalimab plus chemotherapy followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (GASTO 1071).2024Journal of Clinical Oncologyconference-abstract
  24. Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.2024Journal of Clinical Oncologyconference-abstract
  25. Safety and feasibility of esophagectomy following neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: Analysis of two phase 2 clinical trials.2024Journal of Clinical Oncologyconference-abstract
  26. Single-cell transcriptomics reveals the landscape of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and the potential resistance role of LGALS12024Research Squarepreprint
  27. Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.2024Journal of Clinical Oncologyconference-abstract
  28. 1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell 2023Annals of Oncologyarticle
  29. 152. SINTILIMAB PLUS CISPLATIN AND PACLITAXEL INDUCTION TREATMENT FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II CLINICAL TRIAL2023Diseases of the Esophagusarticle
  30. 1576P Comparison of efficacy and safety of first-line systemic therapy combined with or without radiotherapy for stage IVb esophageal squamous cell carcinoma: A propensity score matching analysis2023Annals of Oncologyarticle
  31. 158. PACLITAXEL PLUS CISPLATIN AND 5 FUOROURACIL INDUCTION CHEMOTHERAPY FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: 3-YEAR SURVIVAL RESULT2023Diseases of the Esophagusarticle
  32. 199P Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial2023Annals of Oncologyarticle
  33. 289. RISK FACTOR OF RELAPSE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHO ACHIEVE PATHOLOGIC COMPLETE RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY2023Diseases of the Esophagusarticle
  34. A novel immune-related prognostic signature based on Chemoradiotherapy sensitivity predicts long-term survival in patients with esophageal squamous cell carcinoma.2023Zenodo (CERN European Organization for Nuclear Research)dataset
  35. Chemo-immunotherapy in advanced esophageal squamous cell carcinoma: present and future2023Holistic Integrative Oncologyarticle
  36. Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials2023MedComm – Future Medicinearticle
  37. Data from Characterization of a Novel Mechanism of Genomic Instability Involving the SEI1/SET/NM23H1 Pathway in Esophageal Cancers2023Venue not listedother
  38. Data from CstF64-Induced Shortening of the BID 3′UTR Promotes Esophageal Squamous Cell Carcinoma Progression by Disrupting ceRNA Cross-talk with ZFP36L22023Venue not listedother
  39. Data from CstF64-Induced Shortening of the BID 3′UTR Promotes Esophageal Squamous Cell Carcinoma Progression by Disrupting ceRNA Cross-talk with ZFP36L22023Venue not listedother
  40. Data from Fibroblast Growth Factor Receptor 2–Positive Fibroblasts Provide a Suitable Microenvironment for Tumor Development and Progression in Esophageal Carcinoma2023Venue not listedother
  41. Induction chemotherapy plus definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: Long-term results and exploratory analyses of a randomized controlled trial.2023Journal of Clinical Oncologyconference-abstract
  42. Optimizing Disease-Free Survival Prognosis: The Tumor Regression Grade Combined with Post-Neoadjuvant Pathologic Lymph Node Category (TRG -ypN) Novel Staging Approach Post-Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esop2023SSRN Electronic Journalpreprint
  43. Predicting role of circulating tumor DNA and blood-based tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001).2023Journal of Clinical Oncologyconference-abstract
  44. 1256P Three courses of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective phase II clinical trial2022Annals of Oncologyarticle
  45. 183. IMPACTS OF NEOADJUVANT CHEMORADIOTHERAPY ON THE IMMUNE LANDSCAPE OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  46. 184. THE PROGNOSTIC VALUE AND MOLECULAR PROPERTIES OF TERTIARY LYMPHOID STRUCTURES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  47. 236. TH1 CELL IS THE KEY IMMUNE-ASSOCIATED PREDICTOR OF PATHOLOGICAL COMPLETE RESPONSE FOLLOWING NEOADJUVANT CHEMORADIATION FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  48. 237. DIFFERENTIAL CLONAL EVOLUTION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN RESPONSE TO NEO-ADJUVANT CHEMORADIOTHERAPY2022Diseases of the Esophagusarticle
  49. 359. INTRATUMORAL MICROBIOME IMPACTS IMMUNE INFILTRATES IN TUMOR MICROENVIRONMENT AND PREDICTS PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS2022Diseases of the Esophagusarticle
  50. Abstract 5982: Single-cell RNA sequencing (scRNA-Seq) from mice model reveals metastatic and stemness signatures in esophageal squamous cell carcinoma (ESCC)2022Cancer Researchconference-abstract
  51. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  52. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  53. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  54. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  55. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  56. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  57. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  58. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  59. Additional file 3 of Characteristics and interplay of esophageal microbiota in esophageal squamous cell carcinoma2022Figsharedataset
  60. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  61. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  62. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  63. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  64. AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressin2022Journal of Clinical Oncologyconference-abstract
  65. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figsharedataset
  66. Hematopoietic stem cell-derived fibrocytes as targets and tools for cancer therapy: mechanisms and therapeutic implications2022Research Squarepreprint
  67. Hematopoietic stem cell-derived fibrocytes as targets and tools for cancer therapy: mechanisms and therapeutic implications2022Research Squarepreprint
  68. Identification and validation of an anoikis-related gene signature based on machine learning algorithms in esophageal squamous cell carcinoma2022Research Squarepreprint
  69. Integrated Analysis of Super-Enhancer and Secretome Identifies EFNA1 and MMP13 as Potential Serum Biomarkers for Early Detection of Esophageal Squamous Cell Carcinoma2022SSRN Electronic Journalpreprint
  70. MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway2022Figsharedataset
  71. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figsharedataset
  72. SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.2022Journal of Clinical Oncologyconference-abstract
  73. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  74. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncologyarticle
  75. Abstract 1601: Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma2021Cancer Researchconference-abstract
  76. AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressin2021Journal of Clinical Oncologyconference-abstract
  77. Correction: Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals2021Oncotargeterratum
  78. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  79. Impacts of Cigarette Smoking on Pathologic Response and Survival Among Patients with Esophageal Squamous Cell Carcinoma2021SSRN Electronic Journalpreprint
  80. Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract
  81. Predicting Response to Immunotherapy Plus Chemotherapy in Patients with Esophageal Squamous Cell Carcinoma Using Non-Invasive Radiomic Biomarkers2021Research Squarepreprint
  82. Rps15a Imparts Chemoresistance by Regulating Cd44 Expression and Cell Stemness in Esophageal Squamous Cell Carcinoma2021Research Squarepreprint
  83. The Impact of Anastomosis Location in Patients with Lower Thoracic Esophageal Squamous Cell Carcinoma: A Retrospective Observational Study2021Research Squarepreprint
  84. The efficacy and safety of toripalimab combined with definitive chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 281 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
281
2021–2025
Trials led
129
any status, ClinicalTrials.gov
Open trials led
18
recruiting or about to
Open trials as a site
10
led by another institution
Papers led per year
2021: 565620212022: 484820222023: 585820232024: 616120242025: 55552025

15 hospitals in Guangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 28

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07324824

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  2. Recruiting
    SBRT Versus Surgical Resection for Small HCC
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07381660

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  3. Recruiting
    Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07501351

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  4. Recruiting
    HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07594340

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  5. Recruiting
    HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06737913

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Zhengzhou

  6. Recruiting
    Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07192185

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  7. Recruiting
    Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07238881

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  8. Recruiting
    Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06265350

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  9. Recruiting
    Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06313190

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  10. Recruiting
    Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06446154

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  11. Recruiting
    Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06467799

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  12. Recruiting
    Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05751343

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  13. Recruiting
    Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06031285

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  14. Recruiting
    Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
    Phase
    Phase 3
    Started
    2023-10
    Registry
    NCT06041477

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  15. Recruiting
    FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
    Phase
    Phase 3
    Started
    2023-12
    Registry
    NCT06201065

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  16. Recruiting
    Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
    Phase
    N/A
    Started
    2021-02
    Registry
    NCT04777942

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  17. Not yet recruiting
    Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07870772

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  18. Not yet recruiting
    Liver Cancer Prognosis Investigation Study
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06623734

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  19. Recruiting
    An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07493044

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  20. Recruiting
    Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Registry
    NCT06938880

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  21. Recruiting
    A Study of DEG6498 in Participants With Solid Tumors
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07244835

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou

  22. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  23. Recruiting
    A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06307925

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  24. Recruiting
    Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06157060

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 3 listed hospitals as study sitesGuangzhou

  25. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  26. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

  27. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

  28. Not yet recruiting
    Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06449846

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)Immunotherapy & targeted drugs
Departments in papersMedical oncologyRadiology / nuclear medicinePathology / laboratory medicineRadiation oncology
Papers it led281
  1. Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7 + CD8 + T-cell entry into HCC through high endothelial venules.2026Hepatology (Baltimore, Md.)Free full text
  2. Efficacy and safety of adebrelimab plus bevacizumab in combination with hepatic artery infusion chemotherapy for advanced stage hepatocellular carcinoma: a retrospective cohort study.2026Neoplasma
  3. Comparison of Contrast-Enhanced Ultrasound and CT/MRI in Transarterial Chemoembolization and Hepatic Arterial Infusion Chemotherapy.2026Ultrasound in medicine & biology
  4. Long-Term Outcomes of Transarterial Chemoembolization plus Ablation versus Surgical Resection in Patients with Large BCLC Stage A/B HCC.2025Academic radiology
  5. Single-Nucleus and Spatial Transcriptome Profiling Delineates the Multicellular Ecosystem in Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers.2025BMC cancerFree full text
  7. Severe Rhodococcus equi pneumonia following hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib in hepatocellular carcinoma: a case report.2025BMC infectious diseasesFree full text
  8. Radiological characteristics for guiding intra-arterial therapy in intermediate-stage hepatocellular carcinoma.2025BMC medicineFree full text
  9. Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial.2025BMC medicineFree full text
  10. Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study.2025BMJ openRCTFree full text
  11. Intra-arterial lidocaine improves long-term survival in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolisation: a retrospective propensity score-matched study.2025British journal of anaesthesiaFree full text
  12. Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma.2025British journal of cancerFree full text
  13. Spatial Organization of Macrophages in CTL-Rich Hepatocellular Carcinoma Influences CTL Antitumor Activity.2025Cancer immunology research
  14. Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study.2025Cancer letters
  15. Intracellular IL1α in Peritumoral Monocytes Induces IL8 Production and Inhibits Mitophagy to Promote Stemness and Metastasis of Hepatocellular Carcinoma.2025Cancer researchFree full text
  16. HIF1α Counteracts TGFβ1-Driven TSP1 Expression in Endothelial Cells to Stimulate Angiogenesis in the Hypoxic Tumor Microenvironment.2025Cancer research
  17. A Contrast-Enhanced Ultrasound Cine-Based Deep Learning Model for Predicting the Response of Advanced Hepatocellular Carcinoma to Hepatic Arterial Infusion Chemotherapy Combined With Systemic Therapies.2025Cancer scienceFree full text
  18. METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma.2025Cell death and differentiationFree full text
  19. Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy.2025Cell reports. MedicineFree full text
  20. Regulatory factor X1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by transcriptional regulation of BECN1.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  21. Prognosis predictors of hepatocellular carcinoma after hepatectomy following conversion therapy.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  22. Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis.2025Frontiers in immunologyFree full text
  23. Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.2025Frontiers in immunologyFree full text
  24. Serum GDF15 level as predictive biomarker of clinical outcome in patients with unresectable hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.2025Frontiers in immunologyFree full text
  25. Interventional treatment combined with immunotargeted therapy in unresectable combined hepatocellular-cholangiocarcinoma: a real-world retrospective cohort study.2025Frontiers in immunologyFree full text
  26. PD-1 inhibitor-augmented HAIC-TKI therapy in hepatocellular carcinoma with portal vein tumor thrombosis: real-world survival benefits, safety, and subgroup-specific efficacy.2025Frontiers in immunologyFree full text
  27. Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  28. The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study.2025Hepatology international
  29. Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombus.2025Hepatology international
  30. Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy.2025Immunity
  31. Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors.2025International immunopharmacology
  32. Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma.2025International journal of biological sciencesFree full text
  33. Cyclophilin J Reprograms Tumor-associated Macrophages to Exert an Anti-tumor Effect in Liver Cancer.2025International journal of biological sciencesFree full text
  34. Comparing PD-L1 and PD-1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single-center, real-world study.2025International journal of cancer
  35. Transarterial chemoembolization versus hepatic arterial infusion chemotherapy as first treatment for hepatocellular carcinoma with macrovascular invasion.2025International journal of medical sciencesFree full text
  36. Development and validation of the NTAA prognostic model for BCLC stage B hepatocellular carcinoma undergoing transarterial chemoembolization: a retrospective multicenter cohort study.2025International journal of surgery (London, England)Free full text
  37. Refining risk stratification in hepatocellular carcinoma by integrating tertiary lymphoid structures and microvascular invasion: a multicenter retrospective study.2025International journal of surgery (London, England)Free full text
  38. An automated machine-learning model for prognostic risk stratification of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization.2025International journal of surgery (London, England)Free full text
  39. Neoadjuvant hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for resectable single large hepatocellular carcinoma.2025International journal of surgery (London, England)Free full text
  40. Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort study.2025International journal of surgery (London, England)Free full text
  41. Imaging-based surrogate classification for risk stratification of hepatocellular carcinoma with microvascular invasion to adjuvant hepatic arterial infusion chemotherapy: a multicenter retrospective study.2025International journal of surgery (London, England)Free full text
  42. Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high risk: a propensity score matching study.2025International journal of surgery (London, England)Free full text
  43. Dynamic changes of serum α-fetoprotein predict the prognosis of bevacizumab plus immunotherapy in hepatocellular carcinoma.2025International journal of surgery (London, England)Free full text
  44. Targeting SQLE-mediated cholesterol metabolism to enhance CD8+ T cell activation and immunotherapy efficacy in hepatocellular carcinoma.2025Journal for immunotherapy of cancerFree full text
  45. Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation.2025Journal for immunotherapy of cancerFree full text
  46. MAF1 inhibits hepatocarcinogenesis by fostering an immunostimulatory tumor microenvironment.2025Journal for immunotherapy of cancerFree full text
  47. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  48. Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score Matched Study of 980 Patients.2025Journal of vascular and interventional radiology : JVIR
  49. Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients.2025Korean journal of radiologyFree full text
  50. Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching.2025La Radiologia medicaFree full text
  51. POLRMT enhances lenvatinib resistance in hepatocellular carcinoma cells by maintaining mitochondrial ATP production.2025Life sciences
  52. The Value of no Evidence of Disease (NED) in Intermediate-Stage Hepatocellular Carcinoma After TACE: A Real-World Study.2025Liver international : official journal of the International Association for the Study of the Liver
  53. BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma.2025Molecular cancerFree full text
  54. A case study of a patient with platelet transfusion refractoriness (PTR) combined with human leucocyte antigen (HLA) antibody positivity during hepatic arterial infusion chemotherapy in conjunction with the 'atezolizumab plus bevacizumab' r2025Nursing in critical care
  55. USP14-mediated metabolic competition impairs CD8+ T cell immunosurveillance in hepatocellular carcinoma.2025Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  56. Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma.2025RadiologyRCT
  57. ARL8B regulates lysosomal function and predicts poor prognosis in hepatocellular carcinoma.2025Scientific reportsFree full text
  58. Comparison of the prognostic value of different inflammation-based scores in patients with hepatocellular carcinoma after Lenvatinib therapy.2025World journal of gastroenterologyFree full text
  59. Pseudo-capsulated Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization.2024Academic radiology
  60. Transarterial Chemoembolization Combined with Lenvatinib Plus Sequential Microwave Ablation for Large Hepatocellular Carcinoma Beyond Up-to-Seven Criteria: A Retrospective Cohort Study.2024Academic radiology
  61. Early recurrence of hepatocellular carcinoma in patients after ablation and resection: A propensity score analysis.2024American journal of surgery
  62. Sequential vs. concurrent systemic therapies in combination with FOLFOX-HAIC for locally advanced hepatocellular carcinoma: a single-center, real-world cohort study.2024BMC cancerFree full text
  63. Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.2024BMC medicineFree full text
  64. Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial.2024Cancer communications (London, England)RCTFree full text
  65. Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma.2024Cancer immunology, immunotherapy : CIIFree full text
  66. A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy.2024Cancer immunology, immunotherapy : CIIFree full text
  67. C/EBPα mediates the maturation and antitumor functions of macrophages in human hepatocellular carcinoma.2024Cancer letters
  68. Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: A longitudinal, multicenter study.2024Cancer medicineFree full text
  69. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.2024Cancer medicineFree full text
  70. DNA of Neutrophil Extracellular Traps Binds TMCO6 to Impair CD8+ T-cell Immunity in Hepatocellular Carcinoma.2024Cancer research
  71. Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and Enhances Sorafenib Efficacy.2024Cancer research
  72. UBA2 SUMOylates NQO1 and promotes the proliferation of hepatocellular carcinoma by modulating the MAPK pathway.2024Cancer scienceFree full text
  73. Hypoxia-induced DTL promotes the proliferation, metastasis, and sorafenib resistance of hepatocellular carcinoma through ubiquitin-mediated degradation of SLTM and subsequent Notch pathway activation.2024Cell death & diseaseFree full text
  74. Lipid droplet accumulation mediates macrophage survival and Treg recruitment via the CCL20/CCR6 axis in human hepatocellular carcinoma.2024Cellular & molecular immunologyFree full text
  75. CircATF6 inhibits hepatocellular carcinoma progression by suppressing calreticulin-mediated Wnt/β-catenin signaling pathway.2024Cellular signalling
  76. PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma.2024Clinical and experimental medicineFree full text
  77. Two somatic mutations in the androgen receptor N-terminal domain are oncogenic drivers in hepatocellular carcinoma.2024Communications biologyFree full text
  78. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma.2024Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  79. TMB Signature-Related RCAN2 Promotes Apoptosis by Upregulating EHF/DR5 Pathway in Hepatocellular Carcinoma.2024Frontiers in bioscience (Landmark edition)
  80. Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors.2024Frontiers in cellular and infection microbiologyFree full text
  81. Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  82. Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC.2024Frontiers in immunologyFree full text
  83. Myeloid response evaluated by noninvasive CT imaging predicts post-surgical survival and immune checkpoint therapy benefits in patients with hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  84. Efficacy and safety of atezolizumab-bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study.2024Frontiers in immunologyFree full text
  85. GPER1 signaling restricts macrophage proliferation and accumulation in human hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  86. The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab.2024Frontiers in immunologyFree full text
  87. Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  88. TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study.2024Frontiers in immunologyFree full text
  89. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations.2024Hepatology international
  90. Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma.2024Hepatology internationalFree full text
  91. Efficacy of additional locoregional therapy based on systemic therapy after intrahepatic progression for BCLC stage B/C hepatocellular carcinoma: A real-world study.2024International immunopharmacology
  92. APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways.2024International immunopharmacology
  93. Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study.2024International immunopharmacology
  94. The ARH score, a practical guide to decision-making for retreatment with hepatic arterial infusion chemotherapy in hepatocellular carcinoma patients.2024International immunopharmacology
  95. CircNOP14 increases the radiosensitivity of hepatocellular carcinoma via inhibition of Ku70-dependent DNA damage repair.2024International journal of biological macromolecules
  96. Sorcin Inhibits Mitochondrial Apoptosis by Interacting with STAT3 via NF-κB Pathway.2024International journal of molecular sciencesFree full text
  97. KLF4 Suppresses the Progression of Hepatocellular Carcinoma by Reducing Tumor ATP Synthesis through Targeting the Mir-206/RICTOR Axis.2024International journal of molecular sciencesFree full text
  98. Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study.2024International journal of surgery (London, England)Free full text
  99. Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors.2024International journal of surgery (London, England)Free full text
  100. Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study.2024International journal of surgery (London, England)Free full text
  101. Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study.2024International journal of surgery (London, England)Free full text
  102. Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the function and infiltration of CD8+ T cells.2024Journal for immunotherapy of cancerFree full text
  103. m6A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma.2024Journal of experimental & clinical cancer research : CRFree full text
  104. Magnetic Resonance Deep Learning Radiomic Model Based on Distinct Metastatic Vascular Patterns for Evaluating Recurrence-Free Survival in Hepatocellular Carcinoma.2024Journal of magnetic resonance imaging : JMRI
  105. A multi-parametric prognostic model based on clinicopathologic features: vessels encapsulating tumor clusters and hepatic plates predict overall survival in hepatocellular carcinoma patients.2024Journal of translational medicineFree full text
  106. Myocardial and Cerebral Infarction after Transarterial Bland Microsphere Embolization for Hepatocellular Carcinoma: A Case Report.2024Journal of vascular and interventional radiology : JVIR
  107. Prediction of microvascular invasion in hepatocellular carcinoma patients with MRI radiomics based on susceptibility weighted imaging and T2-weighted imaging.2024La Radiologia medica
  108. TRIM29 modulates proteins involved in PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma.2024Medical oncology (Northwood, London, England)
  109. Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma.2024Molecular cancer therapeutics
  110. SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity.2024Molecular cancer therapeutics
  111. Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS/STING signaling.2024Nature communicationsFree full text
  112. Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma.2024Nature communicationsFree full text
  113. CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression.2024Oncology researchFree full text
  114. Investigation of the correlation between platelet antibodies and peripheral blood cytopenia in patients with hepatocellular carcinoma.2024Scientific reportsFree full text
  115. AXIN1 boosts antiviral response through IRF3 stabilization and induced phase separation.2024Signal transduction and targeted therapyFree full text
  116. Recommended 10-Year Follow-Up Strategy for Small Hepatocellular Carcinoma After Radiofrequency Ablation: A Cost-Effectiveness Evaluation.2024The American journal of gastroenterology
  117. The Prognostic Value of Alpha-Fetoprotein Ratio in Patients With Resectable Alpha-Fetoprotein-Negative Hepatocellular Carcinoma.2024The American surgeon
  118. Diagnostic Performance of Modified Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Patients Without Risk Factors for Hepatocellular Carcinoma: Comparison With World Federation for Ultrasound in Medicine and Biology G2024Ultrasound in medicine & biology
  119. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis.2024World journal of gastroenterologyFree full text
  120. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.2023AJR. American journal of roentgenology
  121. Response evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: magnetic resonance imaging findings.2023Abdominal radiology (New York)Free full text
  122. Effect of Biliary Tract Invasion with Obstructive Jaundice on the Prognosis of Patients With Unresectable Hepatocellular Carcinoma.2023Academic radiology
  123. Editorial: is microwave ablation an alternative to liver resection for hepatocellular carcinoma?2023Alimentary pharmacology & therapeutics
  124. A radiomics-based model can predict recurrence-free survival of hepatocellular carcinoma after curative ablation.2023Asian journal of surgery
  125. CT texture analysis in predicting treatment response and survival in patients with hepatocellular carcinoma treated with transarterial chemoembolization using random forest models.2023BMC cancerFree full text
  126. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma.2023BMC medicineFree full text
  127. Banking of Tumor Tissues: Effect of Preanalytical Variables in the Phase of Pre- and Postacquisition on RNA Integrity.2023Biopreservation and biobanking
  128. Prognostic value of the S100 calcium-binding protein family members in hepatocellular carcinoma.2023Bioscience reportsFree full text
  129. A risk-based postresection follow-up strategy for hepatocellular carcinoma patients.2023Cancer
  130. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.2023Cancer
  131. Cholesterol Efflux Drives the Generation of Immunosuppressive Macrophages to Promote the Progression of Human Hepatocellular Carcinoma.2023Cancer immunology research
  132. Inflammatory bowel disease increases the risk of hepatobiliary pancreatic cancer: A two-sample Mendelian randomization analysis of European and East Asian populations.2023Cancer medicineFree full text
  133. Fructose Metabolism in Tumor Endothelial Cells Promotes Angiogenesis by Activating AMPK Signaling and Mitochondrial Respiration.2023Cancer research
  134. DNA methylation-activated full-length EMX1 facilitates metastasis through EMX1-EGFR-ERK axis in hepatocellular carcinoma.2023Cell death & diseaseFree full text
  135. RFX6 facilitates aerobic glycolysis-mediated growth and metastasis of hepatocellular carcinoma through targeting PGAM1.2023Clinical and translational medicineFree full text
  136. BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma.2023Clinical and translational medicineFree full text
  137. Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC).2023Clinical cancer research : an official journal of the American Association for Cancer Research
  138. Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries.2023Current opinion in pharmacology
  139. Development of nomograms to predict recurrence after conversion hepatectomy for hepatocellular carcinoma previously treated with transarterial interventional therapy.2023European journal of medical researchFree full text
  140. Impact of Quality Control Circle on Patient Outcomes after Hepatocellular Carcinoma Intervention: A Meta-Analysis.2023Expert review of anticancer therapy
  141. Mechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC.2023Frontiers in immunologyFree full text
  142. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  143. Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study.2023Frontiers in immunologyFree full text
  144. Ezetimibe Induces Paraptosis through Niemann-Pick C1-like 1 Inhibition of Mammalian-Target-of-Rapamycin Signaling in Hepatocellular Carcinoma Cells.2023GenesFree full text
  145. A Comprehensive Pan-Cancer Analysis of the Regulation and Prognostic Effect of Coat Complex Subunit Zeta 1.2023GenesFree full text
  146. Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.2023Gut and liverFree full text
  147. Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?2023Hepatology international
  148. Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study.2023Hepatology international
  149. Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma.2023Immunity
  150. The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy.2023International immunopharmacology
  151. Cholesterol and C-reactive protein prognostic score predicted prognosis of immune checkpoint inhibitors based interventional therapies for intermediate-to-advanced hepatocellular carcinoma patients.2023International immunopharmacology
  152. Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial.2023International journal of surgery (London, England)Free full text
  153. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study.2023International journal of surgery (London, England)Free full text
  154. Nomograms for predicting the recurrence probability and recurrence-free survival in patients with hepatocellular carcinoma after conversion hepatectomy based on hepatic arterial infusion chemotherapy: a multicenter, retrospective study.2023International journal of surgery (London, England)Free full text
  155. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study.2023International journal of surgery (London, England)Free full text
  156. Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy.2023Journal for immunotherapy of cancerFree full text
  157. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study.2023Journal of cancer research and clinical oncologyFree full text
  158. Vessels encapsulating tumor clusters: a novel efficacy predictor of hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  159. Repeat hepatectomy versus percutaneous ablation for recurrent hepatocellular carcinoma: emphasis on the impact of early or late recurrence.2023Journal of cancer research and clinical oncologyFree full text
  160. Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study.2023Journal of cancer research and clinical oncologyFree full text
  161. Identification of prognosis-related cyclin-dependent kinases and potential response drugs in hepatocellular carcinoma.2023Journal of cancer research and therapeutics
  162. Development and validation of robust metabolism-related gene signature in the prognostic prediction of hepatocellular carcinoma.2023Journal of cellular and molecular medicineFree full text
  163. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  164. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.2023Journal of gastroenterology
  165. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer.2023Nature communicationsFree full text
  166. SurvivalPath:A R package for conducting personalized survival path mapping based on time-series survival data.2023PLoS computational biologyFree full text
  167. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane: LI-RADS for Diagnosing Hepatocellular Carcinoma.2023Radiology
  168. CT-guided 125I brachytherapy for hepatocellular carcinoma in high-risk locations after transarterial chemoembolization combined with microwave ablation: a propensity score-matched study.2023Radiology and oncologyFree full text
  169. Noninvasive imaging-based machine learning algorithm to identify progressive disease in advanced hepatocellular carcinoma receiving second-line systemic therapy.2023Scientific reportsFree full text
  170. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study.2023Signal transduction and targeted therapyFree full text
  171. Integrated genetic and epigenetic analysis reveals DNA repair alterations in multifocal hepatocellular carcinoma.2023Signal transduction and targeted therapyFree full text
  172. Analysis of the Prognosis Prediction Ability of a Necroptosis-Related Gene Signature and its Relationship With the Hepatocellular Carcinoma Immune Microenvironment Using Bioinformatics Analysis and Experimental Validation.2023Technology in cancer research & treatmentFree full text
  173. A Clinical Tool to Predict the Microvascular Invasion Risk in Patients with Hepatocellular Carcinoma.2023Technology in cancer research & treatmentFree full text
  174. A Model Based on Artificial Intelligence Algorithm for Monitoring Recurrence of HCC after Hepatectomy.2023The American surgeon
  175. Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma.2023The American surgeon
  176. Contrast-enhanced ultrasound liver imaging reporting and data system v2017: patient outcomes after treatment for early-stage hepatocellular carcinoma nodules with category 3-5 and category M.2023The British journal of radiology
  177. Efficacy and Dose-Response Relationship of Stereotactic Body Radiotherapy for Abdominal Lymph Node Metastases from Hepatocellular Carcinoma.2023The oncologistFree full text
  178. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.2022AJR. American journal of roentgenology
  179. S100A9 Derived from Chemoembolization-Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  180. ASO Author Reflections: Neoadjuvant Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin Is an Incredible Helper in Curing Patients with Intermediate-Advanced-Stage and Technically Resectable Hepatocellular 2022Annals of surgical oncology
  181. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.2022Annals of surgical oncology
  182. Dopamine receptor D3 is related to prognosis in human hepatocellular carcinoma and inhibits tumor growth.2022BMC cancerFree full text
  183. Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT‒qPCR validation.2022BMC cancerFree full text
  184. Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy.2022BMC gastroenterologyFree full text
  185. One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma.2022BMC medicineFree full text
  186. Development and Validation of a Novel Nomogram for Predicting Vessels that Encapsulate Tumor Cluster in Hepatocellular Carcinoma.2022Cancer control : journal of the Moffitt Cancer CenterRCTFree full text
  187. TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience.2022Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  188. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback.2022Cancer letters
  189. Nucleoporin 93 mediates β-catenin nuclear import to promote hepatocellular carcinoma progression and metastasis.2022Cancer letters
  190. MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma.2022Cancer research
  191. PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma.2022Cancer researchFree full text
  192. NXN suppresses metastasis of hepatocellular carcinoma by promoting degradation of Snail through binding to DUB3.2022Cell death & diseaseFree full text
  193. CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma.2022Cell death & diseaseFree full text
  194. Retrograde venous coil embolization prior to transarterial chemoembolization in hepatocellular carcinoma with arterio-hepatic venous shunts.2022Diagnostic and interventional radiology (Ankara, Turkey)Free full text
  195. Alpha-Fetoprotein Ratio Predicts Alpha-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy.2022Disease markersFree full text
  196. Immunotherapy in older patients with hepatocellular carcinoma.2022European journal of cancer (Oxford, England : 1990)
  197. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.2022European journal of cancer (Oxford, England : 1990)
  198. TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension.2022European radiologyFree full text
  199. The growth pattern of liver metastases on MRI predicts early recurrence in patients with colorectal cancer: a multicenter study.2022European radiology
  200. Multi-omics analyses of tumor-associated immune-infiltrating cells with the novel immune checkpoint protein tyrosine phosphatase 1B (PTP1B) in extracellular matrix of brain-lower-grade-glioma (LGG) and uveal-melanoma (UVM).2022Frontiers in immunologyFree full text
  201. C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients.2022Frontiers in immunologyFree full text
  202. Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis.2022Hepatology (Baltimore, Md.)Free full text
  203. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.2022Hepatology international
  204. Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: A real-world study.2022International immunopharmacology
  205. SPC25 promotes proliferation and stemness of hepatocellular carcinoma cells via the DNA-PK/AKT/Notch1 signaling pathway.2022International journal of biological sciencesFree full text
  206. Untargeted plasma metabolomics for risk prediction of hepatocellular carcinoma: A prospective study in two Chinese cohorts.2022International journal of cancer
  207. Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  208. Influencing factors related to transcatheter arterial chemoembolization for hepatocellular carcinoma patients achieved tumor response.2022Journal of cancer research and therapeutics
  209. Feasibility and efficacy of superconducting open-configuration magnetic resonance-guided microwave ablation of malignant liver tumors with real-time imaging sequences.2022Journal of cancer research and therapeutics
  210. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).2022Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  211. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.2022Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  212. Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-κB pathway.2022Journal of experimental & clinical cancer research : CRFree full text
  213. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.2022Journal of gastroenterology
  214. Effect and Safety of Prophylactic Parecoxib for Pain Control of Transarterial Chemoembolization in Liver Cancer: A Single-Center, Parallel-Group, Randomized Trial.2022Journal of the American College of Radiology : JACRRCT
  215. A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma.2022Molecular cancerFree full text
  216. Sodium Pump Na + /K + ATPase Subunit α1-Targeted Positron Emission Tomography Imaging of Hepatocellular Carcinoma in Mouse Models.2022Molecular imaging and biology
  217. The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma.2022Molecular medicine (Cambridge, Mass.)Free full text
  218. Downregulation of a mitochondrial micropeptide, MPM, promotes hepatoma metastasis by enhancing mitochondrial complex I activity.2022Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  219. Mitochondrial micropeptide STMP1 promotes G1/S transition by enhancing mitochondrial complex IV activity.2022Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  220. microRNA-375 inhibits the malignant behaviors of hepatic carcinoma cells by targeting NCAPG2.2022Neoplasma
  221. Insufficient ablation induces E3-ligase Nedd4 to promote hepatocellular carcinoma progression by tuning TGF-β signaling.2022Oncogene
  222. Neutrophil extracellular traps induce tumor metastasis through dual effects on cancer and endothelial cells.2022OncoimmunologyFree full text
  223. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.2022Technology in cancer research & treatmentFree full text
  224. Carbonic anhydrase XII mediates the survival and prometastatic functions of macrophages in human hepatocellular carcinoma.2022The Journal of clinical investigationFree full text
  225. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.2022VirusesFree full text
  226. Radiofrequency versus microwave ablation for hepatocellular carcinoma within the Milan criteria in challenging locations: a retrospective controlled study.2021Abdominal radiology (New York)
  227. Radiomics-based model using gadoxetic acid disodium-enhanced MR images: associations with recurrence-free survival of patients with hepatocellular carcinoma treated by surgical resection.2021Abdominal radiology (New York)RCT
  228. LncRNA Lnc-APUE is Repressed by HNF4α and Promotes G1/S Phase Transition and Tumor Growth by Regulating MiR-20b/E2F1 Axis.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  229. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.2021AgingFree full text
  230. The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE.2021AgingFree full text
  231. Comprehensive nutritional index for predicting overall survival in hepatocellular carcinoma patients after multiple transarterial chemoembolization.2021Asia Pacific journal of clinical nutrition
  232. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.2021BMC cancerFree full text
  233. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.2021BMC cancerFree full text
  234. Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria.2021BMC cancerFree full text
  235. Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity.2021Biochemical and biophysical research communications
  236. CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.2021Bioscience reportsFree full text
  237. α-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study.2021British journal of cancerFree full text
  238. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.2021Cancer immunology, immunotherapy : CIIFree full text
  239. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.2021Cancer immunology, immunotherapy : CIIFree full text
  240. The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early-stage hepatocellular carcinoma.2021Cancer medicineFree full text
  241. Surgical strategies for hepatocellular carcinoma located in the left lateral lobe: A propensity score-matched and prognostic nomogram study.2021Cancer medicineFree full text
  242. A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy.2021Cancer medicineFree full text
  243. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.2021Cancer researchFree full text
  244. Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin.2021Cell death & diseaseFree full text
  245. STEAP3 promotes cancer cell proliferation by facilitating nuclear trafficking of EGFR to enhance RAC1-ERK-STAT3 signaling in hepatocellular carcinoma.2021Cell death & diseaseFree full text
  246. TROAP switches DYRK1 activity to drive hepatocellular carcinoma progression.2021Cell death & diseaseFree full text
  247. Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.2021Diagnostic and interventional radiology (Ankara, Turkey)Free full text
  248. Surgical Resection versus Re-Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma after Initial Ablation Therapy.2021Digestive surgery
  249. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.2021Disease markersFree full text
  250. Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection.2021European journal of cancer (Oxford, England : 1990)
  251. Expression of hepatitis B surface antigen in liver tissues can serve as a predictor of prognosis for hepatitis B virus-related hepatocellular carcinoma patients after liver resection.2021European journal of gastroenterology & hepatologyFree full text
  252. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy.2021European journal of radiology
  253. Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis.2021European radiologyFree full text
  254. SNRPC promotes hepatocellular carcinoma cell motility by inducing epithelial-mesenchymal transition.2021FEBS open bioFree full text
  255. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.2021Frontiers in bioscience (Landmark edition)
  256. High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma.2021GenesFree full text
  257. MesKit: a tool kit for dissecting cancer evolution of multi-region tumor biopsies through somatic alterations.2021GigaScienceFree full text
  258. Cancer-Associated Fibroblast-Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression.2021Hepatology (Baltimore, Md.)
  259. A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion.2021Hepatology international
  260. Multi-institutional validation of novel models for predicting the prognosis of patients with huge hepatocellular carcinoma.2021International journal of cancer
  261. Four types of tumor progression after microwave ablation of single hepatocellular carcinoma of ≤5 cm: incidence, risk factors and clinical significance.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  262. The guiding value of microvascular invasion for treating early recurrent small hepatocellular carcinoma.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  263. Single-nodule hepatitis B virus-associated hepatocellular carcinoma smaller than 3 cm: two phenotypes defined by cluster analysis and their association with the outcome of ablation as the first-line therapy.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  264. Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma.2021JAMA network openFree full text
  265. Development and Validation of a Model Including Distinct Vascular Patterns to Estimate Survival in Hepatocellular Carcinoma.2021JAMA network openFree full text
  266. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.2021Journal for immunotherapy of cancerFree full text
  267. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization.2021Journal of cancer research and therapeutics
  268. Application of iron/barium ferrite/carbon-coated iron nanocrystal composites in transcatheter arterial chemoembolization of hepatocellular carcinoma.2021Journal of colloid and interface science
  269. Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma.2021Journal of experimental & clinical cancer research : CRFree full text
  270. Associations between lncRNA-related polymorphisms and hepatocellular carcinoma risk: A two-stage case-control study.2021Journal of gastroenterology and hepatology
  271. Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma.2021Journal of hepatology
  272. Surveillance Strategy after Complete Ablation of Initial Recurrent Hepatocellular Carcinoma: A Risk-Based Machine Learning Study.2021Journal of vascular and interventional radiology : JVIR
  273. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis.2021Journal of vascular and interventional radiology : JVIR
  274. Radiomics Analysis of Susceptibility Weighted Imaging for Hepatocellular Carcinoma: Exploring the Correlation between Histopathology and Radiomics Features.2021Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in MedicineFree full text
  275. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.2021MutagenesisFree full text
  276. DNase1L3 suppresses hepatocellular carcinoma growth via inhibiting complement autocrine effect.2021Neoplasma
  277. Plasma SGIP1 methylation in diagnosis and prognosis prediction in hepatocellular carcinoma.2021Neoplasma
  278. KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma.2021Protein & cellFree full text
  279. Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis.2021Signal transduction and targeted therapyFree full text
  280. Identification of a TGF-β/SMAD/lnc-UTGF positive feedback loop and its role in hepatoma metastasis.2021Signal transduction and targeted therapyFree full text
  281. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.2021Technology in cancer research & treatmentFree full text
Chinese-language papers (not in the count)3
  1. [Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
  3. [Suggestions on the nomenclature of liver cancer].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status163
  1. Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular CarcinomaRecruitingNCT07324824Lead (inferred)Phase 2Start 2026-01
  2. Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II StudyNot yet recruitingNCT07870772Lead (inferred)Phase 2Start 2026-10
  3. HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)RecruitingNCT07594340Lead (inferred)Phase 3Start 2026-05
  4. SBRT Versus Surgical Resection for Small HCCRecruitingNCT07381660Lead (inferred)Phase 3Start 2026-03
  5. Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-lineRecruitingNCT07501351Lead (inferred)Phase 2Start 2026-01
  6. Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & BevacizumabRecruitingNCT07192185Lead (inferred)Phase 2Start 2025-09
  7. HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular CarcinomaRecruitingNCT06737913Lead (inferred)Phase 2Start 2025-01
  8. Liver Cancer Prognosis Investigation StudyNot yet recruitingNCT06623734Lead (inferred)Start 2025-04
  9. Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI TreatmentRecruitingNCT07238881Lead (inferred)Phase 2Start 2025-11
  10. Fruquintinib After ICIs Treatment in Unresectable Hepatocellular CarcinomaRecruitingNCT06446154Lead (inferred)Phase 2Start 2024-12
  11. Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCCRecruitingNCT06467799Lead (inferred)Phase 2Start 2024-09
  12. Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary MetastasesRecruitingNCT06265350Lead (inferred)N/AStart 2024-02
  13. Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)RecruitingNCT06313190Lead (inferred)Phase 2Start 2024-04
  14. Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCCRecruitingNCT06041477Lead (inferred)Phase 3Start 2023-10
  15. FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind TrialRecruitingNCT06201065Lead (inferred)Phase 3Start 2023-12
  16. Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical TrialRecruitingNCT06031285Lead (inferred)Phase 2Start 2023-09
  17. Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical TrialRecruitingNCT05751343Lead (inferred)Phase 2Start 2023-03
  18. Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)RecruitingNCT04777942Lead (inferred)N/AStart 2021-02
  19. Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative TrialActive, not recruitingNCT07380633Lead (inferred)Phase 2Start 2026-01
  20. A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular CarcinomaActive, not recruitingNCT07138885Lead (inferred)Phase 2Start 2025-08
  21. bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular CarcinomaStatus unknownNCT06070636Lead (inferred)N/AStart 2024-05
  22. Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular CarcinomaActive, not recruitingNCT06524466Lead (inferred)Phase 2Start 2024-07
  23. bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCCStatus unknownNCT06061276Lead (inferred)N/AStart 2024-05
  24. Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TStatus unknownNCT05760599Lead (inferred)Phase 2Start 2023-02
  25. HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 TrialStatus unknownNCT05886465Lead (inferred)Phase 2Start 2023-05
  26. HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCCStatus unknownNCT05866172Lead (inferred)Phase 3Start 2023-05
  27. Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCCCompletedNCT06435013Lead (inferred)Start 2023-12
  28. Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)Status unknownNCT06090656Lead (inferred)Phase 2Start 2023-03
  29. TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven CriteriaStatus unknownNCT05883176Lead (inferred)Phase 2Start 2023-06
  30. A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCCCompletedNCT05773105Lead (inferred)Phase 1/Phase 2Start 2023-09
  31. Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular CarcinomaStatus unknownNCT05609695Lead (inferred)Start 2023-03
  32. TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II StudyStatus unknownNCT05882370Lead (inferred)Phase 2Start 2022-12
  33. Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular CarcinomaStatus unknownNCT05573282Lead (inferred)Start 2022-10
  34. Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular CarcinomaStatus unknownNCT05231382Lead (inferred)Phase 3Start 2022-03
  35. A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic AgentsStatus unknownNCT05718492Lead (inferred)N/AStart 2022-10
  36. Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TWithdrawnNCT05886257Lead (inferred)Phase 2Start 2022-12
  37. Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized TrialActive, not recruitingNCT05198609Lead (inferred)Phase 3Start 2022-01
  38. TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver CancerStatus unknownNCT05220020Lead (inferred)Phase 3Start 2022-05
  39. Watch and Wait and Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular CarcinomaCompletedNCT05349331Lead (inferred)Phase 2Start 2022-05
  40. Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular CarcinomaCompletedNCT04945720Lead (inferred)Phase 2Start 2022-04
  41. HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority StudyStatus unknownNCT05476432Lead (inferred)Phase 3Start 2022-07
  42. Accuracy Evaluation of Artificial Intelligence Assisted Liver Tumor Ablation Path PlanningStatus unknownNCT05161624Lead (inferred)Start 2021-12
  43. TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical StudyStatus unknownNCT04796025Lead (inferred)Phase 2Start 2021-09
  44. TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTTCompletedNCT05535998Lead (inferred)Start 2021-01
  45. Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814030Lead (inferred)Phase 2Start 2021-04
  46. PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814043Lead (inferred)Phase 2Start 2021-04
  47. Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCCStatus unknownNCT05002452Lead (inferred)Start 2021-12
  48. The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04961918Lead (inferred)Phase 2Start 2021-07
  49. Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular CarcinomaStatus unknownNCT04724226Lead (inferred)Phase 2Start 2021-09
  50. Neo-TACE-HAIC for BCLC B Stage HCCStatus unknownNCT04424043Lead (inferred)N/AStart 2020-07
  51. Ablation Combined With PD-1 in HCC: Phase II StudyStatus unknownNCT04652440Lead (inferred)Phase 1/Phase 2Start 2020-12
  52. Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCCStatus unknownNCT04663035Lead (inferred)Phase 2Start 2020-12
  53. TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 TrialStatus unknownNCT04531228Lead (inferred)N/AStart 2020-10
  54. Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational StudyStatus unknownNCT04680598Lead (inferred)Start 2020-12
  55. A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC ClassificationStatus unknownNCT04191889Lead (inferred)Phase 2Start 2020-04
  56. The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective StudyCompletedNCT07272265Lead (inferred)N/AStart 2020-10
  57. Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative ResectionStatus unknownNCT04682210Lead (inferred)Phase 3Start 2020-12
  58. Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line TreatmentCompletedNCT07537985Lead (inferred)N/AStart 2020-01
  59. Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 TrialStatus unknownNCT04687163Lead (inferred)Phase 3Start 2020-12
  60. TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular CarcinomaStatus unknownNCT05555316Lead (inferred)Phase 2Start 2019-11
  61. Phase II of Lenvatinib Plus Toripalimab for Advanced HCCWithdrawnNCT03919383Lead (inferred)Phase 2Start 2019-04
  62. Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCCCompletedNCT03939975Lead (inferred)Phase 2Start 2019-06
  63. A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative ResectionStatus unknownNCT04392700Lead (inferred)Phase 3Start 2019-07
  64. Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)Status unknownNCT04167293Lead (inferred)Phase 2/Phase 3Start 2019-11
  65. Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTTStatus unknownNCT04169399Lead (inferred)Phase 2Start 2019-11
  66. The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT03851939Lead (inferred)Phase 2Start 2019-02
  67. HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCCActive, not recruitingNCT03869034Lead (inferred)Phase 2Start 2019-03
  68. HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized TrialStatus unknownNCT04135690Lead (inferred)Phase 2Start 2019-10
  69. Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic MetastasisStatus unknownNCT04170179Lead (inferred)Phase 2Start 2019-11
  70. HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority TrialStatus unknownNCT04667351Lead (inferred)Phase 3Start 2019-03
  71. Neo-TACE-HAIC for PVTT-HCCStatus unknownNCT04181931Lead (inferred)N/AStart 2019-12
  72. HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCCWithdrawnNCT03803254Lead (inferred)Phase 2Start 2019-01
  73. Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03791918Lead (inferred)Phase 3Start 2019-01
  74. HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCCWithdrawnNCT03780634Lead (inferred)Phase 2Start 2019-04
  75. RFA Versus SBRT for Recurrent Small HCCCompletedNCT04047173Lead (inferred)Phase 3Start 2019-08
  76. RFA vs. SBRT for Small HCCStatus unknownNCT03898921Lead (inferred)Phase 3Start 2019-03
  77. HAIC Plus Lenvatinib and Toripalimab for Advanced HCCCompletedNCT04044313Lead (inferred)Phase 2Start 2019-08
  78. The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent HepatectomyStatus unknownNCT03851913Lead (inferred)Phase 3Start 2018-07
  79. TACE-HAIC vs. HAIC for Potentially Resectable HCCStatus unknownNCT03591705Lead (inferred)N/AStart 2018-07
  80. The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.Status unknownNCT04053972Lead (inferred)Phase 3Start 2018-01
  81. TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCCWithdrawnNCT03782831Lead (inferred)Phase 2Start 2018-12
  82. The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)Status unknownNCT03851887Lead (inferred)Phase 2Start 2018-12
  83. HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCCStatus unknownNCT03812783Lead (inferred)Phase 2Start 2018-11
  84. The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04053985Lead (inferred)Phase 3Start 2018-01
  85. Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCCWithdrawnNCT03746249Lead (inferred)Phase 2Start 2018-12
  86. Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCCStatus unknownNCT03812770Lead (inferred)Phase 2Start 2018-08
  87. HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCCStatus unknownNCT03775395Lead (inferred)Phase 3Start 2018-12
  88. HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-BStatus unknownNCT03780049Lead (inferred)Phase 3Start 2018-10
  89. Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03775707Lead (inferred)Phase 2Start 2018-12
  90. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT03164382Lead (inferred)Phase 3Start 2017-03
  91. the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular CarcinomaStatus unknownNCT03777475Lead (inferred)N/AStart 2016-07
  92. The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective StudyCompletedNCT05121571Lead (inferred)N/AStart 2016-04
  93. Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical ResectionTerminatedNCT02867280Lead (inferred)Phase 3Start 2016-06
  94. RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular CarcinomaStatus unknownNCT02964260Lead (inferred)N/AStart 2016-05
  95. HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.CompletedNCT02973685Lead (inferred)Phase 3Start 2016-10
  96. Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-FluorouracilStatus unknownNCT02987699Lead (inferred)Phase 2Start 2016-11
  97. Adjuvant Chemotherapy With FOLFOX in HCC Patients After ResectionStatus unknownNCT02738697Lead (inferred)Phase 3Start 2016-01
  98. HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/BCompletedNCT03048123Lead (inferred)Phase 2Start 2015-10
  99. TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular CarcinomaCompletedNCT02435953Lead (inferred)Phase 3Start 2015-05
  100. Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular CarcinomaCompletedNCT02981498Lead (inferred)Phase 2Start 2015-06
  101. The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled TrialTerminatedNCT02220088Lead (inferred)Phase 2/Phase 3Start 2014-12
  102. Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan CriteriaStatus unknownNCT02138981Lead (inferred)Phase 4Start 2014-05
  103. Combine TACE and RFA Versus TACE Alone for HCC With PVTTStatus unknownNCT02301091Lead (inferred)Phase 3Start 2014-10
  104. TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular CarcinomaStatus unknownNCT01833286Lead (inferred)Phase 3Start 2013-07
  105. Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA ReplicationStatus unknownNCT01894269Lead (inferred)Phase 4Start 2013-07
  106. Primary Liver Cancer Cohort of South ChinaStatus unknownNCT03297255Lead (inferred)Start 2013-01
  107. Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal HypertensionCompletedNCT01642446Lead (inferred)N/AStart 2013-01
  108. CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular CarcinomaStatus unknownNCT04715321Lead (inferred)Start 2013-02
  109. Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCCCompletedNCT01229839Lead (inferred)Phase 3Start 2013-08
  110. TACE Plus Recombinant Human Adenovirus for Hepatocellular CarcinomaStatus unknownNCT01869088Lead (inferred)Phase 3Start 2013-01
  111. A Simple Prognostic Scoring System for Patients Receiving Transarterial Chemoembolization for Hepatocellular CarcinomaCompletedNCT02061956Lead (inferred)Start 2011-01
  112. Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT01409499Lead (inferred)Phase 4Start 2011-01
  113. Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular CarcinomaCompletedNCT01259414Lead (inferred)Phase 3Start 2011-01
  114. Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor ThrombosisStatus unknownNCT01350206Lead (inferred)Phase 4Start 2010-04
  115. Adjuvant TACE to Reduce the HCC Recurrence After ResectionCompletedNCT02788526Lead (inferred)Phase 3Start 2009-06
  116. Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver CancerCompletedNCT00769106Lead (inferred)Phase 3Start 2008-06
  117. Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular CarcinomaStatus unknownNCT00728078Lead (inferred)Phase 2/Phase 3Start 2008-07
  118. TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular CarcinomaStatus unknownNCT00556803Lead (inferred)Phase 4Start 2007-11
  119. Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular CarcinomaStatus unknownNCT00555334Lead (inferred)Phase 4Start 2007-11
  120. Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular CarcinomaStatus unknownNCT00557024Lead (inferred)Phase 4Start 2007-11
  121. Different Regimens of Transarterial Chemoembolization for Hepatocellular CarcinomaCompletedNCT00493402Lead (inferred)Phase 3Start 2007-07
  122. Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous ThrombusTerminatedNCT01600196Lead (inferred)Phase 4Start 2006-01
  123. The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular CarcinomaStatus unknownNCT00720668Lead (inferred)Start 2006-06
  124. Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular CarcinomaStatus unknownNCT00554905Lead (inferred)Phase 4Start 2006-10
  125. Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular CarcinomaStatus unknownNCT00842647Lead (inferred)Start 2006-07
  126. Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels InvasionStatus unknownNCT00501813Lead (inferred)Phase 3Start 2006-10
  127. Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular CarcinomaCompletedNCT02031952Lead (inferred)N/AStart 2005-12
  128. Hepatectomy With or Without Transcatheter Arterial Chemoembolization for Stage IIIA Hepatocellular CarcinomaCompletedNCT00652587Lead (inferred)Phase 3Start 2002-01
  129. HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCCApproved_For_MarketingNCT02436044Lead (inferred)
  130. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular CarcinomaNot yet recruitingNCT07866612Study siteN/AStart 2026-12
  131. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Study siteStart 2026-07
  132. An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular CarcinomaRecruitingNCT07493044Study sitePhase 1Start 2026-03
  133. A Study of DEG6498 in Participants With Solid TumorsRecruitingNCT07244835Study sitePhase 1Start 2025-11
  134. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  135. Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid TumorsRecruitingNCT06938880Study sitePhase 1/Phase 2Start 2025-05
  136. A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid TumorsRecruitingNCT06307925Study sitePhase 1Start 2024-03
  137. Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular CarcinomaNot yet recruitingNCT06449846Study siteStart 2024-06
  138. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  139. Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNARecruitingNCT06157060Study siteStart 2023-11
  140. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedNCT06487559Study sitePhase 1Start 2024-09
  141. Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCCWithdrawnNCT06361758Study sitePhase 2Start 2024-05
  142. A Phase 1 Study of BST02 in Treating Locally Advanced Liver CancerStatus unknownNCT06526832Study sitePhase 1Start 2024-07
  143. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  144. A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC ClassificationStatus unknownNCT05313282Study sitePhase 3Start 2022-06
  145. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  146. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  147. "Cocktail" Therapy for Hepatitis B Related Hepatocellular CarcinomaStatus unknownNCT04317248Study sitePhase 2Start 2020-04
  148. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  149. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  150. NeuWave Microwave Ablation HCC China StudyCompletedNCT03783871Study siteN/AStart 2019-02
  151. Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCCWithdrawnNCT03744247Study sitePhase 3Start 2019-04
  152. Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus InfectionWithdrawnNCT04044651Study sitePhase 2/Phase 3Start 2019-10
  153. Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan CriteriaStatus unknownNCT03469479Study sitePhase 3Start 2018-03
  154. HAIC of FOLFOX vs. HAIC of OXA for Advanced HCCStatus unknownNCT03468231Study sitePhase 3Start 2018-03
  155. A Phase 1 Study of ZSP1241 in Participants With Advanced Solid TumorsStatus unknownNCT03734926Study sitePhase 1Start 2018-11
  156. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  157. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Study sitePhase 2Start 2017-05
  158. HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCCCompletedNCT02856126Study sitePhase 3Start 2016-08
  159. Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCCCompletedNCT02774187Study sitePhase 3Start 2016-05
  160. Efficacy Study of TACE to Treat Hepatocellular Carcinoma After OperationStatus unknownNCT02631499Study sitePhase 4Start 2015-12
  161. Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCCStatus unknownNCT02018757Study sitePhase 2Start 2014-01
  162. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT00617981Study sitePhase 3Start 2008-05
  163. T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma PatientsTerminatedNCT00057382Study sitePhase 2/Phase 3Start 2003-03

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 103 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.1%.

Papers led
103
2021–2025
Trials led
21
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
10
led by another institution
Papers led per year
2021: 131320212022: 171720222023: 262620232024: 252520242025: 20202025

15 hospitals in Guangzhou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 14

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2023-04
    Registry
    NCT05918094

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 7 listed hospitals as study sitesChengdu, Dalian, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou

  2. Recruiting
    Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
    Phase
    Phase 2
    Started
    2023-05
    Registry
    NCT06451211

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  3. Not yet recruiting
    A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07507526

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  4. Not yet recruiting
    Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07701681

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  5. Recruiting
    A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07673887

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  6. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  7. Recruiting
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06873659

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an

  8. Recruiting
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-04
    Registry
    NCT06925243

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  9. Recruiting
    Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06949033

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  10. Recruiting
    Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
    Phase
    Phase 3
    Started
    2025-06
    Registry
    NCT07029269

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an

  11. Recruiting
    A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06172478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou

  12. Recruiting
    A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06500052

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  13. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

  14. Recruiting
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    Phase
    Phase 1
    Started
    2022-06
    Registry
    NCT05365581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsPeritoneal spread & advanced diseaseChemotherapy & combined treatment
Departments in papersMedical oncologyRadiology / nuclear medicinePathology / laboratory medicineClinical trials / research unit
Papers it led103
  1. The Relationship Between Quality of Discharge Teaching and Oral Nutritional Supplementation Adherence in Postoperative Patients With Gastric Cancer: A Chain Mediated Role of Readiness for Hospital Discharge and Medication Beliefs.2026Journal of clinical nursingFree full text
  2. Integrated Multiomics Analysis and Experimental Validation Identify ITPRIPL1 as an Immunoregulatory and Prognostic Biomarker in Gastric Adenocarcinoma.2026Journal of gastroenterology and hepatology
  3. A Clinical-Radiomic Combined Model based on Dual-Layer Spectral CT for Predicting Pathological T4 in Gastric Cancer.2025Academic radiology
  4. The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer.2025Acta pharmacologica SinicaFree full text
  5. First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.2025Advances in therapyFree full text
  6. Novel surveillance protocol for gastric cancer based on CEA: a high-volume multi-center study.2025BMC cancerFree full text
  7. Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration.2025BMC cancerFree full text
  8. Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades.2025Cancer communications (London, England)Free full text
  9. Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer.2025Cell reports. MedicineFree full text
  10. Predictive significance of MPT-driven necrosis-related genes signature in gastric cancer and their impact on the tumor microenvironment.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  11. Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer.2025Frontiers in immunologyFree full text
  12. Construction of exosome non-coding RNA feature for non-invasive, early detection of gastric cancer patients by machine learning: a multi-cohort study.2025GutFree full text
  13. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases.2025GutFree full text
  14. Signature Construction Associated with Tumor-Infiltrating Macrophages Identifies IRF8 as a Novel Biomarker for Immunotherapy in Advanced Gastric Cancer.2025International journal of molecular sciencesFree full text
  15. Multimodal radiopathomics approach for predictions of prognosis and immunotherapy response in patients with gastric cancer: a multicohort retrospective study.2025International journal of surgery (London, England)Free full text
  16. The EGR1-mediated lncRNA TENM3-AS1 potentiates gastric cancer metastasis via reprogramming fatty acid metabolism.2025Molecular cancerFree full text
  17. ALKBH5 suppresses gastric cancer tumorigenesis and metastasis by inhibiting the translation of uncapped WRAP53 RNA isoforms in an m6A-dependent manner.2025Molecular cancerFree full text
  18. A preserved TGFβ cytostatic response through DLD-mediated metabolic modulation undermines anti-TGFβ therapy in gastric cancer.2025Nature communicationsFree full text
  19. The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.2025Nature medicine
  20. Epstein-Barr virus hijacks histone demethylase machinery to drive epithelial malignancy progression through KDM5B upregulation.2025Signal transduction and targeted therapyFree full text
  21. Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.2025Signal transduction and targeted therapyFree full text
  22. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.2025The Lancet. Oncology
  23. Hyperactivation of mTOR/eIF4E Signaling Pathway Promotes the Production of Tryptophan-To-Phenylalanine Substitutants in EBV-Positive Gastric Cancer.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  24. Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population.2024BMC cancerFree full text
  25. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.2024BMJ (Clinical research ed.)RCT
  26. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.2024Cancer communications (London, England)Free full text
  27. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.2024Cancer immunology, immunotherapy : CIIFree full text
  28. The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.2024Cancer immunology, immunotherapy : CIIFree full text
  29. HIPK3 maintains sensitivity to platinum drugs and prevents disease progression in gastric cancer.2024Cancer letters
  30. Nomogram for predicting pathological response to neoadjuvant treatment in patients with locally advanced gastric cancer: Data from a phase III clinical trial.2024Cancer medicineFree full text
  31. Long non-coding RNA NRAV in the 12q24.31 risk locus drives gastric cancer development through glucose metabolism reprogramming.2024Carcinogenesis
  32. The relationship between brain metastasis and HER2 expression status in gastric cancer.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  33. Diagnosis and prognosis prediction of gastric cancer by high-performance serum lipidome fingerprints.2024EMBO molecular medicineFree full text
  34. Construction of a gene model related to the prognosis of patients with gastric cancer receiving immunotherapy and exploration of COX7A1 gene function.2024European journal of medical researchFree full text
  35. Helicobacter pylori-targeted AI-driven vaccines: a paradigm shift in gastric cancer prevention.2024Frontiers in immunologyFree full text
  36. Opioid-free anesthesia attenuates perioperative immunosuppression by regulating macrophages polarization in gastric cancer patients treated with neoadjuvant PD-1 inhibitor.2024Frontiers in immunologyRCTFree full text
  37. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.2024Future oncology (London, England)Free full text
  38. Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival.2024HPB : the official journal of the International Hepato Pancreato Biliary Association
  39. Anti-Helicobacter pylori Treatment in Patients With Gastric Cancer After Radical Gastrectomy.2024JAMA network openFree full text
  40. HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer.2024Journal of experimental & clinical cancer research : CRFree full text
  41. Overexpression of COX7A1 Promotes the Resistance of Gastric Cancer to Oxaliplatin and Weakens the Efficacy of Immunotherapy.2024Laboratory investigation; a journal of technical methods and pathology
  42. Transcriptional landscape and predictive potential of long noncoding RNAs in peritoneal recurrence of gastric cancer.2024Molecular cancerFree full text
  43. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.2024Nature medicineRCT
  44. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.2024Nature medicineRCT
  45. Reinforcement of the stapled duodenal stump during laparoscopic gastrectomy.2024The British journal of surgery
  46. Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.2024The New England journal of medicineFree full text
  47. Double contrast-enhanced ultrasonography improves diagnostic accuracy of T staging compared with multi-detector computed tomography in gastric cancer patients.2024World journal of gastroenterologyFree full text
  48. Adjuvant Chemotherapy for Patients with Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Multicenter, Observational Study.2023Annals of surgical oncology
  49. ASO Author Reflections: The Role of Adjuvant Chemotherapy in Adenocarcinoma of the Esophagogastric Junction.2023Annals of surgical oncology
  50. Combined Use of Tumor Markers in Gastric Cancer: A Novel Method with Promising Prognostic Accuracy and Practicality.2023Annals of surgical oncology
  51. The role of computed tomography features in assessing response to neoadjuvant chemotherapy in locally advanced gastric cancer.2023BMC cancerFree full text
  52. Development, validation, and evaluation of a risk assessment tool for personalized screening of gastric cancer in Chinese populations.2023BMC medicineFree full text
  53. A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.2023Cancer communications (London, England)Free full text
  54. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer.2023Cancer communications (London, England)Free full text
  55. Physical activity and cancer risk: a dose-response analysis for the Global Burden of Disease Study 2019.2023Cancer communications (London, England)Free full text
  56. Novel staging for gastric neuroendocrine neoplasms by incorporating the WHO grading into the TNM staging system.2023Cancer medicineFree full text
  57. Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins.2023Cell reports
  58. A novel nomogram integrated with PDL1 and CEA to predict the prognosis of patients with gastric cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  59. FTO up-regulation induced by MYC suppresses tumour progression in Epstein-Barr virus-associated gastric cancer.2023Clinical and translational medicineFree full text
  60. Preoperative diagnosis of metastatic lymph nodes by CT-histopathologic matching analysis in gastric adenocarcinoma using dual-layer spectral detector CT.2023European radiology
  61. A novel scoring model based on RNA modification "writers" can predict the prognosis and guide immunotherapy in gastric cancer.2023Functional & integrative genomics
  62. Population-based investigation of common and deviating patterns of gastric cancer and oesophageal cancer incidence across populations and time.2023Gut
  63. Epigenetic Regulation of MAP3K8 in EBV-Associated Gastric Carcinoma.2023International journal of molecular sciencesFree full text
  64. Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression.2023Journal of experimental & clinical cancer research : CRFree full text
  65. Circular RNA circTNIK promotes tumor progression and metastasis in gastric cancer by regulating ZEB2.2023Journal of gastroenterology and hepatology
  66. Gastric cancer treatment: recent progress and future perspectives.2023Journal of hematology & oncologyFree full text
  67. TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP.2023Molecular cancer research : MCRFree full text
  68. Diallyl trisulfide inhibits gastric cancer stem cell properties through ΔNp63/sonic hedgehog pathway.2023Molecular carcinogenesis
  69. LncRNA MIR200CHG inhibits EMT in gastric cancer by stabilizing miR-200c from target-directed miRNA degradation.2023Nature communicationsFree full text
  70. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.2023Nature medicineRCTFree full text
  71. ARHGAP15 promotes metastatic colonization in gastric cancer by suppressing RAC1-ROS pathway.2023PLoS geneticsFree full text
  72. Preoperative chemoradiation-induced hematological toxicity and related vertebral dosimetry evaluations in patients with locally advanced gastric cancer: data from a phase III clinical trial.2023Radiation oncology (London, England)RCTFree full text
  73. Clinicopathological and prognostic features of Borrmann type IV gastric cancer versus other Borrmann types: A unique role of signet ring cell carcinoma.2023Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationFree full text
  74. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.2022Annals of surgical oncology
  75. ASO Author Reflections: Adjuvant Chemotherapy Should not be Omitted for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability.2022Annals of surgical oncology
  76. Development and verification of a nomogram for predicting the prognosis of resectable gastric cancer with outlet obstruction.2022BMC cancerFree full text
  77. Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI.2022BMC cancerFree full text
  78. Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer.2022BMC cancerFree full text
  79. Gastric lymphangioma: a case report and review of literature.2022BMC gastroenterologyFree full text
  80. Phosphoserine phosphatase as a prognostic biomarker in patients with gastric cancer and its potential association with immune cells.2022BMC gastroenterologyFree full text
  81. LINC00858 stabilizes RAN expression and promotes metastasis of gastric cancer.2022Biology directFree full text
  82. EBV Infection in Epithelial Malignancies Induces Resistance to Antitumor Natural Killer Cells via F3-Mediated Platelet Aggregation.2022Cancer research
  83. Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients.2022Frontiers in immunologyFree full text
  84. Heterogeneity and evolution of tumour immune microenvironment in metastatic gastroesophageal adenocarcinoma.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  85. Endoscopic excision as a viable alternative to major resection for early duodenal cancers: A population-based cohort study.2022International journal of surgery (London, England)
  86. Whole-Exome Sequencing Among Chinese Patients With Hereditary Diffuse Gastric Cancer.2022JAMA network openFree full text
  87. tRNA-derived fragments in gastric cancer: Biomarkers and functions.2022Journal of cellular and molecular medicineFree full text
  88. Standardizing the classification of gastric cancer patients with limited and adequate number of retrieved lymph nodes: an externally validated approach using real-world data.2022Military Medical ResearchFree full text
  89. A deep learning model and human-machine fusion for prediction of EBV-associated gastric cancer from histopathology.2022Nature communicationsFree full text
  90. Anterograde "No Touch" Radical Distal Gastrectomy for Gastric Cancer of the Antrum.2022The American surgeon
  91. Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis.2021BMC cancerFree full text
  92. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021.2021Cancer communications (London, England)Free full text
  93. MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer.2021Clinics and research in hepatology and gastroenterology
  94. The genomic architecture of EBV and infected gastric tissue from precursor lesions to carcinoma.2021Genome medicineFree full text
  95. Development and Validation of a Computed Tomography-Based Radiomics Signature to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.2021JAMA network openFree full text
  96. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.2021JAMA network openRCTFree full text
  97. Association of preoperative and postoperative CA72-4 with gastric cancer outcome.2021Journal of surgical oncology
  98. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p.2021Molecular cancerFree full text
  99. Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1.2021Molecular cancerFree full text
  100. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.2021OncoimmunologyFree full text
  101. A nomogram to predict risk of lymph node metastasis in early gastric cancer.2021Scientific reportsFree full text
  102. Superiority of log odds of positive lymph nodes (LODDS) for prognostic prediction after gastric cancer surgery: a multi-institutional analysis of 7620 patients in China.2021Surgery today
  103. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 t2021The lancet. Gastroenterology & hepatologyRCT
Chinese-language papers (not in the count)4
  1. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Updates on immunotherapy of gastrointestinal cancers and practical challenges].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Surgical treatment of gastric neuroendocrine neoplasms].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Exploration and thoughts on perioperative treatment of advanced gastric cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status50
  1. Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07701681Lead (inferred)Phase 2Start 2026-08
  2. A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric CancerNot yet recruitingNCT07507526Lead (inferred)Phase 2Start 2026-04
  3. Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric CancerRecruitingNCT06451211Lead (inferred)Phase 2Start 2023-05
  4. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT05918094Lead (inferred)Phase 3Start 2023-04
  5. Neoadjuvant Toripalimab for dMMR/MSI-H Gastric CancerStatus unknownNCT05994456Lead (inferred)Phase 2Start 2023-03
  6. Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLStatus unknownNCT04476459Lead (inferred)Phase 1/Phase 2Start 2020-07
  7. Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric CancerStatus unknownNCT04250948Lead (inferred)Phase 2Start 2019-10
  8. Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker CorrelationsStatus unknownNCT03475589Lead (inferred)Phase 4Start 2018-02
  9. IV Ascorbic Acid in Advanced Gastric CancerStatus unknownNCT03015675Lead (inferred)Phase 3Start 2017-03
  10. Maintenance Treatment With S-1 in Gastric Cancer PatientsStatus unknownNCT03701373Lead (inferred)Phase 2Start 2016-01
  11. ctDNA for Prediction of Relapse in Gastric CancerStatus unknownNCT02887612Lead (inferred)Start 2016-09
  12. Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric CancerStatus unknownNCT04086888Lead (inferred)Start 2016-12
  13. Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B CarriersStatus unknownNCT02777801Lead (inferred)Phase 2Start 2015-06
  14. Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric CancerCompletedNCT02004769Lead (inferred)Phase 2Start 2013-11
  15. S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma PatientsCompletedNCT01824459Lead (inferred)Phase 3Start 2013-04
  16. Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric CancerCompletedNCT01815853Lead (inferred)Phase 3Start 2013-06
  17. Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric CancerCompletedNCT02229058Lead (inferred)Phase 2Start 2012-02
  18. Study of S-1 Plus LV for Advanced Gastric CancerCompletedNCT02090153Lead (inferred)Phase 2Start 2011-07
  19. Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric CancerStatus unknownNCT02229045Lead (inferred)Phase 2Start 2010-11
  20. Trial of S-1 Plus Cisplatin in Gastric CancerStatus unknownNCT01198392Lead (inferred)Phase 3Start 2008-09
  21. Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric CarcinomaStatus unknownNCT02002416Lead (inferred)Start 2006-01
  22. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  23. A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerRecruitingNCT07673887Study sitePhase 3Start 2026-07
  24. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsRecruitingNCT06873659Study sitePhase 1Start 2025-02
  25. Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06949033Study sitePhase 3Start 2025-05
  26. Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric CancerRecruitingNCT07029269Study sitePhase 3Start 2025-06
  27. Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06925243Study sitePhase 3Start 2025-04
  28. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06172478Study sitePhase 2Start 2024-02
  29. A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid TumorsRecruitingNCT06500052Study sitePhase 1Start 2024-07
  30. Prediction of Peritoneal Metastasis for Gastric Cancer Based on RadiomicsRecruitingNCT05722275Study siteStart 2023-01
  31. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Study sitePhase 1Start 2022-06
  32. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Study sitePhase 1/Phase 2Start 2025-01
  33. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  34. Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East AsiaCompletedNCT05606094Study siteStart 2023-03
  35. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  36. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  37. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  38. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  39. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Study sitePhase 1Start 2020-02
  40. A Phase 1 Study of ZSP1241 in Participants With Advanced Solid TumorsStatus unknownNCT03734926Study sitePhase 1Start 2018-11
  41. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Study sitePhase 3Start 2018-01
  42. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  43. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Study siteN/AStart 2017-09
  44. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  45. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal MetastasisStatus unknownNCT03023436Study sitePhase 3Start 2016-01
  46. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  47. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  48. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  49. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  50. A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric CancerCompletedNCT02415023Study sitePhase 1/Phase 2Start 2014-11

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Guangzhou for hepatoblastoma86 hospitals in China for hepatoblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
    Phase
    Phase 2
    Started
    2021-06
    Registry
    NCT07300449

    Age Not stated to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Guangzhou for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic ChordomaActive, not recruitingNCT06787664Study sitePhase 2Start 2025-01

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 19 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
19
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 5520232024: 5520242025: 442025

30 hospitals in Guangzhou for osteosarcoma570 hospitals in China for osteosarcoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
    Phase
    Phase 1
    Started
    2024-09
    Registry
    NCT07648069

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  2. Recruiting
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05830123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicinePathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led19
  1. Biomimetic Targeted Co-Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Lenvatinib Monotherapy Versus Lenvatinib in Combination with PD-1 Blockades as Re-Challenging Treatment for Patients with Metastatic Osteosarcoma: A Real-World Study.2025Drug design, development and therapy
  3. Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma.2025Molecular cancer
  4. PIM3-mediated phosphorylation stabilizes myeloid leukemia factor 2 to promote metastasis in osteosarcoma.2025The Journal of clinical investigation
  5. Magnetic Resonance Imaging Radiomics Predicts Histological Response to Neoadjuvant Chemotherapy in Localized High-grade Osteosarcoma of the Extremities.2024Academic radiology
  6. Up-regulation of RAN by MYBL2 maintains osteosarcoma cancer stem-like cells population during heterogeneous tumor generation.2024Cancer letters
  7. Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial.2024Cancer medicine
  8. Osteosarcoma Cells Secrete CXCL14 That Activates Integrin α11β1 on Fibroblasts to Form a Lung Metastatic Niche.2024Cancer research
  9. Extracellular-vesicle-packaged S100A11 from osteosarcoma cells mediates lung premetastatic niche formation by recruiting gMDSCs.2024Cell reports
  10. Targeting the Lysosomal Degradation of Rab22a-NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  11. Long-term follow-up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities.2023Cancer medicine
  12. Adamantinoma-like ewing sarcoma arising in the pancreatic tail: a case report of a rare entity and review of the literature.2023Diagnostic pathology
  13. A nanodrug combining CD47 and sonodynamic therapy efficiently inhibits osteosarcoma deterioration.2023Journal of controlled release : official journal of the Controlled Release Society
  14. Augmenting L3MBTL2-induced condensates suppresses tumor growth in osteosarcoma.2023Science advances
  15. Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma.2022Cancer chemotherapy and pharmacology
  16. KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis.2022Cell death & disease
  17. Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes.2021Frontiers in immunology
  18. Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes.2021Signal transduction and targeted therapy
  19. H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts.2021Theranostics
Earlier papers (2016–2020)7
  1. Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library.2020Cancer biology & medicine
  2. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma.2020Cancer science
  3. Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma.2020Nature communications
  4. Acetylation dependent functions of Rab22a-NeoF1 Fusion Protein in Osteosarcoma.2020Theranostics
  5. Up-regulation of PCOLCE by TWIST1 promotes metastasis in Osteosarcoma.2019Theranostics
  6. Phosphorylation of IRS4 by CK1γ2 promotes its degradation by CHIP through the ubiquitin/lysosome pathway.2018Theranostics
  7. Radiation-induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma.2016Chinese journal of cancer
All its trials on ClinicalTrials.gov, any status2
  1. Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced SarcomaRecruitingNCT07648069Lead (inferred)Phase 1Start 2024-09
  2. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

12 hospitals in Guangzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

  2. Recruiting
    A Study of Olverembatinib in SDH-deficient GIST.
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06640361

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology
Papers it led2
  1. β-elemene promotes ferroptosis to improve the sensitivity of imatinib in gastrointestinal stromal tumours by targeting N6AMT1.2025Clinical and translational medicine
  2. Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research.2025Signal transduction and targeted therapy
Earlier papers (2016–2020)9
  1. [Past and present of risk stratification of gastrointestinal stromal tumors and its clinical value].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. Ki-67 labeling index may be a promising indicator to identify "very high-risk" gastrointestinal stromal tumor: a multicenter retrospective study of 1022 patients.2018Human pathology
  3. A Novel Pathological Prognostic Score (PPS) to Identify "Very High-Risk" Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST).2018Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  4. Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy.2018Medicine
  5. Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal strom2017Biomedical chromatography : BMC
  6. Prognostic role of tumor necrosis in patients undergoing curative resection for gastric gastrointestinal stromal tumor: a multicenter analysis of 740 cases in China.2017Cancer medicine
  7. [Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Updates on adjuvant therapy in gastrointestinal stromal tumor].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status4
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. A Study of Olverembatinib in SDH-deficient GIST.RecruitingNCT06640361Study sitePhase 3Start 2024-11
  3. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Study sitePhase 2Start 2021-08
  4. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 7 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
7
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 4420242025: 112025

22 hospitals in Guangzhou for neuroblastoma321 hospitals in China for neuroblastoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07584499

    Age 2 years to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  2. Recruiting
    Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06631391

    Age 1 day to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  3. Recruiting
    Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Registry
    NCT06836505

    Age 1 year to 50 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteDongguan, Guangzhou

  4. Recruiting
    Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT06013618

    Age 12 months to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  5. Recruiting
    Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
    Phase
    Not given
    Started
    2022-01
    Registry
    NCT07516678

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  6. Recruiting
    APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05701306

    Age 5 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led7
  1. SLIT3-mediated intratumoral crosstalk induces neuroblastoma differentiation via a spontaneous regression-like program.2025Journal of translational medicine
  2. Mechanism of Drug Resistance to First-Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas.2024Cancer reports (Hoboken, N.J.)
  3. MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma.2024Cell death & disease
  4. SUV39H1 epigenetically modulates the MCPIP1-AURKA signaling axis to enhance neuroblastoma tumorigenesis.2024Oncogene
  5. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.2024Oncoimmunology
  6. ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma.2021Cell death & disease
  7. MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma.2021Cell death & disease
Earlier papers (2016–2020)6
  1. [Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].2018Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. Comparison of Hematological Aspects between Neuroblastoma Patients with and without Bone Marrow Infiltration.2017Annals of clinical and laboratory science
  3. Suberoylanilide hydroxamic acid sensitizes neuroblastoma to paclitaxel by inhibiting thioredoxin-related protein 14-mediated autophagy.2017Cancer science
  4. Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1.2017Investigational new drugs
  5. CaMKII-mediated Beclin 1 phosphorylation regulates autophagy that promotes degradation of Id and neuroblastoma cell differentiation.2017Nature communications
  6. Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migration and invasion.2016Oncotarget
All its trials on ClinicalTrials.gov, any status7
  1. Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.RecruitingNCT06836505Lead sponsorPhase 1/Phase 2Start 2024-12
  2. Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed NeuroblastomaRecruitingNCT06013618Lead sponsorPhase 2Start 2023-06
  3. Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT07584499Lead (inferred)Phase 1Start 2026-05
  4. Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.RecruitingNCT06631391Lead (inferred)Phase 1Start 2024-11
  5. Serial ctDNA and Molecular Residual Disease Monitoring in NeuroblastomaRecruitingNCT07516678Lead (inferred)Start 2022-01
  6. Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study.CompletedNCT05027386Lead (inferred)Phase 1/Phase 2Start 2021-08
  7. APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsRecruitingNCT05701306Study sitePhase 1/Phase 2Start 2023-02

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 3 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.8%.

Papers led
3
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025

9 hospitals in Guangzhou for Ewing sarcoma134 hospitals in China for Ewing sarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06827717

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 16 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.9%.

Papers led
16
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
12
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 2220232024: 6620242025: 442025

14 hospitals in Guangzhou for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 12

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  2. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

  3. Recruiting
    Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07369895

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  4. Recruiting
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06375044

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou

  5. Recruiting
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06508983

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou

  6. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  7. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  8. Recruiting
    Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
    Phase
    Phase 4
    Started
    2023-10
    Registry
    NCT06057402

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan

  9. Recruiting
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    Phase
    Phase 4
    Started
    2022-03
    Registry
    NCT05201781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an

  10. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  11. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  12. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance
Departments in papersMedical oncologyPathology / laboratory medicine
Papers it led16
  1. Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study.2025Annals of medicineFree full text
  2. Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study.2025Hematological oncology
  3. The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma.2025LeukemiaFree full text
  4. Earlier onset of chemotherapy-induced neuropathic pain in females by ICAM-1-mediated accumulation of perivascular macrophages.2025Science advancesFree full text
  5. The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study.2024BMC cancerFree full text
  6. Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma.2024BMC cancerFree full text
  7. Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter 2024Cancer medicineFree full text
  8. Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma.2024Cancer medicineFree full text
  9. Prognosis of hepatitis B virus reactivation in newly diagnosed multiple myeloma in modern era therapy: a retrospective study.2024PeerJFree full text
  10. Epstein-Barr Virus-Positive Plasma Cell Neoplasms in Immunocompetent Patients: A Clinicopathological Study of 15 Cases from South China and Literature Review.2024The American journal of surgical pathology
  11. Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma.2023Annals of hematologyFree full text
  12. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.2023BMC cancerRCTFree full text
  13. Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma.2022International immunopharmacology
  14. Structural and functional characterization of multiple myeloma associated cytoplasmic poly(A) polymerase FAM46C.2021Cancer communications (London, England)Free full text
  15. A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma.2021Leukemia
  16. Fear of cancer recurrence in patients with multiple myeloma: Prevalence and predictors based on a family model analysis.2021Psycho-oncologyFree full text
All its trials on ClinicalTrials.gov, any status35
  1. The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple MyelomaStatus unknownNCT04762745Lead (inferred)Phase 1/Phase 2Start 2021-02
  2. VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaStatus unknownNCT03641456Lead (inferred)Phase 2Start 2020-09
  3. Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory MyelomaWithdrawnNCT02986451Lead (inferred)Phase 2Start 2016-12
  4. CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple MyelomaStatus unknownNCT02362165Lead (inferred)Phase 3Start 2015-04
  5. Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral NeuropathyStatus unknownNCT02093910Lead (inferred)Phase 2Start 2014-04
  6. Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple MyelomaWithdrawnNCT02985333Lead (inferred)Phase 2Start 2014-01
  7. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  8. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  9. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  10. Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT07369895Study sitePhase 1Start 2025-10
  11. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Study sitePhase 1Start 2024-05
  12. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Study sitePhase 3Start 2024-06
  13. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06
  14. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  15. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)RecruitingNCT06057402Study sitePhase 4Start 2023-10
  16. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  17. A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Study sitePhase 4Start 2022-03
  18. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  19. A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06934044Study sitePhase 1Start 2025-05
  20. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  21. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  22. Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05719701Study sitePhase 1/Phase 2Start 2023-03
  23. A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple MyelomaTerminatedNCT05590377Study sitePhase 1/Phase 2Start 2023-01
  24. Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaStatus unknownNCT05422027Study sitePhase 1/Phase 2Start 2022-07
  25. Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantActive, not recruitingNCT05317416Study sitePhase 3Start 2022-03
  26. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  27. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  28. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Study sitePhase 1/Phase 2Start 2021-04
  29. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  30. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  31. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  32. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  33. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  34. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03215030Study sitePhase 1/Phase 2Start 2017-10
  35. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 3 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.3%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

8 hospitals in Guangzhou for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06580301

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsAntibody & targeted drugs
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Guangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment regimensLymphoma & cancer-related HLH
Papers it led1
  1. The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.2023Journal of cancer research and clinical oncologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLHStatus unknownNCT05008666Lead (inferred)Phase 2Start 2021-12
More papers found outside PubMed (not counted)6
  1. Revision of staging system for natural killer T-cell lymphoma: A multicenter study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group.2025Journal of Clinical Oncologyconference-abstract
  2. Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies2025Bloodconference-abstract
  3. Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study2025Bloodconference-abstract
  4. The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis2023Bloodconference-abstract
  5. Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis2022TigerPrints (Clemson University)article
  6. Pattern and Prognosis of Distant Metastases in Patients with Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma2022International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

18 hospitals in Guangzhou for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led1
  1. Thalassaemia in China.2023Blood reviews

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led no English-language PubMed papers on Fanconi anaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Guangzhou for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

20 hospitals in Guangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

中山大学肿瘤防治中心

Sun Yat-sen University Cancer Center

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Centre; Gastric Cancer Center; Sun YatSen University Cancer Center; and Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center/Cancer Hospital; SYSUCC

Suggest a correctionDownload the data